CN1426394A - 新化合物 - Google Patents
新化合物 Download PDFInfo
- Publication number
- CN1426394A CN1426394A CN01808484A CN01808484A CN1426394A CN 1426394 A CN1426394 A CN 1426394A CN 01808484 A CN01808484 A CN 01808484A CN 01808484 A CN01808484 A CN 01808484A CN 1426394 A CN1426394 A CN 1426394A
- Authority
- CN
- China
- Prior art keywords
- phenyl
- propoxy
- compound
- phenoxy
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 236
- 238000000034 method Methods 0.000 claims abstract description 59
- 238000002360 preparation method Methods 0.000 claims abstract description 43
- -1 nitro, carboxyl Chemical group 0.000 claims description 200
- 229910052760 oxygen Inorganic materials 0.000 claims description 101
- 239000001301 oxygen Substances 0.000 claims description 99
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 97
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 74
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 66
- 239000000203 mixture Substances 0.000 claims description 55
- 150000003839 salts Chemical class 0.000 claims description 53
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 38
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 38
- 239000012453 solvate Substances 0.000 claims description 31
- 238000006243 chemical reaction Methods 0.000 claims description 25
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 21
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 20
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 13
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 208000006673 asthma Diseases 0.000 claims description 9
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 150000001721 carbon Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 102000009410 Chemokine receptor Human genes 0.000 claims description 2
- 108050000299 Chemokine receptor Proteins 0.000 claims description 2
- 208000018569 Respiratory Tract disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000002585 base Substances 0.000 description 187
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 167
- 239000000243 solution Substances 0.000 description 132
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 127
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 121
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 117
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 94
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 88
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 82
- 235000019439 ethyl acetate Nutrition 0.000 description 63
- 239000011259 mixed solution Substances 0.000 description 62
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 60
- 238000003756 stirring Methods 0.000 description 60
- 238000005160 1H NMR spectroscopy Methods 0.000 description 54
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 54
- 238000001704 evaporation Methods 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 50
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 45
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 44
- 239000007787 solid Substances 0.000 description 43
- 235000002639 sodium chloride Nutrition 0.000 description 40
- 239000000741 silica gel Substances 0.000 description 39
- 229910002027 silica gel Inorganic materials 0.000 description 39
- 229960001866 silicon dioxide Drugs 0.000 description 39
- 239000002904 solvent Substances 0.000 description 35
- 238000005406 washing Methods 0.000 description 34
- 238000003818 flash chromatography Methods 0.000 description 33
- 239000007864 aqueous solution Substances 0.000 description 32
- 230000008020 evaporation Effects 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 31
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- 239000012074 organic phase Substances 0.000 description 30
- 238000001035 drying Methods 0.000 description 28
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 27
- 239000000047 product Substances 0.000 description 27
- 150000001412 amines Chemical class 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 25
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 24
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 24
- 239000012043 crude product Substances 0.000 description 23
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 20
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 19
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 19
- 229910052757 nitrogen Inorganic materials 0.000 description 19
- 238000013459 approach Methods 0.000 description 18
- 229940073608 benzyl chloride Drugs 0.000 description 18
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 18
- 229920006395 saturated elastomer Polymers 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 16
- 239000012141 concentrate Substances 0.000 description 16
- 235000008504 concentrate Nutrition 0.000 description 16
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 15
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 15
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 15
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 15
- AXJDEHNQPMZKOS-UHFFFAOYSA-N acetylazanium;chloride Chemical compound [Cl-].CC([NH3+])=O AXJDEHNQPMZKOS-UHFFFAOYSA-N 0.000 description 14
- 239000000460 chlorine Substances 0.000 description 14
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 13
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 229960004756 ethanol Drugs 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 206010039083 rhinitis Diseases 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 11
- XCJLXFIGEMUOEE-UHFFFAOYSA-N acetamide;2,2,2-trifluoroacetic acid Chemical compound CC(N)=O.OC(=O)C(F)(F)F XCJLXFIGEMUOEE-UHFFFAOYSA-N 0.000 description 11
- 239000004202 carbamide Substances 0.000 description 11
- 235000013877 carbamide Nutrition 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 10
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 10
- 239000012230 colorless oil Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 150000002924 oxiranes Chemical class 0.000 description 9
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 9
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 8
- 239000003513 alkali Substances 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 150000002576 ketones Chemical class 0.000 description 8
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 8
- 239000000376 reactant Substances 0.000 description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 238000013019 agitation Methods 0.000 description 7
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 7
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 7
- 239000011737 fluorine Substances 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 7
- 238000004007 reversed phase HPLC Methods 0.000 description 7
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 7
- SCILIBBKSJPQSB-UHFFFAOYSA-N 1-$l^{1}-oxidanylpropan-2-ol Chemical compound CC(O)C[O] SCILIBBKSJPQSB-UHFFFAOYSA-N 0.000 description 6
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
- 230000035605 chemotaxis Effects 0.000 description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 229940095102 methyl benzoate Drugs 0.000 description 6
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- ADVGKWPZRIDURE-UHFFFAOYSA-N 2'-Hydroxyacetanilide Chemical compound CC(=O)NC1=CC=CC=C1O ADVGKWPZRIDURE-UHFFFAOYSA-N 0.000 description 5
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 229960000935 dehydrated alcohol Drugs 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000005984 hydrogenation reaction Methods 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 150000004702 methyl esters Chemical class 0.000 description 5
- 229940017219 methyl propionate Drugs 0.000 description 5
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 5
- 239000002808 molecular sieve Substances 0.000 description 5
- 235000015320 potassium carbonate Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 4
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000005864 Sulphur Substances 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Substances CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000012265 solid product Substances 0.000 description 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 3
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 3
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- DZAHXNNEQCZPGJ-UHFFFAOYSA-N CCCCOC(OC)=O.COC(O)=O Chemical class CCCCOC(OC)=O.COC(O)=O DZAHXNNEQCZPGJ-UHFFFAOYSA-N 0.000 description 3
- 108050006947 CXC Chemokine Proteins 0.000 description 3
- 102000019388 CXC chemokine Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229910013684 LiClO 4 Inorganic materials 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 239000000370 acceptor Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000003810 ethyl acetate extraction Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 125000001207 fluorophenyl group Chemical group 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 125000006252 n-propylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 150000003053 piperidines Chemical class 0.000 description 3
- 125000005936 piperidyl group Chemical group 0.000 description 3
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- APCBTRDHCDOPNY-UHFFFAOYSA-N tert-butyl 3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)C1 APCBTRDHCDOPNY-UHFFFAOYSA-N 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- BQJBONTVMVGWPV-UHFFFAOYSA-N (2-hydroxyphenyl)urea Chemical compound NC(=O)NC1=CC=CC=C1O BQJBONTVMVGWPV-UHFFFAOYSA-N 0.000 description 2
- UJVWPZIWWKDJNH-UHFFFAOYSA-N (4-acetamido-2-hydroxyphenyl)arsonic acid Chemical compound CC(=O)NC1=CC=C([As](O)(O)=O)C(O)=C1 UJVWPZIWWKDJNH-UHFFFAOYSA-N 0.000 description 2
- XNYTZADDSVJMRC-UHFFFAOYSA-N (5-chloro-2-hydroxyphenyl)urea Chemical compound NC(=O)NC1=CC(Cl)=CC=C1O XNYTZADDSVJMRC-UHFFFAOYSA-N 0.000 description 2
- YUAXFSCAJYLTAL-UHFFFAOYSA-N 1-(ethoxymethoxy)-2-nitrobenzene Chemical compound C(C)OCOC1=C(C=CC=C1)[N+](=O)[O-] YUAXFSCAJYLTAL-UHFFFAOYSA-N 0.000 description 2
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 2
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical group CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 description 2
- 125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- NXFFJDQHYLNEJK-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1h-cyclopenta[b]indol-3-yl]acetic acid Chemical compound C1=2C(S(=O)(=O)C)=CC(F)=CC=2C=2CCC(CC(O)=O)C=2N1CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-UHFFFAOYSA-N 0.000 description 2
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 2
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 2
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical class OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 2
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 2
- QQURWFRNETXFTN-UHFFFAOYSA-N 5-fluoro-2-nitrophenol Chemical class OC1=CC(F)=CC=C1[N+]([O-])=O QQURWFRNETXFTN-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 2
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DSFVQIUBODXRLL-UHFFFAOYSA-N acetamide;dihydrochloride Chemical compound Cl.Cl.CC(N)=O DSFVQIUBODXRLL-UHFFFAOYSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- PQANGXXSEABURG-UHFFFAOYSA-N cyclohex-2-en-1-ol Chemical compound OC1CCCC=C1 PQANGXXSEABURG-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 108010004073 cysteinylcysteine Proteins 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 2
- 208000024711 extrinsic asthma Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- VUQZKDREOOPLMD-UHFFFAOYSA-N formamide;2,2,2-trifluoroacetic acid Chemical compound NC=O.OC(=O)C(F)(F)F VUQZKDREOOPLMD-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 2
- 229910001486 lithium perchlorate Inorganic materials 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- HGDAFIJKXCFHPG-UHFFFAOYSA-N n-(5-chloro-2-hydroxyphenyl)acetamide Chemical compound CC(=O)NC1=CC(Cl)=CC=C1O HGDAFIJKXCFHPG-UHFFFAOYSA-N 0.000 description 2
- 125000006606 n-butoxy group Chemical group 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- WRDUCVPIKYPYMC-UHFFFAOYSA-N tert-butyl 3-(4-chloroanilino)pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC1NC1=CC=C(Cl)C=C1 WRDUCVPIKYPYMC-UHFFFAOYSA-N 0.000 description 2
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- QLLXNJVUUSJAKY-UHFFFAOYSA-N 1-(2,6-dimethoxyphenoxy)-3-[3-(4-fluorophenoxy)pyrrolidin-1-yl]propan-2-ol Chemical compound COC1=CC=CC(OC)=C1OCC(O)CN1CC(OC=2C=CC(F)=CC=2)CC1 QLLXNJVUUSJAKY-UHFFFAOYSA-N 0.000 description 1
- MMYDGDYSZZWFSU-UHFFFAOYSA-N 1-(2,6-dimethoxyphenoxy)-3-[4-(4-fluorophenoxy)piperidin-1-yl]propan-2-ol Chemical compound COC1=CC=CC(OC)=C1OCC(O)CN1CCC(OC=2C=CC(F)=CC=2)CC1 MMYDGDYSZZWFSU-UHFFFAOYSA-N 0.000 description 1
- XQFRFKZWYYBUNY-UHFFFAOYSA-N 1-(8-chloro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)-3-(1h-indol-7-yloxy)propan-2-ol Chemical compound N1C2=CC=C(Cl)C=C2C(C2)=C1CCN2CC(O)COC1=CC=CC2=C1NC=C2 XQFRFKZWYYBUNY-UHFFFAOYSA-N 0.000 description 1
- CTJJVJITVLQJFC-UHFFFAOYSA-N 1-(8-fluoro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)-3-(1h-indol-7-yloxy)propan-2-ol Chemical compound N1C2=CC=C(F)C=C2C(C2)=C1CCN2CC(O)COC1=CC=CC2=C1NC=C2 CTJJVJITVLQJFC-UHFFFAOYSA-N 0.000 description 1
- VPHFPBPFTWHPDA-UHFFFAOYSA-N 1-[2-[3-[3-(3,4-dichlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-6-methoxyphenyl]ethanone Chemical compound COC1=CC=CC(OCC(O)CN2CC(CC2)OC=2C=C(Cl)C(Cl)=CC=2)=C1C(C)=O VPHFPBPFTWHPDA-UHFFFAOYSA-N 0.000 description 1
- FPYFITADEVYXHT-UHFFFAOYSA-N 1-[2-[3-[3-(3,4-difluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-6-methoxyphenyl]ethanone Chemical compound COC1=CC=CC(OCC(O)CN2CC(CC2)OC=2C=C(F)C(F)=CC=2)=C1C(C)=O FPYFITADEVYXHT-UHFFFAOYSA-N 0.000 description 1
- VYBAABFQLVWYSV-UHFFFAOYSA-N 1-[2-[3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]phenyl]-3-ethylurea;hydrochloride Chemical compound Cl.CCNC(=O)NC1=CC=CC=C1OCC(O)CN1CC(OC=2C=CC(Cl)=CC=2)CC1 VYBAABFQLVWYSV-UHFFFAOYSA-N 0.000 description 1
- RKQLPFAALCGXDA-UHFFFAOYSA-N 1-[2-[3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]phenyl]-3-methylurea;hydrochloride Chemical compound Cl.CNC(=O)NC1=CC=CC=C1OCC(O)CN1CC(OC=2C=CC(Cl)=CC=2)CC1 RKQLPFAALCGXDA-UHFFFAOYSA-N 0.000 description 1
- RDOMSIRDJMZQFG-UHFFFAOYSA-N 1-[2-[3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1OCC(O)CN1CC(OC=2C=CC(Cl)=CC=2)CC1 RDOMSIRDJMZQFG-UHFFFAOYSA-N 0.000 description 1
- MXPVPZCHHMRENY-UHFFFAOYSA-N 1-[2-[3-[3-(4-fluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1OCC(O)CN1CC(OC=2C=CC(F)=CC=2)CC1 MXPVPZCHHMRENY-UHFFFAOYSA-N 0.000 description 1
- DKWBIRJXBULLGN-UHFFFAOYSA-N 1-[2-[3-[3-[(4-fluorophenoxy)methyl]piperidin-1-yl]-2-hydroxypropoxy]-6-methoxyphenyl]ethanone Chemical compound COC1=CC=CC(OCC(O)CN2CC(COC=3C=CC(F)=CC=3)CCC2)=C1C(C)=O DKWBIRJXBULLGN-UHFFFAOYSA-N 0.000 description 1
- QHRFWGPGUXDOIE-UHFFFAOYSA-N 1-[2-[3-[4-(4-chlorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]-6-methoxyphenyl]ethanone Chemical compound COC1=CC=CC(OCC(O)CN2CCC(CC2)OC=2C=CC(Cl)=CC=2)=C1C(C)=O QHRFWGPGUXDOIE-UHFFFAOYSA-N 0.000 description 1
- UQEOYVUGRXXDLM-UHFFFAOYSA-N 1-[2-[3-[4-(4-chlorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1OCC(O)CN1CCC(OC=2C=CC(Cl)=CC=2)CC1 UQEOYVUGRXXDLM-UHFFFAOYSA-N 0.000 description 1
- RRPBPXKIFGTTCU-UHFFFAOYSA-N 1-[2-[3-[4-(4-chlorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]phenyl]propan-1-one Chemical compound CCC(=O)C1=CC=CC=C1OCC(O)CN1CCC(OC=2C=CC(Cl)=CC=2)CC1 RRPBPXKIFGTTCU-UHFFFAOYSA-N 0.000 description 1
- SNLFCYMYNRABCI-UHFFFAOYSA-N 1-[2-[3-[4-(4-fluorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1OCC(O)CN1CCC(OC=2C=CC(F)=CC=2)CC1 SNLFCYMYNRABCI-UHFFFAOYSA-N 0.000 description 1
- FXIQFPJIRUOHNZ-UHFFFAOYSA-N 1-[2-[3-[4-(4-fluorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]phenyl]propan-1-one Chemical compound CCC(=O)C1=CC=CC=C1OCC(O)CN1CCC(OC=2C=CC(F)=CC=2)CC1 FXIQFPJIRUOHNZ-UHFFFAOYSA-N 0.000 description 1
- AHYPEIPJMFXLSK-UHFFFAOYSA-N 1-[3-(3,4-dichlorophenoxy)pyrrolidin-1-yl]-3-(1h-indol-7-yloxy)propan-2-ol Chemical compound C=1C=CC=2C=CNC=2C=1OCC(O)CN(C1)CCC1OC1=CC=C(Cl)C(Cl)=C1 AHYPEIPJMFXLSK-UHFFFAOYSA-N 0.000 description 1
- QJXVMCMSNPYFAY-UHFFFAOYSA-N 1-[3-(3,4-dichlorophenoxy)pyrrolidin-1-yl]-3-(2-methoxyphenoxy)propan-2-ol Chemical compound COC1=CC=CC=C1OCC(O)CN1CC(OC=2C=C(Cl)C(Cl)=CC=2)CC1 QJXVMCMSNPYFAY-UHFFFAOYSA-N 0.000 description 1
- KIBYECUCMQMOEK-UHFFFAOYSA-N 1-[3-(3,4-difluorophenoxy)pyrrolidin-1-yl]-3-(1h-indol-7-yloxy)propan-2-ol Chemical compound C=1C=CC=2C=CNC=2C=1OCC(O)CN(C1)CCC1OC1=CC=C(F)C(F)=C1 KIBYECUCMQMOEK-UHFFFAOYSA-N 0.000 description 1
- RGVRNVVPHMGSRP-UHFFFAOYSA-N 1-[3-(3,4-difluorophenoxy)pyrrolidin-1-yl]-3-(2-methoxyphenoxy)propan-2-ol Chemical compound COC1=CC=CC=C1OCC(O)CN1CC(OC=2C=C(F)C(F)=CC=2)CC1 RGVRNVVPHMGSRP-UHFFFAOYSA-N 0.000 description 1
- OBAQEZKEEATYLC-UHFFFAOYSA-N 1-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-3-(1h-indol-7-yloxy)propan-2-ol Chemical compound C=1C=CC=2C=CNC=2C=1OCC(O)CN(C1)CCC1OC1=CC=C(Cl)C=C1 OBAQEZKEEATYLC-UHFFFAOYSA-N 0.000 description 1
- QVMUMFLLVWORJV-UHFFFAOYSA-N 1-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-3-(2,6-dimethoxyphenoxy)propan-2-ol Chemical compound COC1=CC=CC(OC)=C1OCC(O)CN1CC(OC=2C=CC(Cl)=CC=2)CC1 QVMUMFLLVWORJV-UHFFFAOYSA-N 0.000 description 1
- AKWIFIHWWBVSPE-UHFFFAOYSA-N 1-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-3-(2-methoxyphenoxy)propan-2-ol Chemical compound COC1=CC=CC=C1OCC(O)CN1CC(OC=2C=CC(Cl)=CC=2)CC1 AKWIFIHWWBVSPE-UHFFFAOYSA-N 0.000 description 1
- BHQCLOGTSTZCTH-UHFFFAOYSA-N 1-[3-(4-fluorophenoxy)pyrrolidin-1-yl]-3-(1h-indol-7-yloxy)propan-2-ol Chemical compound C=1C=CC=2C=CNC=2C=1OCC(O)CN(C1)CCC1OC1=CC=C(F)C=C1 BHQCLOGTSTZCTH-UHFFFAOYSA-N 0.000 description 1
- BFWIUIIIURTQDH-UHFFFAOYSA-N 1-[3-(4-fluorophenoxy)pyrrolidin-1-yl]-3-(2-methoxyphenoxy)propan-2-ol Chemical compound COC1=CC=CC=C1OCC(O)CN1CC(OC=2C=CC(F)=CC=2)CC1 BFWIUIIIURTQDH-UHFFFAOYSA-N 0.000 description 1
- YQTSGGHLBASULT-UHFFFAOYSA-N 1-[3-[(4-fluorophenoxy)methyl]piperidin-1-yl]-3-(2-methoxyphenoxy)propan-2-ol Chemical compound COC1=CC=CC=C1OCC(O)CN1CC(COC=2C=CC(F)=CC=2)CCC1 YQTSGGHLBASULT-UHFFFAOYSA-N 0.000 description 1
- UXLKCLQLCDPLQN-UHFFFAOYSA-N 1-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-3-(2-methoxyphenoxy)propan-2-ol Chemical compound COC1=CC=CC=C1OCC(O)CN1CCC(OC=2C=C(Cl)C(Cl)=CC=2)CC1 UXLKCLQLCDPLQN-UHFFFAOYSA-N 0.000 description 1
- LQTHERZCUCWRHG-UHFFFAOYSA-N 1-[4-(4-chlorophenoxy)piperidin-1-yl]-3-(2-methoxyphenoxy)propan-2-ol Chemical compound COC1=CC=CC=C1OCC(O)CN1CCC(OC=2C=CC(Cl)=CC=2)CC1 LQTHERZCUCWRHG-UHFFFAOYSA-N 0.000 description 1
- YBZLGBDIUOVESN-UHFFFAOYSA-N 1-[4-(4-fluorophenoxy)piperidin-1-yl]-3-(2-methoxyphenoxy)propan-2-ol Chemical compound COC1=CC=CC=C1OCC(O)CN1CCC(OC=2C=CC(F)=CC=2)CC1 YBZLGBDIUOVESN-UHFFFAOYSA-N 0.000 description 1
- VBTPAYQPEMGVLO-UHFFFAOYSA-N 1-[7-[3-(8-chloro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)-2-hydroxypropoxy]indol-1-yl]ethanone Chemical compound N1C2=CC=C(Cl)C=C2C(C2)=C1CCN2CC(O)COC1=C2N(C(=O)C)C=CC2=CC=C1 VBTPAYQPEMGVLO-UHFFFAOYSA-N 0.000 description 1
- OUSMLSITTJKPNA-UHFFFAOYSA-N 1-[7-[3-(8-fluoro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)-2-hydroxypropoxy]indol-1-yl]ethanone Chemical compound N1C2=CC=C(F)C=C2C(C2)=C1CCN2CC(O)COC1=C2N(C(=O)C)C=CC2=CC=C1 OUSMLSITTJKPNA-UHFFFAOYSA-N 0.000 description 1
- IQBTTXKGEGYPOI-UHFFFAOYSA-N 1-[7-[3-[3-(3,4-dichlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]indol-1-yl]ethanone Chemical compound C=12N(C(=O)C)C=CC2=CC=CC=1OCC(O)CN(C1)CCC1OC1=CC=C(Cl)C(Cl)=C1 IQBTTXKGEGYPOI-UHFFFAOYSA-N 0.000 description 1
- UGWTUVHOFVFPOT-UHFFFAOYSA-N 1-[7-[3-[3-(3,4-difluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]indol-1-yl]ethanone Chemical compound C=12N(C(=O)C)C=CC2=CC=CC=1OCC(O)CN(C1)CCC1OC1=CC=C(F)C(F)=C1 UGWTUVHOFVFPOT-UHFFFAOYSA-N 0.000 description 1
- YMMQRIMRPSDHAG-UHFFFAOYSA-N 1-[7-[3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]indol-1-yl]ethanone Chemical compound C=12N(C(=O)C)C=CC2=CC=CC=1OCC(O)CN(CC1)CCC1OC1=CC=C(Cl)C(Cl)=C1 YMMQRIMRPSDHAG-UHFFFAOYSA-N 0.000 description 1
- QSSXJPIWXQTSIX-UHFFFAOYSA-N 1-bromo-2-methylbenzene Chemical compound CC1=CC=CC=C1Br QSSXJPIWXQTSIX-UHFFFAOYSA-N 0.000 description 1
- LNNXOEHOXSYWLD-UHFFFAOYSA-N 1-bromobut-2-yne Chemical compound CC#CCBr LNNXOEHOXSYWLD-UHFFFAOYSA-N 0.000 description 1
- LUBVCBITQHEVCJ-UHFFFAOYSA-N 1-trimethylsilylpyrrolidin-2-one Chemical compound C[Si](C)(C)N1CCCC1=O LUBVCBITQHEVCJ-UHFFFAOYSA-N 0.000 description 1
- WUEPMEXUMQVEGN-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;2,2,2-trifluoro-n-[2-[2-[(2,2,2-trifluoroacetyl)amino]ethylamino]ethyl]acetamide Chemical compound OC(=O)C(F)(F)F.FC(F)(F)C(=O)NCCNCCNC(=O)C(F)(F)F WUEPMEXUMQVEGN-UHFFFAOYSA-N 0.000 description 1
- PIPWSBOFSUJCCO-UHFFFAOYSA-N 2,2-dimethylpiperazine Chemical compound CC1(C)CNCCN1 PIPWSBOFSUJCCO-UHFFFAOYSA-N 0.000 description 1
- OYIDUDAFETVZLJ-UHFFFAOYSA-N 2-(ethoxymethoxy)-4-fluoro-1-nitrobenzene Chemical compound CCOCOC1=CC(F)=CC=C1[N+]([O-])=O OYIDUDAFETVZLJ-UHFFFAOYSA-N 0.000 description 1
- LIYLZRRAZDJBHQ-UHFFFAOYSA-N 2-[3-[3-(3,4-dichlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1OCC(O)CN1CC(OC=2C=C(Cl)C(Cl)=CC=2)CC1 LIYLZRRAZDJBHQ-UHFFFAOYSA-N 0.000 description 1
- AAQPRMBFQMBKCJ-UHFFFAOYSA-N 2-[3-[3-(3,4-difluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1OCC(O)CN1CC(OC=2C=C(F)C(F)=CC=2)CC1 AAQPRMBFQMBKCJ-UHFFFAOYSA-N 0.000 description 1
- VGEAKGVEESETKL-UHFFFAOYSA-N 2-[3-[3-(4-fluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1OCC(O)CN1CC(OC=2C=CC(F)=CC=2)CC1 VGEAKGVEESETKL-UHFFFAOYSA-N 0.000 description 1
- LZRQUVROKOYOKI-UHFFFAOYSA-N 2-[3-[3-[(4-chlorophenoxy)methyl]piperidin-1-yl]-2-hydroxypropoxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1OCC(O)CN1CC(COC=2C=CC(Cl)=CC=2)CCC1 LZRQUVROKOYOKI-UHFFFAOYSA-N 0.000 description 1
- RQGURKMXKITTSG-UHFFFAOYSA-N 2-[3-[3-[(4-fluorophenoxy)methyl]piperidin-1-yl]-2-hydroxypropoxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1OCC(O)CN1CC(COC=2C=CC(F)=CC=2)CCC1 RQGURKMXKITTSG-UHFFFAOYSA-N 0.000 description 1
- DNNXBZJPRXQNBZ-UHFFFAOYSA-N 2-[3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1OCC(O)CN1CCC(OC=2C=C(Cl)C(Cl)=CC=2)CC1 DNNXBZJPRXQNBZ-UHFFFAOYSA-N 0.000 description 1
- YZQFHSSAYSQXAV-UHFFFAOYSA-N 2-[3-[4-(3,4-difluorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1OCC(O)CN1CCC(OC=2C=C(F)C(F)=CC=2)CC1 YZQFHSSAYSQXAV-UHFFFAOYSA-N 0.000 description 1
- UTNIEDSXKGRYHT-UHFFFAOYSA-N 2-[[2-[3-[3-(4-cyanophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]benzoyl]amino]acetic acid Chemical compound C1CC(OC=2C=CC(=CC=2)C#N)CN1CC(O)COC1=CC=CC=C1C(=O)NCC(O)=O UTNIEDSXKGRYHT-UHFFFAOYSA-N 0.000 description 1
- SWFNPENEBHAHEB-UHFFFAOYSA-N 2-amino-4-chlorophenol Chemical compound NC1=CC(Cl)=CC=C1O SWFNPENEBHAHEB-UHFFFAOYSA-N 0.000 description 1
- 125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 description 1
- CGPYNUAPVFBCFD-UHFFFAOYSA-N 2-oxabicyclo[3.1.0]hexane Chemical compound C1COC2CC21 CGPYNUAPVFBCFD-UHFFFAOYSA-N 0.000 description 1
- CJWQGCUNKQPNBU-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]pyrrolidin-2-one Chemical compound C1=CC(Cl)=CC=C1CC1C(=O)NCC1 CJWQGCUNKQPNBU-UHFFFAOYSA-N 0.000 description 1
- DRCCEAKVCHKXQK-UHFFFAOYSA-N 3-[2-[3-[3-[(4-fluorophenoxy)methyl]piperidin-1-yl]-2-hydroxypropoxy]phenyl]propanoic acid Chemical compound C1CCC(COC=2C=CC(F)=CC=2)CN1CC(O)COC1=CC=CC=C1CCC(O)=O DRCCEAKVCHKXQK-UHFFFAOYSA-N 0.000 description 1
- GAWNBKUTBVLIPL-UHFFFAOYSA-N 3-fluoro-2-nitrophenol Chemical compound OC1=CC=CC(F)=C1[N+]([O-])=O GAWNBKUTBVLIPL-UHFFFAOYSA-N 0.000 description 1
- MMNKVWGVSHRIJL-UHFFFAOYSA-N 4'-hydroxy-3'-nitroacetophenone Chemical class CC(=O)C1=CC=C(O)C([N+]([O-])=O)=C1 MMNKVWGVSHRIJL-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NRMGSPWZPSIZJU-UHFFFAOYSA-N 4-[1-[2-hydroxy-3-(2-propanoylphenoxy)propyl]pyrrolidin-3-yl]oxybenzonitrile Chemical compound CCC(=O)C1=CC=CC=C1OCC(O)CN1CC(OC=2C=CC(=CC=2)C#N)CC1 NRMGSPWZPSIZJU-UHFFFAOYSA-N 0.000 description 1
- ZYZQSCWSPFLAFM-UHFFFAOYSA-N 4-amino-2-chlorophenol Chemical compound NC1=CC=C(O)C(Cl)=C1 ZYZQSCWSPFLAFM-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-BKLSDQPFSA-N 4-hydroxy-L-proline Chemical compound OC1C[NH2+][C@H](C([O-])=O)C1 PMMYEEVYMWASQN-BKLSDQPFSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- NQXUSSVLFOBRSE-UHFFFAOYSA-N 5-methyl-2-nitrophenol Chemical class CC1=CC=C([N+]([O-])=O)C(O)=C1 NQXUSSVLFOBRSE-UHFFFAOYSA-N 0.000 description 1
- 101800001401 Activation peptide Proteins 0.000 description 1
- 102400000069 Activation peptide Human genes 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100031092 C-C motif chemokine 3 Human genes 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 102100021984 C-C motif chemokine 4-like Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- ACEDTKJQGPESKT-UHFFFAOYSA-N C1(=CC=CC=C1)O.C(C)(=O)NC1=C(C=CC=C1O)[As](O)(O)=O Chemical compound C1(=CC=CC=C1)O.C(C)(=O)NC1=C(C=CC=C1O)[As](O)(O)=O ACEDTKJQGPESKT-UHFFFAOYSA-N 0.000 description 1
- YTJIFFULAFWWJV-UHFFFAOYSA-N C1CC(OC=2C=C(Cl)C(Cl)=CC=2)CCN1CC(O)COC1=CC=CC=C1CCC(O)=O Chemical compound C1CC(OC=2C=C(Cl)C(Cl)=CC=2)CCN1CC(O)COC1=CC=CC=C1CCC(O)=O YTJIFFULAFWWJV-UHFFFAOYSA-N 0.000 description 1
- FHZKTRMRUHAQFN-UHFFFAOYSA-N C1CC(OC=2C=C(F)C(F)=CC=2)CCN1CC(O)COC1=CC=CC=C1C(=O)NCC(O)=O Chemical compound C1CC(OC=2C=C(F)C(F)=CC=2)CCN1CC(O)COC1=CC=CC=C1C(=O)NCC(O)=O FHZKTRMRUHAQFN-UHFFFAOYSA-N 0.000 description 1
- BSEDBILQDNVYHR-UHFFFAOYSA-N C1CC(OC=2C=C(F)C(F)=CC=2)CCN1CC(O)COC1=CC=CC=C1CCC(O)=O Chemical compound C1CC(OC=2C=C(F)C(F)=CC=2)CCN1CC(O)COC1=CC=CC=C1CCC(O)=O BSEDBILQDNVYHR-UHFFFAOYSA-N 0.000 description 1
- GRUGLQSYEFNMPB-UHFFFAOYSA-N C1CC(OC=2C=CC(Cl)=CC=2)CCN1CC(O)COC1=CC=CC=C1C(=O)NCC(O)=O Chemical compound C1CC(OC=2C=CC(Cl)=CC=2)CCN1CC(O)COC1=CC=CC=C1C(=O)NCC(O)=O GRUGLQSYEFNMPB-UHFFFAOYSA-N 0.000 description 1
- HQWXJMNCXXCNOL-UHFFFAOYSA-N C1CC(OC=2C=CC(F)=CC=2)CCN1CC(O)COC1=CC=CC=C1C(=O)NCC(O)=O Chemical compound C1CC(OC=2C=CC(F)=CC=2)CCN1CC(O)COC1=CC=CC=C1C(=O)NCC(O)=O HQWXJMNCXXCNOL-UHFFFAOYSA-N 0.000 description 1
- RCWWGCFVSROGCH-UHFFFAOYSA-N C1CCC(COC=2C=CC(Cl)=CC=2)CN1CC(O)COC1=CC=CC=C1C(=O)NCC(O)=O Chemical compound C1CCC(COC=2C=CC(Cl)=CC=2)CN1CC(O)COC1=CC=CC=C1C(=O)NCC(O)=O RCWWGCFVSROGCH-UHFFFAOYSA-N 0.000 description 1
- XKNXNKYOEVZINI-UHFFFAOYSA-N C1CCC(COC=2C=CC(Cl)=CC=2)CN1CC(O)COC1=CC=CC=C1CCC(O)=O Chemical compound C1CCC(COC=2C=CC(Cl)=CC=2)CN1CC(O)COC1=CC=CC=C1CCC(O)=O XKNXNKYOEVZINI-UHFFFAOYSA-N 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- XIZATRTTYMTECC-UHFFFAOYSA-N CC=1C=CC(=C(OCOCC)C1)[N+](=O)[O-] Chemical compound CC=1C=CC(=C(OCOCC)C1)[N+](=O)[O-] XIZATRTTYMTECC-UHFFFAOYSA-N 0.000 description 1
- XZZNTUTXGPUSCH-VBIIVCKISA-N CC[C@@H](C1)N(CC(COC(C=CC=C2)=C2NC(C)=O)O)C[C@H]1OC(C=C1)=CC(Cl)=C1Cl Chemical compound CC[C@@H](C1)N(CC(COC(C=CC=C2)=C2NC(C)=O)O)C[C@H]1OC(C=C1)=CC(Cl)=C1Cl XZZNTUTXGPUSCH-VBIIVCKISA-N 0.000 description 1
- 108091008928 CXC chemokine receptors Proteins 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- ACBRDXYEZXNEIR-UHFFFAOYSA-N FC(C(=O)O)(F)F.C=N.C=N.C=N.C=N Chemical compound FC(C(=O)O)(F)F.C=N.C=N.C=N.C=N ACBRDXYEZXNEIR-UHFFFAOYSA-N 0.000 description 1
- 208000027445 Farmer Lung Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000009388 Job Syndrome Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 206010024227 Lepromatous leprosy Diseases 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010062164 Seronegative arthritis Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- WCTDKLDLPONEKN-UHFFFAOYSA-N [2-[3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]phenyl]urea Chemical compound NC(=O)NC1=CC=CC=C1OCC(O)CN1CC(OC=2C=CC(Cl)=CC=2)CC1 WCTDKLDLPONEKN-UHFFFAOYSA-N 0.000 description 1
- YHYBMYFOAAUSRR-UHFFFAOYSA-N [C].[Pt]=O Chemical compound [C].[Pt]=O YHYBMYFOAAUSRR-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical class 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- CELPHAGZKFMOMR-UHFFFAOYSA-N azanium;dichloromethane;methanol;hydroxide Chemical compound [NH4+].[OH-].OC.ClCCl CELPHAGZKFMOMR-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- AJSHDAOMUKXVDC-UHFFFAOYSA-N butan-1-amine;sulfuric acid Chemical compound CCCC[NH3+].OS([O-])(=O)=O AJSHDAOMUKXVDC-UHFFFAOYSA-N 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- PSBABBDEUFNFKJ-UHFFFAOYSA-N cyclopent-2-en-1-ol Chemical compound OC1CCC=C1 PSBABBDEUFNFKJ-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- XNMQEEKYCVKGBD-UHFFFAOYSA-N dimethylacetylene Natural products CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 208000022195 farmer lung disease Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000003350 kerosene Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- GQEDFZBZDWBFIH-QWRGUYRKSA-N methyl (2s,4s)-4-(4-chlorophenoxy)pyrrolidine-2-carboxylate Chemical class C1N[C@H](C(=O)OC)C[C@@H]1OC1=CC=C(Cl)C=C1 GQEDFZBZDWBFIH-QWRGUYRKSA-N 0.000 description 1
- RNFUHDBUTFMERX-UHFFFAOYSA-N methyl 2-[(2-hydroxybenzoyl)amino]-2-methylpropanoate Chemical class COC(=O)C(C)(C)NC(=O)C1=CC=CC=C1O RNFUHDBUTFMERX-UHFFFAOYSA-N 0.000 description 1
- ITTHNWIVJRLOLO-UHFFFAOYSA-N methyl 2-[[2-[3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]benzoyl]amino]-2-methylpropanoate Chemical compound COC(=O)C(C)(C)NC(=O)C1=CC=CC=C1OCC(O)CN1CC(OC=2C=CC(Cl)=CC=2)CC1 ITTHNWIVJRLOLO-UHFFFAOYSA-N 0.000 description 1
- SJHKDUFERPKWDB-UHFFFAOYSA-N methyl 2-[[2-[3-[3-(4-fluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]benzoyl]amino]-2-methylpropanoate Chemical compound COC(=O)C(C)(C)NC(=O)C1=CC=CC=C1OCC(O)CN1CC(OC=2C=CC(F)=CC=2)CC1 SJHKDUFERPKWDB-UHFFFAOYSA-N 0.000 description 1
- PKOSZUPRPIRFIF-UHFFFAOYSA-N methyl 3-[2-[3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]phenyl]propanoate Chemical class COC(=O)CCC1=CC=CC=C1OCC(O)CN1CC(OC=2C=CC(Cl)=CC=2)CC1 PKOSZUPRPIRFIF-UHFFFAOYSA-N 0.000 description 1
- MRVWUOPLHITFDN-UHFFFAOYSA-N methyl 3-[2-[3-[3-(4-fluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]phenyl]propanoate Chemical class COC(=O)CCC1=CC=CC=C1OCC(O)CN1CC(OC=2C=CC(F)=CC=2)CC1 MRVWUOPLHITFDN-UHFFFAOYSA-N 0.000 description 1
- CWDJLXQIDVZQDR-UHFFFAOYSA-N methyl 3-[2-[3-[4-(4-chlorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]phenyl]propanoate Chemical class COC(=O)CCC1=CC=CC=C1OCC(O)CN1CCC(OC=2C=CC(Cl)=CC=2)CC1 CWDJLXQIDVZQDR-UHFFFAOYSA-N 0.000 description 1
- YZVNDBXUNUQOLW-UHFFFAOYSA-N methyl 3-[2-[3-[4-(4-fluorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]phenyl]propanoate Chemical class COC(=O)CCC1=CC=CC=C1OCC(O)CN1CCC(OC=2C=CC(F)=CC=2)CC1 YZVNDBXUNUQOLW-UHFFFAOYSA-N 0.000 description 1
- GQEDFZBZDWBFIH-UHFFFAOYSA-N methyl 4-(4-chlorophenoxy)pyrrolidine-2-carboxylate Chemical class C1NC(C(=O)OC)CC1OC1=CC=C(Cl)C=C1 GQEDFZBZDWBFIH-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- KCOHNRMFXQLTCW-UHFFFAOYSA-N n-(4-chlorophenyl)piperidin-4-amine Chemical compound C1=CC(Cl)=CC=C1NC1CCNCC1 KCOHNRMFXQLTCW-UHFFFAOYSA-N 0.000 description 1
- ZSYRYBOMHWXRDF-UHFFFAOYSA-N n-(4-fluorophenyl)piperidin-4-amine Chemical compound C1=CC(F)=CC=C1NC1CCNCC1 ZSYRYBOMHWXRDF-UHFFFAOYSA-N 0.000 description 1
- GXAIOAIGWKRNIF-UHFFFAOYSA-N n-(5-acetyl-2-hydroxyphenyl)acetamide Chemical compound CC(=O)NC1=CC(C(C)=O)=CC=C1O GXAIOAIGWKRNIF-UHFFFAOYSA-N 0.000 description 1
- NZRCPNJOFMGJPO-UHFFFAOYSA-N n-[2-[2-hydroxy-3-[3-(4-methoxyphenoxy)pyrrolidin-1-yl]propoxy]phenyl]acetamide Chemical compound C1=CC(OC)=CC=C1OC1CN(CC(O)COC=2C(=CC=CC=2)NC(C)=O)CC1 NZRCPNJOFMGJPO-UHFFFAOYSA-N 0.000 description 1
- OLUIFDUXSFCMFP-UHFFFAOYSA-N n-[2-[3-(8-chloro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)-2-hydroxypropoxy]-4-fluorophenyl]acetamide Chemical compound CC(=O)NC1=CC=C(F)C=C1OCC(O)CN1CC(C2=CC(Cl)=CC=C2N2)=C2CC1 OLUIFDUXSFCMFP-UHFFFAOYSA-N 0.000 description 1
- NQXKGNVOZPLZFD-UHFFFAOYSA-N n-[2-[3-(8-chloro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)-2-hydroxypropoxy]-4-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC=C(C)C=C1OCC(O)CN1CC(C2=CC(Cl)=CC=C2N2)=C2CC1 NQXKGNVOZPLZFD-UHFFFAOYSA-N 0.000 description 1
- HJXTUHFNJFGPKW-UHFFFAOYSA-N n-[2-[3-(8-chloro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)-2-hydroxypropoxy]-5-fluorophenyl]acetamide Chemical compound CC(=O)NC1=CC(F)=CC=C1OCC(O)CN1CC(C2=CC(Cl)=CC=C2N2)=C2CC1 HJXTUHFNJFGPKW-UHFFFAOYSA-N 0.000 description 1
- SGWYUMVCYDJSDQ-UHFFFAOYSA-N n-[2-[3-(8-chloro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)-2-hydroxypropoxy]-5-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C)=CC=C1OCC(O)CN1CC(C2=CC(Cl)=CC=C2N2)=C2CC1 SGWYUMVCYDJSDQ-UHFFFAOYSA-N 0.000 description 1
- SOMAAHQRBOTAQC-UHFFFAOYSA-N n-[2-[3-(8-chloro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)-2-hydroxypropoxy]-5-phenylphenyl]acetamide Chemical compound C=1C=C(OCC(O)CN2CC=3C4=CC(Cl)=CC=C4NC=3CC2)C(NC(=O)C)=CC=1C1=CC=CC=C1 SOMAAHQRBOTAQC-UHFFFAOYSA-N 0.000 description 1
- QNSCIKGEWXTILN-UHFFFAOYSA-N n-[2-[3-(8-chloro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(O)CN1CC(C2=CC(Cl)=CC=C2N2)=C2CC1 QNSCIKGEWXTILN-UHFFFAOYSA-N 0.000 description 1
- JQSHSKZXGCZOMY-UHFFFAOYSA-N n-[2-[3-(8-fluoro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)-2-hydroxypropoxy]-4-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC=C(C)C=C1OCC(O)CN1CC(C2=CC(F)=CC=C2N2)=C2CC1 JQSHSKZXGCZOMY-UHFFFAOYSA-N 0.000 description 1
- QPDTUPDMJYQGEV-UHFFFAOYSA-N n-[2-[3-(8-fluoro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)-2-hydroxypropoxy]-5-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C)=CC=C1OCC(O)CN1CC(C2=CC(F)=CC=C2N2)=C2CC1 QPDTUPDMJYQGEV-UHFFFAOYSA-N 0.000 description 1
- SMBABFGRRDRQJL-UHFFFAOYSA-N n-[2-[3-(8-fluoro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)-2-hydroxypropoxy]-5-phenylphenyl]acetamide Chemical compound C=1C=C(OCC(O)CN2CC=3C4=CC(F)=CC=C4NC=3CC2)C(NC(=O)C)=CC=1C1=CC=CC=C1 SMBABFGRRDRQJL-UHFFFAOYSA-N 0.000 description 1
- OOKLHYPTMVSBRZ-UHFFFAOYSA-N n-[2-[3-(8-fluoro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(O)CN1CC(C2=CC(F)=CC=C2N2)=C2CC1 OOKLHYPTMVSBRZ-UHFFFAOYSA-N 0.000 description 1
- NOMLLELOQYXVIH-UHFFFAOYSA-N n-[2-[3-[3-(3,4-dichlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-5-phenylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C=2C=CC=CC=2)=CC=C1OCC(O)CN(C1)CCC1OC1=CC=C(Cl)C(Cl)=C1 NOMLLELOQYXVIH-UHFFFAOYSA-N 0.000 description 1
- HGNIDALZAVHSJF-UHFFFAOYSA-N n-[2-[3-[3-(3,4-dichlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(O)CN1CC(OC=2C=C(Cl)C(Cl)=CC=2)CC1 HGNIDALZAVHSJF-UHFFFAOYSA-N 0.000 description 1
- RHZAIGHQGUAMFQ-UHFFFAOYSA-N n-[2-[3-[3-(3,4-difluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-5-phenylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C=2C=CC=CC=2)=CC=C1OCC(O)CN(C1)CCC1OC1=CC=C(F)C(F)=C1 RHZAIGHQGUAMFQ-UHFFFAOYSA-N 0.000 description 1
- JLHMXBQSWSTPPQ-UHFFFAOYSA-N n-[2-[3-[3-(3,4-difluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(O)CN1CC(OC=2C=C(F)C(F)=CC=2)CC1 JLHMXBQSWSTPPQ-UHFFFAOYSA-N 0.000 description 1
- ZCGQELYDYMAKCP-UHFFFAOYSA-N n-[2-[3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-4-fluorophenyl]acetamide Chemical compound CC(=O)NC1=CC=C(F)C=C1OCC(O)CN1CC(OC=2C=CC(Cl)=CC=2)CC1 ZCGQELYDYMAKCP-UHFFFAOYSA-N 0.000 description 1
- DPXZHWBZPVPZCR-UHFFFAOYSA-N n-[2-[3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-4-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC=C(C)C=C1OCC(O)CN1CC(OC=2C=CC(Cl)=CC=2)CC1 DPXZHWBZPVPZCR-UHFFFAOYSA-N 0.000 description 1
- UZXJHDGHJOEFPO-UHFFFAOYSA-N n-[2-[3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-5-cyanophenyl]acetamide Chemical compound CC(=O)NC1=CC(C#N)=CC=C1OCC(O)CN1CC(OC=2C=CC(Cl)=CC=2)CC1 UZXJHDGHJOEFPO-UHFFFAOYSA-N 0.000 description 1
- GWTPBGQICZEEFZ-UHFFFAOYSA-N n-[2-[3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-5-fluorophenyl]acetamide Chemical compound CC(=O)NC1=CC(F)=CC=C1OCC(O)CN1CC(OC=2C=CC(Cl)=CC=2)CC1 GWTPBGQICZEEFZ-UHFFFAOYSA-N 0.000 description 1
- ZGYCCYGURVETKP-UHFFFAOYSA-N n-[2-[3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-5-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C)=CC=C1OCC(O)CN1CC(OC=2C=CC(Cl)=CC=2)CC1 ZGYCCYGURVETKP-UHFFFAOYSA-N 0.000 description 1
- GZCCMXPBRGPJCF-UHFFFAOYSA-N n-[2-[3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-5-phenylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C=2C=CC=CC=2)=CC=C1OCC(O)CN(C1)CCC1OC1=CC=C(Cl)C=C1 GZCCMXPBRGPJCF-UHFFFAOYSA-N 0.000 description 1
- JZJGLRRCNWYFCK-UHFFFAOYSA-N n-[2-[3-[3-(4-fluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-4-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC=C(C)C=C1OCC(O)CN1CC(OC=2C=CC(F)=CC=2)CC1 JZJGLRRCNWYFCK-UHFFFAOYSA-N 0.000 description 1
- FREBHOAWPILZSJ-UHFFFAOYSA-N n-[2-[3-[3-(4-fluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-5-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C)=CC=C1OCC(O)CN1CC(OC=2C=CC(F)=CC=2)CC1 FREBHOAWPILZSJ-UHFFFAOYSA-N 0.000 description 1
- JQEXRSJLIKDALP-UHFFFAOYSA-N n-[2-[3-[3-(4-fluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-5-phenylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C=2C=CC=CC=2)=CC=C1OCC(O)CN(C1)CCC1OC1=CC=C(F)C=C1 JQEXRSJLIKDALP-UHFFFAOYSA-N 0.000 description 1
- VYOTVKBILABBCP-UHFFFAOYSA-N n-[2-[3-[3-[(3,4-difluorophenoxy)methyl]piperidin-1-yl]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(O)CN1CC(COC=2C=C(F)C(F)=CC=2)CCC1 VYOTVKBILABBCP-UHFFFAOYSA-N 0.000 description 1
- QOLYCTATAJACKM-UHFFFAOYSA-N n-[2-[3-[4-(3,4-dichloroanilino)piperidin-1-yl]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(O)CN1CCC(NC=2C=C(Cl)C(Cl)=CC=2)CC1 QOLYCTATAJACKM-UHFFFAOYSA-N 0.000 description 1
- ACFXKJABHQBAHQ-UHFFFAOYSA-N n-[2-[3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]-4-fluorophenyl]acetamide Chemical compound CC(=O)NC1=CC=C(F)C=C1OCC(O)CN1CCC(OC=2C=C(Cl)C(Cl)=CC=2)CC1 ACFXKJABHQBAHQ-UHFFFAOYSA-N 0.000 description 1
- KBLGAWULZUADJW-UHFFFAOYSA-N n-[2-[3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]-5-(trifluoromethyl)phenyl]acetamide Chemical compound CC(=O)NC1=CC(C(F)(F)F)=CC=C1OCC(O)CN1CCC(OC=2C=C(Cl)C(Cl)=CC=2)CC1 KBLGAWULZUADJW-UHFFFAOYSA-N 0.000 description 1
- CLMSZCUTOQFSJS-UHFFFAOYSA-N n-[2-[3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]-5-fluorophenyl]acetamide Chemical compound CC(=O)NC1=CC(F)=CC=C1OCC(O)CN1CCC(OC=2C=C(Cl)C(Cl)=CC=2)CC1 CLMSZCUTOQFSJS-UHFFFAOYSA-N 0.000 description 1
- HJNQNRLZXHRIFJ-UHFFFAOYSA-N n-[2-[3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]-5-phenylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C=2C=CC=CC=2)=CC=C1OCC(O)CN(CC1)CCC1OC1=CC=C(Cl)C(Cl)=C1 HJNQNRLZXHRIFJ-UHFFFAOYSA-N 0.000 description 1
- MOIFLEQNMCZVFV-UHFFFAOYSA-N n-[2-[3-[4-(4-chloroanilino)piperidin-1-yl]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(O)CN1CCC(NC=2C=CC(Cl)=CC=2)CC1 MOIFLEQNMCZVFV-UHFFFAOYSA-N 0.000 description 1
- KHBUVDGWAHKZBC-UHFFFAOYSA-N n-[2-[3-[4-(4-chlorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]-4-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC=C(C)C=C1OCC(O)CN1CCC(OC=2C=CC(Cl)=CC=2)CC1 KHBUVDGWAHKZBC-UHFFFAOYSA-N 0.000 description 1
- PUIKOTNZTNASDA-UHFFFAOYSA-N n-[2-[3-[4-(4-chlorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]-5-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C)=CC=C1OCC(O)CN1CCC(OC=2C=CC(Cl)=CC=2)CC1 PUIKOTNZTNASDA-UHFFFAOYSA-N 0.000 description 1
- IKKKQDKSODKSOV-UHFFFAOYSA-N n-[2-[3-[4-(4-chlorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(O)CN1CCC(OC=2C=CC(Cl)=CC=2)CC1 IKKKQDKSODKSOV-UHFFFAOYSA-N 0.000 description 1
- QKSZJGLFGVYVOX-UHFFFAOYSA-N n-[2-[3-[4-(4-fluorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(O)CN1CCC(OC=2C=CC(F)=CC=2)CC1 QKSZJGLFGVYVOX-UHFFFAOYSA-N 0.000 description 1
- MZDRHDBZCFEEPZ-UHFFFAOYSA-N n-[3-acetyl-2-[3-(8-chloro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)-2-hydroxypropoxy]-5-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C)=CC(C(C)=O)=C1OCC(O)CN1CC(C2=CC(Cl)=CC=C2N2)=C2CC1 MZDRHDBZCFEEPZ-UHFFFAOYSA-N 0.000 description 1
- QFSWFKDEDIARGH-UHFFFAOYSA-N n-[3-acetyl-2-[3-(8-fluoro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)-2-hydroxypropoxy]-5-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C)=CC(C(C)=O)=C1OCC(O)CN1CC(C2=CC(F)=CC=C2N2)=C2CC1 QFSWFKDEDIARGH-UHFFFAOYSA-N 0.000 description 1
- SZHXVARCWXKSAS-UHFFFAOYSA-N n-[3-acetyl-2-[3-[3-(3,4-dichlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-5-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C)=CC(C(C)=O)=C1OCC(O)CN1CC(OC=2C=C(Cl)C(Cl)=CC=2)CC1 SZHXVARCWXKSAS-UHFFFAOYSA-N 0.000 description 1
- XMSISDWMWSMQFH-UHFFFAOYSA-N n-[3-acetyl-2-[3-[3-(3,4-difluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-5-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C)=CC(C(C)=O)=C1OCC(O)CN1CC(OC=2C=C(F)C(F)=CC=2)CC1 XMSISDWMWSMQFH-UHFFFAOYSA-N 0.000 description 1
- KMOOKMKWXJKGOV-UHFFFAOYSA-N n-[3-acetyl-2-[3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-5-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C)=CC(C(C)=O)=C1OCC(O)CN1CC(OC=2C=CC(Cl)=CC=2)CC1 KMOOKMKWXJKGOV-UHFFFAOYSA-N 0.000 description 1
- VWHUXRFAAKDQJN-UHFFFAOYSA-N n-[3-acetyl-2-[3-[3-(4-fluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]-5-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C)=CC(C(C)=O)=C1OCC(O)CN1CC(OC=2C=CC(F)=CC=2)CC1 VWHUXRFAAKDQJN-UHFFFAOYSA-N 0.000 description 1
- PCBCCTTVHBYTOS-UHFFFAOYSA-N n-[3-acetyl-2-[3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]-5-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C)=CC(C(C)=O)=C1OCC(O)CN1CCC(OC=2C=C(Cl)C(Cl)=CC=2)CC1 PCBCCTTVHBYTOS-UHFFFAOYSA-N 0.000 description 1
- YVITYRDMYGRNNV-UHFFFAOYSA-N n-[4-[1-[3-(2-acetamidophenoxy)-2-hydroxypropyl]piperidin-4-yl]oxyphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1OC1CCN(CC(O)COC=2C(=CC=CC=2)NC(C)=O)CC1 YVITYRDMYGRNNV-UHFFFAOYSA-N 0.000 description 1
- DLQCCFVENFUHSQ-UHFFFAOYSA-N n-[4-[1-[3-(2-acetylphenoxy)-2-hydroxypropyl]piperidin-4-yl]oxyphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1OC1CCN(CC(O)COC=2C(=CC=CC=2)C(C)=O)CC1 DLQCCFVENFUHSQ-UHFFFAOYSA-N 0.000 description 1
- ABBYBQMCWKEBOY-UHFFFAOYSA-N n-[4-fluoro-2-[3-[3-(4-fluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=C(F)C=C1OCC(O)CN1CC(OC=2C=CC(F)=CC=2)CC1 ABBYBQMCWKEBOY-UHFFFAOYSA-N 0.000 description 1
- DVOIXUGUFFVFAO-UHFFFAOYSA-N n-[5-acetyl-2-[3-[3-(3,4-dichlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC(C(C)=O)=CC=C1OCC(O)CN1CC(OC=2C=C(Cl)C(Cl)=CC=2)CC1 DVOIXUGUFFVFAO-UHFFFAOYSA-N 0.000 description 1
- XVWKFDLTGXGYKL-UHFFFAOYSA-N n-[5-chloro-2-[3-[3-(4-chlorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC(Cl)=CC=C1OCC(O)CN1CC(OC=2C=CC(Cl)=CC=2)CC1 XVWKFDLTGXGYKL-UHFFFAOYSA-N 0.000 description 1
- MFDCXLFWYSMGDK-UHFFFAOYSA-N n-[5-chloro-2-[3-[3-(4-fluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC(Cl)=CC=C1OCC(O)CN1CC(OC=2C=CC(F)=CC=2)CC1 MFDCXLFWYSMGDK-UHFFFAOYSA-N 0.000 description 1
- MKUVOPOIFBWBAN-UHFFFAOYSA-N n-[5-chloro-2-[3-[3-(4-fluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]phenyl]acetamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC(=O)NC1=CC(Cl)=CC=C1OCC(O)CN1CC(OC=2C=CC(F)=CC=2)CC1 MKUVOPOIFBWBAN-UHFFFAOYSA-N 0.000 description 1
- QVWXUKKRUNDKKY-UHFFFAOYSA-N n-[5-chloro-2-[3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC(Cl)=CC=C1OCC(O)CN1CCC(OC=2C=C(Cl)C(Cl)=CC=2)CC1 QVWXUKKRUNDKKY-UHFFFAOYSA-N 0.000 description 1
- AEYWAHVKINRSCJ-UHFFFAOYSA-N n-[5-fluoro-2-[3-[3-(4-fluorophenoxy)pyrrolidin-1-yl]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC(F)=CC=C1OCC(O)CN1CC(OC=2C=CC(F)=CC=2)CC1 AEYWAHVKINRSCJ-UHFFFAOYSA-N 0.000 description 1
- KUDPGZONDFORKU-UHFFFAOYSA-N n-chloroaniline Chemical compound ClNC1=CC=CC=C1 KUDPGZONDFORKU-UHFFFAOYSA-N 0.000 description 1
- MGNPLIACIXIYJE-UHFFFAOYSA-N n-fluoroaniline Chemical compound FNC1=CC=CC=C1 MGNPLIACIXIYJE-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229910001392 phosphorus oxide Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical class [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KWYICLWTBWQGST-JSGCOSHPSA-N tert-butyl (2s,4s)-4-(4-chlorophenoxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound C1[C@@H](CO)N(C(=O)OC(C)(C)C)C[C@H]1OC1=CC=C(Cl)C=C1 KWYICLWTBWQGST-JSGCOSHPSA-N 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- VSAISIQCTGDGPU-UHFFFAOYSA-N tetraphosphorus hexaoxide Chemical compound O1P(O2)OP3OP1OP2O3 VSAISIQCTGDGPU-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- YDJXDYKQMRNUSA-UHFFFAOYSA-N tri(propan-2-yl)silane Chemical compound CC(C)[SiH](C(C)C)C(C)C YDJXDYKQMRNUSA-UHFFFAOYSA-N 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 201000005539 vernal conjunctivitis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
Abstract
本发明提供通式(I)的化合物、其制备方法、含有它们的药用组合物及其治疗用途,其中Q、R、R2、R4,R5、R6、R7和R8按本说明书中定义。
Description
本发明涉及新的化合物、其制备方法、含有它们的药用组合物及其治疗用途。
US 5789402描述了某些据称可用于治疗如下疾病的吲哚衍生物,这些疾病由神经系统影响的5-羟色胺的紊乱引起或受此影响,特别是那些与5-羟色胺1A受体有关的疾病以及与5-羟色胺吸收有关的疾病。
在各种疾病和紊乱(包括哮喘和过敏性疾病),以及自身免疫疾病(如类风湿性关节炎和动脉粥样硬化)的免疫和炎症反应中,趋化因子起着重要作用。这些小的分泌性分子是一种特征为保守的四个半胱氨酸基元的8-14kDa蛋白质的生长超家族。可将这种趋化因子超家族分为呈现特征结构基元的主要两组,即Cys-X-Cys(C-X-C)和Cys-Cys(C-C)族。它们区别在于在半胱氨酸残基和类似的序列的NH-近侧对之间插入单个氨基酸。
C-X-C趋化因子包括几种有效的化学引诱物和嗜中性白细胞激活剂,如白细胞介素-8(IL-8)和嗜中性白细胞活化肽2(NAP-2)。
C-C趋化因子包括有效的单核细胞和淋巴细胞(但不包括嗜中性白细胞)的化学引诱物,如人体单核细胞趋化蛋白1-3(MCP-1、MCP-2和MCP-3)、RANTES(调节激活、正常T细胞的表达和分泌)、eotaxin和巨噬细胞炎性蛋白1α和1β(MIP-1α和MIP-1β)。
研究表明:趋化因子的作用由G-蛋白偶联受体的亚族介导,其中将这些受体表示为CCR1、CCR2、CCR2A、CCR2B、CCR3、CCR4、CCR5、CCR6、CCR7、CCR8、CCR9、CCR10、CXCR1、CXCR2、CXCR3和CXCR4。由于调节这些受体的药物可用于治疗如前提到的那些紊乱和疾病,所以这些受体代表药物研制的好的靶向。
因此本发明提供一种通式(I)化合物或其药学上可接受的盐或溶剂化物:
其中:
R或者代表基团:
或者代表基团:
m是0、1、2或3;
R1各自独立代表卤素、氰基、硝基、羧基、羟基、C3-6环烷基、C1-C6烷氧基、C1-C6烷氧基羰基、C1-C6卤代烷基、C1-C6卤代烷氧基、-NR9R10、C3-C6环烷基氨基、C1-C6烷硫基、C1-C6烷基羰基、C1-C6烷基羰基氨基、磺酰氨基(-SO2NH2)、C1-C6烷基磺酰基、-C(O)NR11R12、-NR13C(O)-(NH)PR14、苯基或者任选被羧基或C1-C6烷氧基羰基取代的C1-C6烷基;
p是0或1;
X代表氧或硫原子或者CH2、CH(CH3)、OCH2、CH2O、CH2NH、NH或羰基,Y代表氮原子或者CH或C(OH)基团,条件是当X代表氧或硫原子或者CH2O、CH2NH或NH时,Y代表CH;
Z1代表键或者基团(CH2)q,其中q是1或2;
Z2代表键或者基团CH2,条件是Z1和Z2不同时代表键;
Q代表氧或硫原子或者CH2或NH;
R2代表以下基团: 或
n是0、1或2;
R3各自独立代表C1-C6烷基、C1-C6烷氧基羰基、-CH2OH或羧基;
R4、R5、R6和R7各自独立代表氢原子或C1-C6烷基,或者R4、R5、R6和R7一起代表C1-C4亚烷基链,并连接与其相连的两个碳原子形成4-至7-元饱和碳环,或者R5、R6和R7各自代表氢原子而R4和R8同与其相连的碳原子一起形成5-至6-元饱和碳环;
R8代表氢原子、C1-C6烷基,或者按如上说明与R4相连;
R9和R10各自独立代表氢原子或C1-C6烷基,或者R9和R10同与其相连的氮原子一起形成4-至7-元饱和杂环;
R11和R12各自独立代表氢原子或者任选被C1-C6烷氧基羰基取代的C1-C6烷基;
R13代表氢原子或者C1-C6烷基;
R14代表氢原子或者任选被羧基、C1-C6烷氧基或C1-C6烷氧基羰基取代的C1-C6烷基;
R15代表羧基、C1-C6烷基羰基、C1-C6烷氧基羰基、C1-C6烷氧基羰基C1-C6烷基或者基团-NR17R18、-NHSO2CH3、-NHC(O)CH3、-C(O)NR17R18、-NHC(O)NR17R18、-OC(O)NR17R18、-OCH2C(C)NR17R18、-NHC(O)OR17’或者-OR17”;
t是0、1、2或3;
R16各自独立代表卤素、氰基、硝基、羧基、羟基、C3-C6环烷基、C1-C6烷氧基、C1-C6烷氧基羰基、C1-C6卤代烷基、C1-C6卤代烷氧基、-NR19R20、C3-C6环烷基氨基、C1-C6烷硫基、C1-C6烷基羰基、C1-C6烷基羰基氨基、磺酰氨基(-SO2NH2)、C1-C6烷基磺酰基、-C(O)NR21R22、-NR23C(O)(NH)vR24、苯基或者任选被羧基或C1-C6烷氧基羰基取代的C1-C6烷基;
R17和R18各自独立代表(i)氢原子,(ii)可含有至少一个选自氮、氧和硫杂原子的5-至6-元饱和或不饱和环,该环可任选被至少一个选自卤素、甲基和三氟甲基的取代基取代,或者(iii)可任选被至少一个选自卤素、三氟甲基、羧基、C1-C6烷氧基羰基和5-至6-元饱和或不饱和环的取代基取代的C1-C6烷基,所述5-至6-元饱和或不饱和环含有至少一个选自氮、氧和硫的杂原子,并可任选被至少一个选自卤素、甲基和三氟甲基的取代基取代,或者
R17和R18同与其相连的氮原子一起形成4-至7-元饱和杂环;
R17’代表氢原子或者任选被羧基或C1-C6烷氧基羰基取代的C1-C6烷基;
R17”定义同上述R17,但R17”不代表氢原子;
R19和20各自独立代表氢原子或C1-C6烷基,或者R19和R20同与其相连的氮原子一起形成4-至7-元饱和杂环;
R21和R22各自独立代表氢原子或者任选被C1-C6烷氧基羰基取代的C1-C6烷基;
v是0或1;
R23代表氢原子或者C1-C6烷基;
R24代表氢原子或者任选被羧基、C1-C6烷氧基或C1-C6烷氧基羰基取代的C1-C6烷基;
条件是当X是氧原子或者基团CH2,Y是CH,Z1和Z2各自代表基团CH2,并且Q是氧原子时,R2不是未取代的吲哚基。
在本说明书的内容中,烷基取代基或取代基中的烷基部分可以是直链或支链。
另一方面,本发明提供一种通式(I’)化合物或其药学上可接受的盐或溶剂化物:
其中:
m是0、1、2或3;
R1各自独立代表卤素、氰基、硝基、羧基、羟基、C3-C6环烷基、C1-C6烷氧基、C1-C6烷氧基羰基、C1-C6卤代烷基、C1-C6卤代烷氧基、-NR9R10、C3-C6环烷基氨基、C1-C6烷硫基、C1-C6烷基羰基、C1-C6烷基羰基氨基、磺酰氨基、C1-C6烷基磺酰基、-C(O)NR11R12、-NR13C(O)-(NH)PR14、苯基或者任选被羧基或C1-C6烷氧基羰基取代的C1-C6烷基;
p是0或1;
X代表氧或硫原子或者CH2、CH(CH3)、OCH2、CH2O、CH2NH、NH或者羰基,Y代表氮原子或者CH或C(OH)基团,条件是当X代表氧或硫原子或者CH2O、CH2NH或NH基团时,Y代表CH基团;
Z1代表键或者基团(CH2)q,其中q是1或2;
Z2代表键或者基团CH2,条件是Z1和Z2不同时代表键;
Q代表氧或硫原子或者基团CH2或NH;
R2代表以下基团:
n是0、1或2;
R3各自独立代表C1-C6烷基、C1-C6烷氧基羰基、-CH2OH或羧基;
R4、R5、R6和R7各自独立代表氢原子或者C1-C6烷基,或者R4、R5、R6和R7一起代表C1-C4亚烷基链,并连接与其相连的两个碳原子形成4-至7-元饱和碳环,或者R5、R6和R7各自代表氢原子而R4和R8同与其相连的碳原子一起形成5-至6-元饱和碳环;
R8代表氢原子、C1-C6烷基,或者按如上说明与R4相连;
R9和R10各自独立代表氢原子或者C1-C6烷基,或者R9和R10同与其相连的氮原子一起形成4-至7-元饱和杂环;
R11和R12各自独立代表氢原子或者任选被C1-C6烷氧基羰基取代的C1-C6烷基;
R13代表氢原子或者C1-C6烷基;
R14代表氢原子或者任选被羧基、C1-C6烷氧基或C1-C6烷氧基羰基取代的C1-C6烷基;
R15代表羧基、C1-C6烷基羰基、C1-C6烷氧基羰基、C1-C6烷氧基羰基C1-C6烷基或者基团-NR17R18、-NHSO2CH3、-NHC(O)CH3、-C(O)NR17R18、-NHC(O)NR17R18、-OC(O)NR17R18、-OCH2C(O)NR17R18、-NHC(O)OR17’或者-OR17”;
t是0、1、2或3;
R16各自独立代表卤素、氰基、硝基、羧基、羟基、C3-C6环烷基、C1-C6烷氧基、C1-C6烷氧基羰基、C1-C6卤代烷基、C1-C6卤代烷氧基、-NR19R20、C3-C6环烷基氨基、C1-C6烷硫基、C1-C6烷基羰基、C1-C6烷基羰基氨基、磺酰氨基(-SO2NH2)、C1-C6烷基磺酰基、-C(O)NR21R22、-NR23C(O)(NH)vR24、苯基或者任选被羧基或C1-C6烷氧基羰基取代的C1-C6烷基;
R17和R18各自独立代表(i)氢原子,(ii)可含有至少一个选自氮、氧和硫杂原子的5-至6-元饱和或不饱和环,该环可任选被至少一个选自卤素、甲基和三氟甲基的取代基取代,或者(iii)可任选被至少一个选自卤素、三氟甲基、羧基、C1-C6烷氧基羰基和5-至6-元饱和或不饱和环的取代基取代的C1-C6烷基,所述5-至6-元饱和或不饱和环含有至少一个选自氮、氧和硫的杂原子,并可任选被至少一个选自卤素、甲基和三氟甲基的取代基取代,或者
R17和R18同与其相连的氮原子一起形成4-至7-元饱和杂环;
R17’代表氢原子或者任选被羧基或C1-C6烷氧基羰基取代的C1-C6烷基;
R17”定义同上述R17,但R17”不代表氢原子;
R19和R20各自独立代表氢原子或C1-C6烷基,或者R19和R20同与其相连的氮原子一起形成4-至7-元饱和杂环;
R21和R22各自独立代表氢原子或者任选被C1-C6烷氧基羰基取代的C1-C6烷基;
v是0或1;
R23代表氢原子或者C1-C6烷基;
R24代表氢原子或者任选被羧基、C1-C6烷氧基或C1-C6烷氧基羰基取代的C1-C6烷基。
另一方面,本发明提供一种通式(I”)化合物或其药学上可接受的盐或溶剂化物:其中:
m是0、1、2或3;
R1各自独立代表卤素、氰基、硝基、羧基、羟基、C3-C6环烷基、
C1-C6烷氧基、C1-C6烷氧基羰基、C1-C6卤代烷基、C1-C6卤代烷氧基、-NR9R10、C3-C6环烷基氨基、C1-C6烷硫基、C1-C6烷基羰基、C1-C6烷基羰基氨基、磺酰氨基、C1-C6烷基磺酰基、-C(O)NR11R12、-NR13C(O)-(NH)PR14、苯基或者任选被羧基或C1-C6烷氧基羰基取代的C1-C6烷基;
p是0或1;
X代表氧或硫原子或者CH2、CH(CH3)、OCH2、CH2O、CH2NH、NH或者羰基,Y代表氮原子或者CH或C(OH)基团,条件是当X代表氧或硫原子或者CH2O、CH2NH或NH时,Y代表CH;
Z1代表键或者基团(CH2)q,其中q是1或2;
Z2代表键或者基团CH2,条件是Z1和Z2不同时代表键;
Q代表氧或硫原子或者CH2或NH;
n是0、1或2;
R3各自独立代表C1-C6烷基、C1-C6烷氧基羰基、-CH2OH或羧基;
R4、R5、R6和R7各自独立代表氢原子或C1-C6烷基,或者R4、R5、R6和R7一起代表C1-C4亚烷基链,并连接与其相连的两个碳原子形成4-至7-元饱和碳环,或者R5、R6和R7各自代表氢原子而R4和R8同与其相连的碳原子一起形成5-至6-元饱和碳环;
R8代表氢原子、C1-C6烷基,或者按如上说明与R4相连;
R9和R10各自独立代表氢原子或C1-C6烷基,或者R9和R10同与其相连的氮原子一起形成4-至7-元饱和杂环;
R11和R12各自独立代表氢原子或者任选被C1-C6烷氧基羰基取代的C1-C6烷基;
R13代表氢原子或者C1-C6烷基;
R14代表氢原子或者任选被羧基、C1-C6烷氧基或C1-C6烷氧基羰基取代的C1-C6烷基;
条件是当X是氧原子或者CH2,Y是CH,Z1和Z2各自代表CH2,并且Q是氧原子时,R2不是未取代的吲哚基。
其中:
R代表基团:
m是0、1、2或3;
R1各自独立代表卤素、氰基、硝基、羧基、羟基、C3-C6环烷基、C1-C6烷氧基、C1-C6烷氧基羰基、C1-C6卤代烷基、C1-C6卤代烷氧基、-NR9R10、C3-C6环烷基氨基、C1-C6烷硫基、C1-C6烷基羰基、C1-C6烷基羰基氨基、磺酰氨基、C1-C6烷基磺酰基、-C(O)NR11R12、-NR13C(O)-(NH)PR14、苯基或者任选被羧基或C1-C6烷氧基羰基取代的C1-C6烷基;
p是0或1;
Q代表氧或硫原子或者CH2或NH;
R4、R5、R6和R7各自独立代表氢原子或C1-C6烷基,或者R4、R5、R6和R7一起代表C1-C4亚烷基链,并连接与其相连的两个碳原子形成4-至7-元饱和碳环,或者R5、R6和R7各自代表氢原子而R4和R8同与其相连的碳原子一起形成5-至6-元饱和碳环;
R8代表氢原子、C1-C6烷基,或者按如上说明与R4相连;
R9和R10各自独立代表氢原子或C1-C6烷基,或者R9和R10同与其相连的氮原子一起形成4-至7-元饱和杂环;
R11和R12各自独立代表氢原子或者任选被C1-C6烷氧基羰基取代的C1-C6烷基;
R13代表氢原子或者C1-C6烷基;
R14代表氢原子或者任选被羧基、C1-C6烷氧基或C1-C6烷氧基羰基取代的C1-C6烷基;
R15代表羧基、C1-C6烷基羰基、C1-C6烷氧基羰基、C1-C6烷氧基羰基C1-C6烷基或者-NR17R18、-NHSO2CH3、-NHC(O)CH3、-C(O)NR17R18、-NHC(O)NR17R18、-OC(O)NR17R18、-OCH2C(O)NR17R18、-NHC(O)OR17’或者-OR17”;
t是0、1、2或3;
R16各自独立代表卤素、氰基、硝基、羧基、羟基、C3-C6环烷基、C3-C6烷氧基、C1-C6烷氧基羰基、C1-C6卤代烷基、C1-C6卤代烷氧基、-NR19R20、C3-C6环烷基氨基、C1-C6烷硫基、C1-C6烷基羰基、C1-C6烷基羰基氨基、磺酰氨基(-SO2NH2)、C1-C6烷基磺酰基、-C(O)NR21R22、-NR23C(O)(NH)vR24、苯基或者任选被羧基或C1-C6烷氧基羰基取代的C1-C6烷基;
R17和R18各自独立代表(i)氢原子,(ii)可含有至少一个选自氮、氧和硫杂原子的5-至6-元饱和或不饱和环,该环可任选被至少一个选自卤素、甲基和三氟甲基的取代基取代,或者(iii)可任选被至少一个选自卤素、三氟甲基、羧基、C1-C6烷氧基羰基和5-至6-元饱和或不饱和环的取代基取代的C1-C6烷基,所述5-至6-元饱和或不饱和环含有至少一个选自氮、氧和硫的杂原子,并可任选被至少一个选自卤素、甲基和三氟甲基的取代基取代,或者
R17和R18同与其相连的氮原子一起形成4-至7-元饱和杂环;
R17’代表氢原子或者任选被羧基或C1-C6烷氧基羰基取代的C1-C6烷基;
R17”定义同上述R17,但R17”不代表氢原子;
R19和20各自独立代表氢原子或C1-C6烷基,或者R19和R20同与其相连的氮原子一起形成4-至7-元饱和杂环;
R21和R22各自独立代表氢原子或者任选被C1-C6烷氧基羰基取代的C1-C6烷基;
v是0或1;
R23代表氢原子或者C1-C6烷基;
R24代表氢原子或者任选被羧基、C1-C6烷氧基或C1-C6烷氧基羰基取代的C1-C6烷基。
整数m优选是0、1或2。
R1各自独立代表卤素(如氯、氟、溴或碘)、氰基、硝基、羧基、羟基、C3-C6环烷基(环丙基、环丁基、环戊基或环己基)、C1-C6,优选C1-C4烷氧基(如甲氧基、乙氧基、正丙氧基或正丁氧基)、C1-C6,优选C1-C4烷氧基羰基(如甲氧基羰基或乙氧基羰基)、C1-C6,优选C1-C4卤代烷基(如三氟甲基)、C1-C6,优选C1-C4卤代烷氧基(如三氟甲氧基)、-NR9R10、C3-C6环烷基氨基(如环丙基氨基、环丁基氨基、环戊基氨基或环己基氨基)、C1-C6,优选C1-C4烷硫基(如甲硫基或乙硫基)、C1-C6,优选C1-C4烷基羰基(如甲基羰基、乙基羰基、正丙基羰基、异丙基羰基、正丁基羰基、正戊基羰基或正己基羰基)、C1-C6,优选C1-C4烷基羰基氨基(如甲基羰基氨基或乙基羰基氨基)、磺酰氨基、C1-C6,优选C1-C4烷基磺酰基(如甲磺酰基、乙磺酰基、正丙基磺酰基、异丙基磺酰基、正丁基磺酰基、正戊基磺酰基或正己基磺酰基)、-C(O)NR11R12、-NR13C(O)-(NH)PR14、苯基或者任选被羧基或C1-C6,优选C1-C4烷氧基羰基(如甲氧基羰基或乙氧基羰基)取代的C1-C6,优选C1-C4烷基(如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或正己基)。
最优选R1各自独立代表卤素(尤其是氯或氟)、氰基、硝基、C1-C6烷氧基(特别是甲氧基)、C1-C6烷基羰基(特别是甲基羰基)或者C1-C6烷基羰基氨基(尤其是甲基羰基氨基)。
X优选代表氧原子或者CH2、OCH2、CH2O、NH或者羰基。
Y优选代表氮原子或者CH。
X-Y的优选组合包括O-CH、OCH2-CH、NH-CH、CH2O-CH、CH2-N、C(O)-N和CH2-CH。
Y、Z1和Z2的优选组合包括:
Y | Z1 | Z2 |
CH | CH2 | 键 |
CH | 键 | CH2 |
CH | CH2 | CH2 |
CH | (CH2)2 | 键 |
N | CH2 | CH2 |
Q优选代表氧原子。
R3各自独立代表C1-C6,优选C1-C4烷基(如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或正己基)、C1-C6,优选C1-C4烷氧基羰基(如甲氧基羰基或乙氧基羰基)、-CH2OH或羧基。R3优选代表甲基、甲氧基羰基、乙氧基羰基、-CH2OH或羧基。
R4、R5、R6和R7各自独立代表氢原子或者C1-C6,优选C1-C4烷基(如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或正己基),或者R4、R5、R6和R7一起代表C1-C4亚烷基链,并连接与其相连的两个碳原子形成4-至7-元饱和碳环(如环己基或优选环戊基),或者R5、R6和R7各自代表氢原子而R4和R8同与其相连的碳原子一起形成5-至6-元饱和碳环(优选环戊基)。
R8代表氢原子、C1-C6,优选C1-C4烷基(如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或正己基),或者按如上说明与R4相连。
R9和R10各自独立代表氢原子或者C1-C6,优选C1-C4烷基(如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或正己基),或者R9和R10同与其相连的氮原子一起形成4-至7-元饱和杂环(优选吡咯烷基或哌啶基)。
R11和R12各自独立代表氢原子或者任选被C1-C6,优选C1-C4烷氧基羰基取代基取代的C1-C6,优选C1-C4烷基(如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或正己基)。
R13代表氢原子或者C1-C6,优选C1-C4烷基(如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或正己基)。
R14代表氢原子或者任选被羧基、C1-C6,优选C1-C4烷氧基或C1-C6,优选C1-C4烷氧基羰基取代的C1-C6,优选C1-C4烷基(如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或正己基)。
R15代表羧基、C1-C6,优选C1-C4烷基羰基(如甲基羰基、乙基羰基、正丙基羰基、异丙基羰基、正丁基羰基、正戊基羰基或正己基羰基)、C1-C6,优选C1-C4烷氧基羰基(如甲氧基羰基或乙氧基羰基)、C1-C6烷氧基羰基C1-C6烷基,优选C1-C4烷氧基羰基C1-C4烷基(如甲氧基羰基甲基或甲氧基羰基乙基)或者-NR17R18、-NHSO2CH3、-NHC(O)CH3、-C(O)NR17R18、-NHC(O)NR17R18、-OC(O)NR17R18、-OCH2C(O)NR17R18、-NHC(O)OR17’或者-OR17”。
R15优选代表C1-C4烷氧基(特别是甲氧基)、C1-C4烷基羰基(特别是甲基羰基或乙基羰基)、C1-C4烷氧基羰基C1-C4烷基(特别是甲氧基羰基甲基或甲氧基羰基乙基)、-NHC(O)CH3、-C(O)NR17R18、-NHSO2CH3或-NHC(O)NR17R18。
R16各自独立代表卤素(如氯、氟、溴或碘)、氰基、硝基、羧基、羟基、C3-C6环烷基(环丙基、环丁基、环戊基或环己基)、C1-C6,优选C1-C4烷氧基(如甲氧基、乙氧基、正丙氧基或正丁氧基)、C1-C6,优选C1-C4烷氧基羰基(如甲氧基羰基或乙氧基羰基)、C1-C6,优选C1-C4卤代烷基(如三氟甲基)、C1-C6,优选C1-C4卤代烷氧基(如三氟甲氧基)、-NR19R20、C3-C6环烷基氨基(如环丙基氨基、环丁基氨基、环戊基氨基或环己基氨基)、C1-C6,优选C1-C4烷硫基(如甲硫基或乙硫基)、C1-C6,优选C1-C4烷基羰基(如甲基羰基、乙基羰基、正丙基羰基、异丙基羰基、正丁基羰基、正戊基羰基或正己基羰基)、C1-C6,优选C1-C4烷基羰基氨基(如甲基羰基氨基或乙基羰基氨基)、磺酰氨基、C1-C6,优选C1-C4烷基磺酰基(如甲磺酰基、乙磺酰基、正丙基磺酰基、异丙基磺酰基、正丁基磺酰基、正戊基磺酰基或正己基磺酰基)、-C(O)N21R22、-NR23C(O)-(NH)vR14、苯基或者任选被羧基或C1-C6,优选C1-C4烷氧基羰基(如甲氧基羰基或乙氧基羰基)取代的C1-C6,优选C1-C4烷基(如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或正己基)。
优选R16各自独立代表卤素(尤其是氯或氟)、羟基、氰基、C1-C4烷氧基(特别是甲氧基)、C1-C4烷氧基羰基(特别是甲氧基羰基)、C1-C4卤代烷基(特别是三氟甲基)、C1-C4烷基羰基(尤其是甲基羰基)、苯基或C1-C4烷基(如甲基或叔丁基)。
R17和R18各自独立代表(i)氢原子,(ii)可含有至少一个(如独立为1、2或3个)选自氮、氧和硫杂原子的5-至6-元饱和或不饱和环(如环戊基、环己基、吡咯基、咪唑基、吡啶基、吡嗪基、哒嗪基、嘧啶基、噻吩基或呋喃基),该环可任选被至少一个(如独立为1、2或3个)选自卤素(如氯、氟、溴或碘)、甲基和三氟甲基的取代基取代,或者(iii)C1-C6,优选C1-C4烷基(如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或正己基),该烷基可任选被至少一个选自卤素(如氯、氟、溴或碘)、三氟甲基、羧基、C1-C6,优选C1-C4烷氧基羰基(尤其是甲氧基羰基)和5-至6-元饱和或不饱和环(如环戊基、环己基、吡咯基、咪唑基、吡啶基、吡嗪基、哒嗪基、嘧啶基、噻吩基或呋喃基)的取代基取代,所述5-至6-元饱和或不饱和环可含有至少一个(如独立为1、2或3个)选自氮、氧和硫的杂原子,并可任选被至少一个(如独立为1、2或3个)选自卤素(如氯、氟、溴或碘)、甲基和三氟甲基的取代基取代,或者
R17和R18同与其相连的氮原子一起形成4-至7-元饱和杂环(如吡咯烷基或哌啶基)。
R17′代表氢原子或者任选被羧基或更优选C1-C6,优选C1-C4烷氧基羰基(特别是甲氧基羰基)取代的C1-C6,优选C1-C4烷基(如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或正己基)。
R19和R20各自独立代表氢原子或者C1-C6,优选C1-C4烷基(如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或正己基),或者R19和R20同与其相连的氮原子一起形成4-至7-元饱和杂环(如吡咯烷基或哌啶基)。
R21和R22各自独立代表氢原子或者任选被C1-C6,优选C1-C4烷氧基羰基取代的C1-C6,优选C1-C4烷基(如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或正己基)。
R23代表氢原子或者C1-C6,优选C1-C4烷基(如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或正己基)。
R24代表氢原子或者任选被羧基、C1-C6,优选C1-C4烷氧基或C1-C6,优选C1-C4烷氧基羰基取代的C1-C6,优选C1-C4烷基(如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基或正己基)。
本发明的优选化合物包括:N-(2-{3-[3R,S-(4-氯-苯氧基)-吡咯烷-1-基]-2R,S-羟基-丙氧基}-苯基)-乙酰胺盐酸盐,N-(5-氯-2-{3-[3R,S-(4-氯-苯氧基)-吡咯烷-1-基]2R,S-羟基-丙氧基}-苯基)-乙酰胺盐酸盐,N-(2-{3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基丙氧基}苯基)-乙酰胺,1-(2-氨基苯氧基)-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-丙醇二盐酸盐,N-(2-{3-[3-(3,4-二氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}苯基)-乙酰胺盐酸盐,2-{3-[4-(4-氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酸甲酯,2-(2-{3-[4-(3,4-二氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-2-甲基-丙酸甲酯,N-[2-({(1R,2S,3R)*-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基环戊基}氧基)苯基]乙酰胺,N-[2-({(1S,2S,3R)*-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基环戊基}氧基)苯基]乙酰胺,N-[2-({(2,3-反式)-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基环己基}氧基)苯基]乙酰胺,N-(5-氯-2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,N-(3-乙酰基-2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺,N-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4-甲基-苯基)-乙酰胺,N-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-氟-苯基)-乙酰胺,1-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-3-(1H-吲哚-7-基氧基)-丙-2-醇,1-(7-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮,N-(4-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-联苯-3-基)-乙酰胺,N-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4-氟-苯基)-乙酰胺,N-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺,N-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,N-(5-氯-2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,N-(3-乙酰基-2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺,N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4-甲基-苯基)-乙酰胺,N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-氟-苯基)-乙酰胺,1-[3-(4-氯-苯氧基)-吡咯烷-1-基]-3-(1H-吲哚-7-基氧基)-丙-2-醇,1-(7-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮,N-(4-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-联苯-3-基)-乙酰胺,N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4-氟-苯基)-乙酰胺,N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺,N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,N-(5-氯-2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,N-(3-乙酰基-2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺,N-(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4-甲基-苯基)-乙酰胺,N-(5-氟-2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,1-[3-(4-氟-苯氧基)-吡咯烷-1-基]-3-(1H-吲哚-7-基氧基)-丙-2-醇,1-(7-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮,N-(4-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-联苯-3-基)-乙酰胺,N-(4-氟-2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,N-(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺,N-(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,N-(5-氯-2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,N-(3-乙酰基-2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺,N-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4-甲基-苯基)-乙酰胺,N-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-氟-苯基)-乙酰胺,1-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-3-(1H-吲哚-7-基氧基)-丙-2-醇,1-(7-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮,N-(4-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-联苯-3-基)-乙酰胺,N-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4-氟-苯基)-乙酰胺,N-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺,N-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,N-(5-氯-2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,N-(3-乙酰基-2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺,N-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-4-甲基-苯基)-乙酰胺,N-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-5-氟-苯基)-乙酰胺,1-(7-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮,N-(4-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]2-羟基-丙氧基}-联苯-3-基)-乙酰胺,N-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-4-氟-苯基)-乙酰胺,N-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺,N-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,N-(5-氯-2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,N-(3-乙酰基-2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺,N-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-4-甲基-苯基)-乙酰胺,N-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-5-氟-苯基)-乙酰胺,1-(7-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮,N-(4-{3-[4-(4-氯-苯氧基)-哌啶-1-基]2-羟基-丙氧基}-联苯-3-基)-乙酰胺,N-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-4-氟-苯基)-乙酰胺,N-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺,N-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,N-{5-氯-2-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-苯基}-乙酰胺,N-{3-乙酰基-2-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-5-甲基-苯基}-乙酰胺,N-{2-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-4-甲基-苯基}-乙酰胺,N-{2-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-5-氟-苯基}-乙酰胺,1-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-3-(1H-吲哚-7-基氧基)-丙-2-醇,1-{7-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-吲哚-1-基}-乙酮,N-{4-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-联苯-3-基}-乙酰胺,N-{2-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-4-氟-苯基}-乙酰胺,N-{2-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-5-甲基-苯基}-乙酰胺,N-{2-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-苯基}-乙酰胺,N-{5-氯-2-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-苯基}-乙酰胺,N-{3-乙酰基-2-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-5-甲基-苯基}-乙酰胺,N-{2-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-4-甲基-苯基}-乙酰胺,N-{5-氟-2-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-苯基}-乙酰胺,1-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-3-(1H-吲哚-7-基氧基)-丙-2-醇,1-{7-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-吲哚-1-基}-乙酮,N-{4-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-联苯-3-基}-乙酰胺,N-{4-氟-2-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-苯基}-乙酰胺,N-{2-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-5-甲基-苯基}-乙酰胺,N-{2-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基}-苯基}-乙酰胺,N-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,3-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯,1-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-3-(2,6-二甲氧基-苯氧基)-丙-2-醇,1-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-3-(2-甲氧基-苯氧基)-丙-2-醇,2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺,1-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮,1-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酮,3-(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯,1-(2,6-二甲氧基-苯氧基)-3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-丙-2-醇,1-[3-(4-氟-苯氧基)-吡咯烷-1-基]-3-(2-甲氧基-苯氧基)-丙-2-醇,(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟奈丙氧基}-苯甲酰氨基)-乙酸甲酯,(2-{3-[3-(4-氯-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯,2-(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-2-甲基-丙酸甲酯,2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺,1-(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-6-甲氧基-苯基)-乙酮,1-(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮,1-(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酮,N-[2-(3-{[1-(3,4-二氯苄基)-4-哌啶基]氨基}-2-羟基丙氧基)-4-甲基苯基]乙酰胺,3-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯,1-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-3-(2-甲氧基-苯氧基)-丙-2-醇,(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯,2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺,1-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-6-甲氧基-苯基)-乙酮,1-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮,1-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酮,N-(2-{3-[4-(3,4-二氯苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺,3-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯,1-[3-(4-氯-苯氧基)-吡咯烷-1-基]-3-(2,6-二甲氧基-苯氧基)-丙-2-醇,1-[3-(4-氯-苯氧基)-吡咯烷-1-基]-3-(2-甲氧基-苯氧基)-丙-2-醇,(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯,2-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-2-甲基-丙酸甲酯,2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺,1-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-6-甲氧基-苯基)-乙酮,1-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮,1-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酮,N-(2-{3-[3-(4-氰基-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,3-(2-{3-[3-(4-氰基-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯,(2-{3-[3-(4-氰基-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯,2-{3-[3-(4-氰基-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-N,N-二甲基苯甲酰胺,4-{1-[2-羟基-3-(2-丙酰基-苯氧基)-丙基]-吡咯烷-3-基氧基}-苄腈,N-(2-{2-羟基-3-[3-(4-甲氧基-苯氧基)-吡咯烷-1-基]-丙氧基}-苯基)-乙酰胺,N-(4-氯-2-{3-[4-(3,4-二氯苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺,3-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯,1-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-3-(2-甲氧基-苯氧基)-丙-2-醇,(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯,2-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-2-甲基-丙酸甲酯,2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺,1-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-6-甲氧基-苯基)-乙酮,1-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮,1-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酮,N-(2-{3-[4-(3,4-二氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,3-(2-{3-[4-(3,4-二氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯,2-{3-[4-(3,4-二氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺,1-(2-{3-[4-(3,4-二氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮,(2-{3-[4-(3,4-二氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯,N-(2-{3-[3-(3,4-二氟-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,N-(2-{3-[4-(4-氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,3-(2-{3-[4-(4-氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯,1-(2,6-二甲氧基-苯氧基)-3-[4-(4-氟-苯氧基)-哌啶-1-基]-丙-2-醇,1-[4-(4-氟-苯氧基)-哌啶-1-基]-3-(2-甲氧基-苯氧基)-丙-2-醇,1-(2-{3-[4-(4-氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酮,2-{3-[4-(4-氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺,1-(2-{3-[4-(4-氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮,(2-{3-[4-(4-氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯,N-(2-{3-[3-(4-氟-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,3-(2-{3-[3-(4-氟-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯,1-[3-(4-氟-苯氧基甲基)-哌啶-1-基]-3-(2-甲氧基-苯氧基)-丙-2-醇,1-(2-{3-[3-(4-氟-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酮,2-(2-{3-[3-(4-氟-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-2-甲基-丙酸甲酯,2-{3-[3-(4-氟-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺,1-(2-{3-[3-(4-氟-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-6-甲氧基-苯基)-乙酮,N-(2-{3-[4-(4-乙酰氨基-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,N-(4-{1-[3-(2-乙酰基-苯氧基)-2-羟基-丙基]-哌啶-4-基氧基}-苯基)-乙酰胺,N-(4-氰基-2-{3-[4-(3,4-二氯苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺,3-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯,1-[4-(4-氯-苯氧基)-哌啶-1-基]-3-(2-甲氧基-苯氧基)-丙-2-醇,1-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酮,2-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-2-甲基-丙酸甲酯,2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺,1-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-6-甲氧基-苯基)-乙酮,1-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮,(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯,N-(2-{3-[3-(4-氯-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)乙酰胺,3-(2-{3-[3-(4-氯-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯,1-(2-{3-[3-(4-氯-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酮,2-{3-[3-(4-氯-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺,1-(2-{3-[3-(4-氯-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮,N-[2-({(1R,2R)-2-[4-(3,4-二氯苯氧基)-1-哌啶基]-1-羟基环戊基}甲氧基)苯基]乙酰胺,(2S,4R)-1-{3-[2-(乙酰氨基)苯氧基]-2-羟基丙基}-4-[(4-氯苄基)氧基]-2-吡咯烷甲酸甲酯盐酸盐,N-(2-{3-[4-(3,4-二氯苯胺基)-1-哌啶基]-2-羟基丙氧基}-4-甲基苯基)乙酰胺,N-(2-{3-[4-(4-氯苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺,N-(4-氯-2-{3-[4-(4-氯苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)-乙酰胺,N-(2-{3-[4-(4-氯苯胺基)-1-哌啶基]-2-羟基丙氧基}-4-氰基苯基)乙酰胺,N-(2-{3-[4-(4-氯苯胺基)-1-哌啶基]-2-羟基丙氧基}-4-甲基苯基)乙酰胺,N-(5-氯-2-{3-[4-(4-氟苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺,N-(5-氯-2-{3-[4-(3,4-二氟苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺,N-(5-氰基-2-{3-[4-(4-氟苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺,N-(5-氰基-2-{3-[4-(3,4-二氟苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺,N-(2-{3-[4-(4-氟苯胺基)-1-哌啶基]-2-羟基丙氧基}-4-甲基苯基)乙酰胺,N-(2-{3-[4-(3,4-二氟苯胺基)-1-哌啶基]-2-羟基丙氧基}-4-甲基苯基)乙酰胺,N-(2-{3-[3(S)-(4-氯-苯氧基)-吡咯烷-1-基]-2-(R)-羟基-丙氧基-苯基)乙酰胺,N-(2-{3-[3S-(4-氯-苯氧基)-吡咯烷-1-基]-2S-羟基-丙氧基}苯基)乙酰胺盐酸盐,N-(2-{3-[3(R)-(4-氯-苯氧基)-吡咯烷-1-基]-2-(S)-羟基-丙氧基-苯基)乙酰胺,N-[5-氯-2-({(2S)-3-[(3S)-3-(4-氯-苯氧基)-吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺,N-[5-氯-2-({(2R)-3-[(3R)-3-(4-氯-苯氧基)-吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺,N-[5-氯-2-({(2S)-3-[(3R)-3-(4-氯-苯氧基)-吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺,N-[5-氯-2-({(2R)-3-[(3 S)-3-(4-氯-苯氧基)-吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺,N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4,5-二氟-苯基)乙酰胺,N-{5-氯-2-[2-羟基-3-(3-苯氧基-吡咯烷-1-基)-丙氧基]-苯基}-乙酰胺,N-(5-氯-2-{2-羟基-3-[3-(4-硝基-苯氧基)-吡咯烷-1-基]-丙氧基}-苯基}-乙酰胺,N-(5-乙酰基-2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,4-乙酰氨基-3-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酸甲酯,N-(3-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-萘-2-基)-乙酰胺,N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-氰基-苯基)-乙酰胺,4-乙酰氨基-3-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酸甲酯,N-(3-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-萘-2-基)-乙酰胺,N-(5-氰基-2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺,N-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-5-三氟甲基-苯基)-乙酰胺,N-(5-氯-2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺三氟乙酸盐,N-(5-乙酰基-2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺三氟乙酸盐,N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}苯基)-甲磺酰胺,N-(5-氯-2-[3-[3,4-二氯苯氧基)-1-吡咯烷基(pyrrodinyl)]-2-羟基丙氧基]-苯基)脲,1-(3-{2-[(氨基羰基)氨基]苯氧基}-2-羟基丙基)-3-(4-氯苯氧基)吡咯烷鎓2,2,2-三氟乙酸盐,1-(3-{2-[(氨基羰基)氨基]苯氧基}-2-羟基丙基)-3-(3,4-二氯苯氧基)吡咯烷鎓2,2,2-三氟乙酸盐,1-(3-{2-[(氨基羰基)氨基]-4-氯苯氧基}-2-羟基丙基)-3-(4-氯苯氧基)吡咯烷鎓2,2,2-三氟乙酸盐,N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}苯基)-N’-乙基脲盐酸盐,N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}苯基)-N’-甲基脲盐酸盐,(2S,4S)-1-{3-[2-(乙酰氨基)苯氧基]-2-羟基丙基}-4-(4-氯苯氧基)-2-吡咯烷甲酸;与三氟乙酸的化合物,(2S,4S)-1-{3-[2-(乙酰氨基)苯氧基]-2-羟基丙基}-4-(3,4-二氯苯氧基)-2-吡咯烷甲酸乙酯;三氟乙酸盐,N-[2-({(2S)-3-[(2S,4S)-4-(4-氯苯氧基)-2-(羟甲基)吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺;三氟乙酸盐,N-[2-({(2R)-3-[(2S,4S)-4-(4-氯苯氧基)-2-(羟甲基)吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺;三氟乙酸盐,N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基-2-甲基丙氧基}苯基)乙酰胺盐酸盐,N-(2-{(1S*,2R*,3S*)-3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-环戊基氧基}-苯基)-乙酰胺,N-(2-{(1R*,2R*,3S*)-3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-环戊基氧基}-苯基)-乙酰胺,N-(2-{(2R*,3R*)-3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丁氧基}-苯基)-乙酰胺,N-(2-{(1 S*,2R*,3S*)-3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-环戊基氧基}-苯基)-乙酰胺,N-(2-{(2R*,3S*)-3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丁氧基}-苯基)-乙酰胺,N-(2-{(2R*,3R*)-3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丁氧基}-苯基)-乙酰胺,N-(2-{(2R*,3 S*)-3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丁氧基}-苯基)-乙酰胺,N-(2-{(1S*,2R*,3S*)-3-[4-(3-氯-苯氧基)-哌啶-1-基]-2-羟基-环戊基氧基}-苯基)-乙酰胺,N-[5-氯-2-({(1S,2R,3S)*-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基环戊基}氧基)苯基]乙酰胺,N-[4-氟-2-({(1S,2R,3S)*-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基环戊基}氧基)苯基]乙酰胺,N-(2-{3-[4-(3,4-二氯苄基)-1-哌嗪基]-2-羟基丙氧基}-苯基)乙酰胺二盐酸盐,N-(2-{3-[4-(3,4-二氯苄基)-1-哌嗪基]-2-羟基丙氧基}-4-氟苯基)乙酰胺,N-(2-{3-[4-(3,4-二氯苄基)-2,5-二甲基-1-哌嗪基]-2-羟基丙氧基}苯基)乙酰胺,N-(5-氯-2-{3-[4-(3,4-二氯苄基)-1-哌嗪基]-2-羟基丙氧基}苯基)乙酰胺,N-(5-氯-2-{3-[4-(3,4-二氯苄基)-2,5-二甲基-1-哌嗪基]-2-羟基丙氧基}苯基)乙酰胺,N-(2-{3-[4-(3,4-二氯苄基)-2,5-二甲基-1-哌嗪基]-2-羟基丙氧基}-4-甲基苯基)乙酰胺,N-(2-{3-[4-(3,4-二氯苄基)-2,5-二甲基-1-哌嗪基]-2-羟基丙氧基}-4-氟苯基)乙酰胺,N-(2-{3-[(S*R*)-4-(3,4-二氯苄基)-2,5-二甲基-1-哌嗪基]-2-羟基丙氧基}苯基)乙酰胺,N-(2-{3-[(S*R*)-4-(4-氯苄基)-2,5-二甲基-1-哌嗪基]-2-羟基丙氧基}苯基)乙酰胺,N-(5-氯-2-{3-[(S*R*)-4-(3,4-二氯苄基)-2,5-二甲基哌嗪基]-2-羟基丙氧基}苯基)乙酰胺,N-(5-氯-2-{3-[(S*R*)-4-(4-氯苄基)-2,5-二甲基哌嗪基]-2-羟基丙氧基}苯基)乙酰胺,1-(5-氯-2-{3-[4-(4-氯苯甲酰基)-1-哌嗪基]-2-羟基丙氧基}苯基)-1-乙酮,N-(5-氰基-2-{3-[(S*R*)-4-(3,4-二氯苄基)-2,5-二甲基哌嗪基]-2-羟基丙氧基}苯基)乙酰胺,N-(2-{3-[(S*R*)-4-(4-氯苄基)-2,5-二甲基哌嗪基]-2-羟基丙氧基}-5-氰基苯基)乙酰胺,N-(5-氯-2-{3-[4-(4-氯苄基)-1-哌嗪基]-2-羟基丙氧基}-苯基)乙酰胺,N-(4-氯-2-{3-[4-(4-氯苄基)-2,5-二甲基-1-哌嗪基]-2-羟基丙氧基}苯基)乙酰胺,N-(2-{3-[4-(4-氯苯甲酰基)-1-哌嗪基]-2-羟基丙氧基}-5-氰基苯基)乙酰胺,N-(2-{3-[4-(4-氯苯甲酰基)-1-哌嗪基]-2-羟基丙氧基}-4-甲基苯基)乙酰胺,N-[5-氯-2-({(1R,2S,3R)-3-[(3S)-3-(4-氯苯氧基)吡咯烷基]-2-羟基环戊基}氧基)苯基]乙酰胺,N-{2-[(2S)-(3-{(3S)-3-[(4-氯苯基)氧基]-1-吡咯烷基}-2-羟基丙基)氧基]-4-氟苯基}乙酰胺,N-[2-({(2S)-3-[(3S)-3-(4-氯苄基)吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺盐酸盐,N-(5-氯-2-{3-[3-(4-氯苄基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)乙酰胺三氟乙酸盐,N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}-4-甲基苯基)-1-吡咯烷甲酰胺三氟乙酸盐,N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}-4-羟基苯基)乙酰胺三氟乙酸盐,N-[2-({(2S)-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基丙基}氧基)-4-氟苯基]乙酰胺三氟乙酸盐,N-(2-(3-(4-氯-苯氧基)-吡咯烷-1-基)-2-羟基-丙氧基)-4,6-二氟苯基)乙酰胺盐酸盐,N-[2-({(2S)-3-[(2S,4S)-4-(4-氯苯氧基)-2-甲基吡咯烷基]-2-羟基丙基}氧基)-4-氟苯基]乙酰胺三氟乙酸盐,N-[2-({(2S)-3-[(3R)-3-(4-氯苄基)吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺盐酸盐,N-{2-[(2R)-(3-{(3S)-3-[(4-氯苯基)氧基]-1-吡咯烷基}-2-羟基丙基)氧基]-4-氟苯基}乙酰胺,N-[2-({(2S)-3-[(2R,4S)-4-(4-氯苯氧基)-2-甲基吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺三氟乙酸盐,N-{2-[(2S)-(3-{(3R)-3-[(4-氯苯基)氧基]-1-吡咯烷基}-2-羟基丙基)氧基]-4-氟苯基}乙酰胺,N’-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}-4-甲基苯基)-N,N-二甲基脲三氟乙酸盐,N-(2-{3-[3-(4-氯苯胺基)-1-吡咯烷基]-2-羟基丙氧基}苯基)乙酰胺,N-{2-[(3-{3-[(4-氯苯基)氧基]-1-吡咯烷基}-2-羟基-1-甲基丙基)氧基]苯基}乙酰胺盐酸盐,N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}-4-甲氧基苯基)乙酰胺盐酸盐,N-(2-[3-(4-氯-苄氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺三氟乙酸盐,N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-2-甲基-丙氧基}-苯基)-乙酰胺,N-(2-{(1S,2R,3S)*-3-[(3S)-3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-环戊基氧基}-5-氯-苯基)乙酰胺(非对映体混合物),N-[2-({(2R,3S)*-3-[(3S)-3-(4-氯苯氧基)吡咯烷基]-2-羟基丁基}氧基)-4-甲基苯基]乙酰胺(非对映体混合物),N-{2-[(3-{4-[(3,4-二氯苯基)氧基]-1-哌啶基}-2-羟基-2-甲基丙基)氧基]-4-氟苯基}乙酰胺盐酸盐,N-(2-{(1S,2R,3S)*-3-[(3S)-3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-环戊基氧基}-4-氟-苯基)-乙酰胺(非对映体混合物),N-(5-氯-2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}苯基)-乙酰胺,N-(5-氯-2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}苯基)-乙酰胺,N-(4-氰基-2-{3-[4-(3,4-二氯苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺,N-(4-羟基-2-{(1S,2R,3S)*-3-[(3S)-3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-环戊基氧基}-苯基)-乙酰胺(非对映体混合物),N-(4-羟基-2-{(1S,2R,3S)-3-[(3S)-3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-环戊基氧基}-苯基)-乙酰胺,N-(4-羟基-2-{(1R,2S,3R)-3-[(3S)-3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-环戊基氧基}-苯基)-乙酰胺,N-[2-({(1S,2R,3S)-3-[(3S)-3-(4-氯苯氧基)-吡咯烷基]-2-羟基环戊基}氧基)苯基]乙酰胺,N-[2-({(1R,2S,3R)-3-[(3S)-3-(4-氯苯氧基)吡咯烷基]-2-羟基环戊基}氧基)苯基]乙酰胺,N-[5-氯-2-({(1S,2R,3S)-3-[(3S)-3-(4-氯苯氧基)吡咯烷基]-2-羟基环戊基}氧基)苯基]乙酰胺,N-{5-氯-2-[((1S,2R,3S)*-3-{[1-(4-氯苄基)-4-哌啶基]氨基}-2-羟基环戊基)氧基]苯基}乙酰胺(外消旋体混合物),以及N-[2-({(2S)-3-[(3S)-3-(4-氯苯氧基)吡咯烷基]-2-羟基丙基}氧基)-4-羟基苯基]乙酰胺。
本发明还提供一种制备如上定义的式(I)化合物的方法,它包括:(a)使下述通式(II)化合物与下述通式(III)化合物反应,
其中Q、R2、R4、R5、R6、R7和R8同式(I)中的定义;或者
(b)使下述通式(IV)化合物与下述通式(V)化合物反应,其中R、R4、R5、R6、R7和R8同式(I)中的定义,
L1-Q-R2 (V)其中L1代表氢原子或活性基团(例如当Q为CH2时为Li),Q和R2同式(I)中的定义;然后任选将式(I)化合物转化为另一个式(I)化合物;并且如果需要,可形成式(I)化合物的药学上可接受的盐或溶剂化物。
一方面中,本发明还提供一种制备如上定义的式(I’)化合物的方法,它包括:(a)使下述通式(II’)化合物与下述通式(III’)化合物反应,
R-H (II’)其中R同式(I’)化合物中的定义,其中Q、R2、R4、R5、R6、R7和R8同式(I’)中的定义;或者(b)使以下通式(IV’)化合物与以下通式(V’)化合物反应,其中R、R4、R5、R6、R7和R8同式(I’)中的定义,
L1-Q-R2 (V’)其中L1代表氢原子或活性基团(例如当Q为CH2时为Li),Q和R2同式(I’)中的定义;然后任选将式(I’)化合物转化为另一个式(I’)化合物;并且如果需要,可形成式(I’)化合物的药学上可接受的盐或溶剂化物。
另一方面,本发明还提供一种制备如上定义的式(I”)化合物的方法,它包括:(a)使以下通式(II”)化合物与以下通式(III”)化合物反应,
R-H (II”)其中R同式(I”)中的定义,其中Q、R2、R4、R5、R6、R7和R8同式(I”)中的定义;或者(b)使以下通式(IV”)化合物与以下通式(V”)化合物反应,其中R、R4、R5、R6、R7和R8同式(I”)中的定义,
L1-Q-R2 (V”)其中L1代表氢原子或活性基团(例如当Q为CH2时为Li),Q和R2同式(I”)中的定义;然后任选将式(I”)化合物转化为另一个式(I”)化合物;并且如果需要,可形成式(I”)化合物的药学上可接受的盐或溶剂化物。
另一方面,本发明还提供一种制备如上定义的式(I)化合物的方法,它包括:(a)使以下通式(II)化合物与以下通式(III)化合物反应,
R-H (II)其中R同式(I)中的定义,其中Q、R2、R4、R5、R6、R7和R8同式(I)中的定义;或者(b)使以下(IV)通式化合物与以下通式(V)化合物反应,其中R、R4、R5、R6、R7和R8同式(I)中的定义,
L1-Q-R2 (V)其中L1代表氢原子或活性基团(例如当Q为CH2时为Li),Q和R2同式(I)中的定义;然后任选将式(I)化合物转化为另一个式(I)化合物;并且如果需要,可形成式(I)化合物的药学上可接受的盐或溶剂化物。
本发明的方法可方便地在溶剂例如有机溶剂如醇类(如甲醇或乙醇)、烃类(如甲苯)或乙腈中,在例如15℃或15℃以上(如在20-120℃范围内的温度)的温度下进行。
式(II)、(II’)、(II”)、(II)、(III)、(III’)、(III”)、(III)、(IV)、(IV’)、(IV”)、(IV)、(V)、(V’)、(V”)和(V)化合物或者可由市售提供、或者是文献中熟知的化合物或者可采用已知的技术很容易制备出来。
采用标准方法,可将式(I)、(I’)、(I”)或(I)化合物转化为式(I)、(I’)、(I”)或(I)的其它化合物。例如在盐酸存在下,通过水解反应,可将其中R15代表-NHC(O)CH3的式(I)化合物转化为其中R15代表-NH2的另一个式(I)合物。
本领域技术熟练人员将清楚:在本发明的方法中,原料或中间体化合物的某些官能团(如羟基或氨基)需要通过保护基保护。因此,在适当的阶段,式(I)、(I’)、(I”)或(I)化合物的制备可包括除去一或多个保护基。
官能团的保护和脱保护可见Plenum Press(1973)出版,J.W.F.McOmie编辑的“Protective Groups in Organic Chemistry”以及T.W.Greene and P.G.M.Wuts,Wiley-Interscience(1991)的第二版“Protective Groups in Organic Synthesis”。
可将以上式(I)、(I’)、(I”)或(I)化合物转化为其药学上可接受的盐或溶剂化物,优选为酸加成盐,如盐酸盐、氢溴酸盐、磷酸盐、乙酸盐、富马酸盐、马来酸盐、酒石酸盐、柠檬酸盐、草酸盐、甲磺酸盐或对甲苯磺酸盐。
式(I)、(I’)、(I”)或(I)化合物可存在立体异构体形式。需清楚:本发明包括应用式(I)、(I’)、(I”)或(I)化合物的所有几何和光学异构体及其混合物,包括外消旋混合物。其互变异构体及混合物的应用也形成本发明的一部分。对映体纯的形式特别符合要求。
式(I)、(I’)、(I”)或(I)化合物具有药用活性,尤其可作为趋化因子受体(特别是MIP-1α趋化因子受体)活性的调节剂,并可用于治疗自身免疫、炎性、增生性和增生过高性(hyper prlifevative)疾病以及免疫调节的疾病,包括移植器官或组织的排斥和获得性免疫缺陷综合症(AIDS)。
这些症状的实例是:
(1)(呼吸道)气道疾病包括肺慢性阻塞性病疾(COPD),如不可逆性COPD;气喘,如支气管性气喘、变应性哮喘、内因性所喘、外因性气喘和尘埃性哮喘,尤其是慢性或顽痼疾性哮喘(如晚期哮喘和气道高反应性(hyperresponsiveness));支气管炎;急性鼻炎、变应性鼻炎、萎缩性鼻炎和慢性鼻炎,包括干酪性鼻炎、肥厚性鼻炎、脓炎鼻炎、干性鼻炎和药物性鼻炎;膜性鼻炎,包括格鲁布性、纤维蛋白性、假膜性鼻炎和腺病性鼻炎;季节性鼻炎,包括神经性鼻炎(枯草热)和血管舒缩性鼻炎;结节病、农民肺和相关疾病、纤维化肺和自发的间质性肺病;
(2)(骨和关节)类风湿性关节炎、血清反应阴性的脊椎关节炎(包括关节强硬性脊椎炎、牛皮癣性关节炎和Reiter病)、Behcet病、Sjogren综合征和全身性硬皮病;
(3)(皮肤)牛皮癣、特应性皮炎、接触性皮炎和其它湿疹性皮炎、脂溢性皮炎、扁平苔癣、天疱疮、大疱天疱疮、大疱性表皮松解、荨麻疹、angiodermas、脉管炎、红斑、皮肤嗜酸红细胞增多、色素层炎、斑秃和春季结膜炎;
(4)(胃肠道)腹腔疾病、直肠炎、嗜酸性胃肠炎、肥大细胞增多症、Crohn病、溃疡性结肠炎、作用于远离肠处的食物变态反应,如偏头痛、鼻炎和湿疹;
(5)(其它组织和全身性疾病)多发性硬化症、动脉粥样硬化、获得性免疫缺陷综合症(AIDS)、红斑狼疮、系统性狼疮、红斑、桥本氏甲状腺炎甲状腺炎、重症肌无力、I型糖尿病、肾变病综合征、嗜酸性筋膜炎(eosinophilia fascitis)、高免疫球蛋白E血症综合征、瘤型麻风、sezary综合征和自发性血小板减少紫癜;
(6)(同种异体移植排斥)如肾、心脏、肝、肺、骨髓、皮肤和角膜移植后的急性和慢性疾病;以及对抗宿主的慢性移植疾病;
(7)癌症,特别是非小细胞肺癌(NSCLC)和鳞状肉瘤;
(8)与CXCR2趋化因子水平升高有关的血管生成疾病(如NSCLC);
(9)胰囊性纤维变性、休克、心脏、脑、外周末端的再灌注损伤、脓毒症;
因此,本发明提供用于治疗作用的式(I)、(I’)、(I”)或(I)的化合物或其药学上可接受的盐或溶剂化物。
另一方面,本发明提供以上定义的式(I)、(I’)、(I”)或(I)化合物或其药学上可接受的盐或溶剂化物在制备用于治疗作用的药物中的应用。
在本说明书的内容中,除有特别说明外,术语“治疗”还包括“预防”。术语“治疗的”和“治疗上”也应当作相应解释。
本发明还提供一种治疗患有炎症或有患上该病危险的患者的方法,该方法包括给予该患者治疗有效量的以上定义的式(I)、(I’)、(I”)或(I)化合物或其药学上可接受的盐或溶剂化物。
本发明还提供一种治疗患有呼吸道疾病或有患上该病危险的患者的方法,该方法包括给予该患者治疗有效量的以上定义的式(I)、(I’)、(I”)或(I)化合物或其药学上可接受的盐或溶剂化物。
对于以上提到的治疗用途,给药剂量一般随所用的化合物、给药方式、所要求的治疗效果以及治疗的病症而变化。式(I)、(I’)、(I”)或(I)化合物的日剂量可在0.001mg/kg-30mg/kg范围内。
可将式(I)、(I’)、(I”)或(I)化合物及其药学上可接受的盐和溶剂化物独立使用,但一般常以药用组合物的形式给药,在该组合物中式(I)、(I’)、(I”)或(I)化合物/盐/溶剂化物(活性组分)与药学上可接受的佐剂、稀释剂或载体相结合。根据给药方式的不同,药用组合物中优选含有0.05-99%w(重量百分数),更优选0.05-80%w,再更优选0.10-70%w,更加优选0.10-50%w的活性组分,所有重量百分数均以总组合物为基础。
本发明还提供一种药用组合物,它包含以上定义的式(I)、(I’)、(I”)或(I)化合物或其药学上可接受的盐或溶剂化物并结合药学上可接受的佐剂、稀释剂或载体。
本发明还提供一种制备本发明药用组合物的方法,它包括将以上定义的式(I)、(I’)、(I”)或(I)化合物或其药学上可接受的盐或溶剂化物与药学上可接受的佐剂、稀释剂或载体混合。
本发明药用组合物可以以溶液、悬浮液、七氟烷气雾剂和干粉制剂的形式局部给予(如给予肺部和/或呼吸道或者皮肤);或者全身给予,如以片剂、胶囊剂、糖浆剂、粉末剂或颗粒剂形式口服给予,或者以溶液剂或混悬剂形式非肠道给予,或者以栓剂或透皮吸收形式皮下给予或直肠给予。
现在参考下列说明性的实施例,进一步解释本发明,其中1H NMR光谱采用Varian Unity Inova 400记录。采用氘代氯仿的中心溶剂峰(δH7.27ppm)作为内标。低分辨质谱和准确质量的测定采用装备有APCI/ESI离子化室的Hewlett-Packard 1100 LC-MS系统记录。所有溶剂和市售试剂都是试验室级别并是标准使用试剂。化合物所用的命名法采用ACD/IUPAC命名原则。实施例1N-(2-{3-[3R,S-(4-氯-苯氧基)-吡咯烷-1-基]-2R,S-羟基-丙氧基}-苯基)-乙酰胺盐酸盐(i)3-羟基-吡咯烷-1-甲酸叔丁基酯
在通氮气下,将吡咯烷-3-醇(16.25g,186.5mmol)和二碳酸二叔丁基酯(40.7g,186.5mmol)的无水THF(50ml)溶液搅拌过夜。减压浓缩,经硅胶快速层析纯化(EtOAc∶庚烷,7∶3)得到31.9g(91%该副标题化合物。1H-NMR(400MHz,DMSO-d6):δ4.87(d,1H,J=3.4Hz),4.21(bs,1H),3.31-3.22(m,3H),3.10(d,1H,J=11.5Hz),1.83(m,1H),1.72(m,1H),1.39(s,9H)。APCI-MS:m/z132[MH+-56](ii)3-(4-氯-苯氧基)-吡咯烷
在通氮气下,将3-羟基-吡咯烷-1-甲酸叔丁基酯(2.1g,9.9mmol)和三苯膦(2.59g,9.9mmol)溶于无水THF(35ml)中。将该溶液冷却至0℃,加入溶于无水THF(10ml)中的4-氯苯酚(1.28g,9.9mmol),接着加入偶氮二甲酸二乙酯(DEAD)(1.55ml,9.9mmol)。15分钟后,移去冰浴,将反应物搅拌过夜。减压浓缩反应混合液,将残留物与乙醚搅拌。滤除固体的氧化三苯膦。将该溶液用氢氧化钠(1M)洗涤3次,浓缩。用EtOAc/庚烷为洗脱剂将该BOC-保护的产物经硅胶快速层析纯化。将其溶于二氯甲烷(35ml)和三氟乙酸(17ml)中。室温下,将反应混合液搅拌过夜,浓缩,经硅胶快速层析纯化(MeOH∶CHCl3∶NH3,100∶100∶1)得到副标题化合物(1.72g,88%)。1H-NMR(400MHz,DMSO-d6):δ7.30(d,2H,J=8.9Hz),6.91(d,2H,J=8.9Hz),4.82(m,1H),3.03(dd,1H,J=12.3,5.4Hz),2.82(m,3H),1.99(m,1H),1.72(m,1H)。APCI-MS:m/z198[MH+](iii)N-(2-{3-[3R,S-(4-氯-苯氧基)-吡咯烷-1-基]2R,S-羟基-丙氧基}-苯基)-乙酰胺盐酸盐
在75℃下,在密闭的小瓶中,将3-(4-氯-苯氧基)-吡咯烷(0.059g,0.298mmol)和N-乙酰基-2-(2,3-环氧基丙氧基)苯胺(0.062g,0.299mmol)的EtOH(1.5ml,99.5%)溶液搅拌3小时。反应完毕后,蒸发溶剂,残留物经硅胶纯化(CH2Cl2∶MeOH,98∶2~97∶3)得到88 mg标题化合物的游离胺。将该胺溶于MeOH∶水1∶1(30ml)中,将该溶液用2M盐酸酸化。蒸发甲醇,将残留的水溶液冷冻干燥得到92mg(70%)的标题化合物,为白色固体。APCI-MS:m/z405.2,407.2[MH+,同位素方式]实施例2N-(5-氯-2-{3-[3R,S-(4-氯-苯氧基)-吡咯烷-1-基]-2R,S-羟基-丙氧基}-苯基)-乙酰胺盐酸盐(i)N-(5-氯-2-羟基-苯基)-乙酰胺
将4-氨基-2-氯苯酚(2.0g,13.9mmol)和乙酸酐(1.77g,17.3mmol)的水(40ml)溶液剧烈搅拌5分钟。然后在搅拌下,将反应混合液加热至60℃下30分钟,然后冷却。形成粉色固体,过滤收集沉淀,用水洗涤2次,干燥得到1.8g(70%)的该副标题化合物。1H-NMR(400MHz,DMSO-d6):δ 10.09(1H,s);9.25(1H,bs);7.93(1H,s);6.93(1H,dd,J 8.8,2.7Hz);6.84(1H,d,J 8.6Hz);2.09(3H,s)。APCI-MS:m/z 186.0[MH+](ii)N-(5-氯-2-环氧乙烷基甲氧基-苯基)-乙酰胺
在50℃、搅拌下,将N-(5-氯-2-羟基-苯基)-乙酰胺(0.499g,2.68mmol)、K2CO3(0.60g,4.35mmol)和表溴醇(0.405g,2.95mmol)的DMF(5ml)溶液加热2小时。然后将混合液在EtOAc和水40+40ml之间分配。将有机相用水洗涤2次,用盐水洗涤1次。最后真空浓缩得到粗产物。该粗产物经硅胶纯化(庚烷∶EtOAc,1∶1)得到0.43g(66%)白色固体。1H-NMR(400MHz,CDCl3):δ 8.46(1H,d,J 2.3Hz);7.90(1H,bs);6.98(1H,dd,J 8.7,2.4Hz);6.83(1H,d,J 8.8Hz);4.36(1H,dd,J11.5,2.4Hz);3.94(1H,dd,J 11.6,6.0Hz);3.41-3.36(1H,m);2.97(1H,dd,J 4.7,4.2Hz);2.80(1H,dd,J 4.6,2.6Hz);2.23(3H,s)。(iii)N-(5-氯-2-{3-[3R,S-(4-氯-苯氧基)-吡咯烷-1-基]-2R,S-羟基-丙氧基}-苯基)-乙酰胺盐酸盐
根据实施例1步骤(iii)中说明的类似方法制备。实施例3N-(2-{3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基丙氧基}苯基)-乙酰胺
根据实施例1中所述方法制备。通过C18-柱层析纯化和分离出收率为73%的游离胺(H2O∶CH3CN,0.1M NH4OAc缓冲液,梯度30%~95%CH3CN)。APCI-MSm/z:453,455[MH+]1H-NMR(400MHz,CDCl3):δ7.32(d,1H),7.01(d,1H),6.85-8.80(m,2H),6.78-6.69(m,3H),4.31(m,1H),4.15-4.09(m,1H),4.18-3.18(bs,3H),2.91(m,1H),2.71(m,1H),2.62-2.52(m,3H),2.35(m,1H),2.05-1.93(m,2H),1.89-1.77(m,2H)。实施例41-(2-氨基苯氧基)-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-丙醇二盐酸盐
将N-(2-{3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺(1.418g,3.13mmol)溶于50ml HCl(35%水溶液,puriss)中,回流过夜。过滤沉淀产物,干燥得到0.835g(65%)的标题化合物。APCI-MS:m/z411,413[MH+]1H-NMR(400MHz,CDCl3):δ8.39-3.31(m,2H),7.31(d,1H),7.01-6.98(m,3H),6.94-6.91(m,1H),6.75(dd,1H),4.31(m,1H),4.12-4.02(m,2H),3.92(dd,1H),2.90(m,1H),2.69(m,1H),2.62-2.51(m,2H),2.46(dd,1H),2.34(m,1H),2.18(s,3H),2.04-1.93(m,2H),1.89-1.77(m,2H)。实施例5N-(2-{3-[3-(3,4-二氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}苯基)-乙酰胺盐酸盐
根据实施例1中所述方法制备,得到68mg(68%)的标题化合物,为白色固体。APCI-MS:m/z439,441[MH+]实施例62-{3-[4-(4-氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酸甲酯(i)2-环氧乙烷基甲氧基-苯甲酸甲酯
根据实施例2步骤(ii)中说明的方法制备。1H-NMR(400MHz,CDCl3):δ7.81(1H,dd,J 7.7,1.7Hz);7.46(1H,dt,J7.7,1.7Hz);7.05-6.98(2H,m);4.33(1H,dd,J 11.3,3.0Hz);4.11(1H,dd,J 11.3,4.8Hz);3.90(3H,s);3.43-3.37(1H,m);2.93-2.90(2H,m)。(ii)2-{3-[4-(4-氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酸甲酯
根据实施例1步骤(ii)中说明的方法制备。分离出游离的胺。1H-MR(400MHz,CDCl3):δ7.81(1H,dd,J 8.1,1.8Hz);7.46(1H,dt,J7.8,1.7Hz);7.03-6.91(4H,m);6.86-6.82(2H,m);4.28-4.10(3H,m);4.08-4.00(1H,m);3.88(3H,s);2.92-2.84(1H,m);2.83-2.76(1H,m);2.66-2.53(2H,m);2.46(1H,t,J 10.2Hz);2.36(1H,t,J 10.2Hz);2.02-1.92(2H,m);1.86-1.74(2H,m);1.63(1H,bs)APCI-MS:m/z404.2[MH+]实施例72-(2-{3-[4-(3,4-二氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-2-甲基-丙酸甲酯(i)2-[(2-羟基苯甲酰基)氨基]-2-甲基丙酸甲酯
向乙酸2-(氯羰基)苯基酯(20mmol,3.96g)的甲苯(50ml)溶液中,加入N-乙基-N,N-二异丙基胺(22mmol,2.84g)和2-甲基苯胺(22mmol,2.27g)。室温下,将反应混合液搅拌过夜,然后将混合液用250ml甲苯稀释,用1.8%HCl水溶液(250ml)和饱和NaCl水溶液(250ml)洗涤。有机相经Na2SO4干燥,减压浓缩。将残留物溶于MeOH(50mL)中并加入3滴浓硫酸。将混合液回流2小时,减压浓缩。将残留物溶于250mLEtOAc中,用饱和NaHCO3水溶液(250ml)和饱和NaCl水溶液(250ml)洗涤。有机相经Na2SO4干燥,减压浓缩。得到的粗产物不经进一步纯化使用。APCI-MS:m/z238[MH+](ii)2-甲基-2-{[2-(2-环氧乙烷基甲氧基)苯甲酰基]氨基}丙酸甲酯
在回流温度下,将2-[(2-羟基苯甲酰基)氨基]-2-甲基丙酸甲酯、K2CO3(20mmol,2.68g)和2-(氯甲基)环氧乙烷(20mmol,2.03g)的乙腈(60ml)溶液搅拌过夜。将反应混合液用EtOAc稀释,用1.8%HCl水溶液(250ml)和饱和NaCl水溶液(250ml)洗涤。有机相经Na2SO4干燥,减压浓缩。残留物经C18-柱纯化(H2O∶CH3CN,0.1M NH4OAc缓冲液,梯度10%~95%CH3CN)得到副标题化合物(244mg,5%收率,两步)。APCI-MS:m/z 294[MH+]1H-NMR(400MHz,CDCl3):δ8.40(s,1H),8.14(dd,1H),7.41(dt,1H),7.07(t,1H),6.90(d,1H),4.44(dd,1H),4.07(dd,1H),3.74(s,3H),3.45(m,1H),2.94(dd,1H),2.84(dd,1H),1.64(d,6H)。(iii)2-(2-{3-[4-(3,4-二氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-2-甲基-丙酸甲酯
将4-(3,4-二氟苯氧基)哌啶(0.03ml,0.5M)的甲苯溶液与2-甲基-2-{[2-(2-环氧乙烷基甲氧基)苯甲酰基]氨基}丙酸甲酯(0.03ml,0.5M)的甲苯溶液混合。将混合液用0.20ml甲苯和0.05ml甲醇稀释。在100℃下,在密闭小瓶中,将该反应混合液搅拌过夜。真空浓缩产物,可不经进一步纯化使用。APCI-MS:m/z507[MH+]1H-NMR(400MHz,CDCl3):δ8.13(s,1H),7.90(dd,1H),7.33(dt,1H),7.07-6.96(m,2H),6.89(d,1H),6.73-6.68(m,1H),6.58-6.55(m,1H),4.77-4.72(m,1H),4.49(bs,1H),4.20-4.13(m,2H),3.69(s,3H),3.58-3.44(m,2H),3.39-3.26(m,4H),2.54-2.40(m,2H),2.13-2.04(m,2H),1.60(d,6H)。实施例8N-[2-({(1R,2S,3R)*-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基环戊基}氧基)苯基]乙酰胺和N-[2-({(1S,2S,3R)*-3-[4-(3,4-二氯苯氧基)-1-哌啶基]2-羟基环戊基}氧基)苯基]乙酰胺(i)N-[2-(2-环戊烯-1-基氧基)苯基]乙酰胺
在0℃下,向氢化钠(煤油中60%;297mg,7.43mmol,1.1当量)的DMF(3ml)悬浮液中,滴加2-乙酰氨基-苯酚(1.02g,6.75mmol,1.0当量)的DMF(12ml)溶液。30分钟后,通过注射器加入氯环戊-2-烯(R.Moffett,Organic Synthesis,Wiley:New York 1963,Collect.Vol.IV,p.238-241)(762mg,0.76ml,7.43mmol,1.1当量),继续搅拌过夜。水溶液处理,接着经硅胶快速层析纯化(庚烷/乙酸乙酯,2∶1继续至1∶1)得到992mg(68%)副标题化合物,为深黄色油状物。1H-NMR(400MHz,CDCl3):δ8.35(1H,d,J 8.0Hz),7.73(1H,bs),7.00(1H,td,J 7.9,1.5Hz),6.90-6.95(2H,m),6.17(1H,m),5.95(1H,m),5.36(1H,d,J 5.9Hz),2.59(1H,m),2.38(2H,m),2.17(3H,s),1.97(1H,m)。MS-ESI+:m/z218.1[MH+](ii)N-{2-(6-氧杂双环[3.1.0]己-2-基氧基)苯基}乙酰胺
向冰浴冷却的N-[2-(2-环戊烯-1-基氧基)苯基]乙酰胺(149mg,686μmol,1.0当量)的二氯甲烷(4ml)溶液中,加入间氯过苯甲酸(85%;146μmol,1.1当量)。在缓慢升至室温下,搅拌过夜,然后将反应混合液用叔丁基(甲基)醚稀释,顺次用5%饱和硫酸氢钠溶液、氢氧化钠和盐水洗涤,经硫酸钠干燥。蒸发溶剂,经硅胶快速层析(乙酸乙酯/庚烷,2∶3继续至乙酸乙酯)生成93mg(58%)的副标题化合物,为反式(少量)和顺式(大量)非对映异构体环氧化物的混合物,浅黄色油状物。通过1H-NMR测得顺/反式比为2∶1。1H-NMR(400MHz,CDCl3):δ8.39(1H[A],m),8.34(1H[B],d,J 8.2Hz),7.91(1H[A],bs),7.59(1H,[B],bs),6.92-7.25(3H[A]+3H[B],m),4.89(1H[B],d,J 5.2Hz),4.77(1H[A],td,J 8.0,1.3Hz),3.66(1H[B],m),3.64(1H[B],m),3.60(1H,[A],m),3.54(1H[A],m),2.23(1H[B],d,J 8.4Hz),2.21(3H[A],s),2.19(3H[B],s),2.10(2H[A],m),1.72-1.92(m),1.53-1.63(m),(2H[A]+3H[B])。(A=反式,B=顺式)MS-ESI+:m/z 234.1[MH+](iii)N-[2-({(1R,2S,3R)*-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基环戊基}氧基)苯基]乙酰胺和N-[2-({(1S,2S,3R)*-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基环戊基}氧基)苯基]乙酰胺
将N-{2-(6-氧杂双环[3.1.0]己-2-基氧基)苯基}乙酰胺(反式和顺式非对映体的外消旋混合物)(87mg,373μmol,1.0当量)和4-(3,4-二氯苯氧基)哌啶(92mg,394μmol,1.06当量)溶于2M高氯酸锂的乙腈(3ml)溶液中,在85℃下,在密封管中加热过夜。水溶液处理,接着将粗产物经硅胶快速层析(庚烷/乙酸乙酯/甲醇/氨=1∶3∶0∶0继续至0∶90∶10∶1至0∶80∶20∶3)分离出两种非对映体加成产物,得到24mg(14%)的(1S,2S,3R)非对映体(先洗脱出)和75mg(42%)后洗脱的(1R,2S,3R)非对映体。(1S,2S,3R)非对映体:1H-NMR(400MHz,CDCl3):δ8.27(1H,dd,J 7.6,1.7Hz),7.91(1H,s),7.29(1H,d,J 8.9Hz),6.88-7.00(4H,m),6.73(1H,dd,J 8.9,2.8Hz),4.45(1H,m),4.28(1H,七重峰,J 3.6Hz),4.18(1H,dd,J 7.1,4.6Hz),2.87(3H,m),2.71(1H,q,J 7.5Hz),2.15(3H,s),2.11(1H,m),1.78-2.02(7H,m)。MS-APCI+:m/z479.1[MH+](1R,2S,3R)非对映体:1H-NMR(400MHz,CDCl3):δ8.20-8.25(2H,m),7.29(1H,d,J 8.9Hz),6.91-7.00(4H,m),6.74(1H,dd,J 8.9,2.8Hz),4.46(1H,bq,J 4.8Hz),4.29(1H,m),4.13(1H,d,J 7.2Hz),2.95(2H,m),2.84(2H,m),2.50(2H,m),2.15(3H,s),1.93-2.07(5H,m),1.82(2H,m),1.58(1H,m)。MS-APCI+:m/z479.1[MH+]实施例9N-[2-({(2,3-反式)-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基环己基}氧基)苯基]乙酰胺(i)N-[2-(2-环己烯-1-基氧基)苯基]乙酰胺
将2-环己烯醇(491mg,0.49ml,5.00mmol,1.0当量)、2-乙酰氨基苯酚(756mg,5.00mmol,1.0当量)和三苯膦(1.44g,5.50mmol,1.1当量)溶于THF(10ml)中,通过水浴保持在室温下。滴加溶于THF(3ml)中的偶氮二甲酸二乙酯(871mg,0.78ml,5.00mmol,1.0当量),之后将反应混合液搅拌过夜。萃取处理,再经硅胶快速层析(庚烷/叔丁基(甲基)醚=1∶1)得到224mg(19%)的标题化合物,为黄色油状物。MS-ESI+:m/z232.2[MH+](ii)N-[2-(7-氧杂双环[4.1.0]庚-2-基氧基)苯基]乙酰胺
在0℃下,向N-[2-(2-环己烯-1-基氧基)苯基]乙酰胺(76mg,329μmol,1.0当量)的二氯甲烷(5ml)溶液中,加入间氯苯甲酸(85%;121mg,559μmol,1.7当量)。继续搅拌过夜,期间将反应混合液缓慢升至室温。将该非均质混合液用乙酸乙酯稀释,并用饱和亚硫酸钠、5%氢氧化钠和盐水洗涤。经硫酸钠干燥,蒸发溶剂,经硅胶快速层析得到59mg(73%)的标题化合物,为非对映异构体混合物(比率A∶B=反式∶顺式=5∶3[1H-NMR])。1H-NMR(400MHz,CDCl3):δ8.35(1H[A]+1H[B],m),8.02(1H[A],bs),7.70(1H[B],bs),6.95-7.04(3H[A]+3H[B],m),4.62(1H[A],dd,J 8.4,5.5,2.1Hz),4.55(1H[B],dd,J 7.5,6.7Hz),3.30-3.36(2H[A]+1H[B],m),3.19(1H[B],t,J 3.6Hz),1.26-2.23(10H[A]+10H[B],m)。LC/MS-ESI+:m/z248.1[MH+(A)],248.2[MH+(B)](iii)N-[2-({(2,3-反式)-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基环己基}氧基)苯基]乙酰胺
将N-[2-(7-氧杂双环[4.1.0]庚-2-基氧基)苯基]乙酰胺的非对映体混合物(59mg,239μmol,1.0当量)和4-(3,4-二氯苯氧基)哌啶(56mg,239μmol,1.06当量)溶于2M高氯酸锂的乙腈(2ml)溶液中,在85℃下,在密封管中加热过夜。水溶液处理,接着经硅胶快速层析(庚烷/乙酸乙酯/甲醇=50∶100∶3)得到86mg(75%)的黄色油状物,为比率为69∶31=A∶B(1H-NMR)的非对映体混合物。反相柱上未发现能分离该非对映体混合物。由于混合物光谱复杂,不能分别给出多量和少量非对映体的相对立体化学性质。1H-NMR(400MHz,CDCl3):δ9.48(1H[A],bs),9.25(1H[B],bs),8.46(1H[A]+1H[B],t,J 9.1Hz),7.22-7.32(2H[A]+1H[B],m),6.93-7.08(4H[A]+5H[B],m),6.72-6.76(1H[A]+1H[B],m),4.08-4.30(3H[A]+3H[B],m),3.55-3.64(2H[A]+1H[B],m),2.96-3.07(2H[A]+2H[B],m),2.71(2H[A]+3H[B],m),2.19(3H[A],s),2.16(3H[B],s),1.47-2.37(10H[A]+10H[B],m)。MS-ESI+:m/z493.1[MH+(A,B)]
下列化合物根据以上实施例中所述的类似途径制备。实施例10N-(5-氯-2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z473.1475.1[MH+]实施例11N-(3-乙酰基-2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺APCI-MS:m/z495.1497.1[MH+]实施例12N-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4-甲基-苯基)-乙酰胺APCI-MS:m/z453.1455.1[MH+]实施例13N-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-氟-苯基)-乙酰胺APCI-MS:m/z457.1459.1[MH+]实施例141-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-3-(1H-吲哚-7-基氧基)-丙-2-醇APCI-MS:m/z421.1 423.1[MH+]实施例151-(7-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮APCI-MS:m/z463.1465.1[MH+]实施例16N-(4-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-联苯-3-基)-乙酰胺APCI-MS:m/z515.1517.1[MH+]实施例17N-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4-氟-苯基)-乙酰胺APCI-MS:m/z457.1459.1[MH+]实施例18N-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺APCI-MS:m/z453.1455.1[MH+]实施例19N-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z439.1441.1[MH+]实施例20N-(5-氯-2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z439.1441.1[MH+]实施例21N-(3-乙酰基-2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺APCI-MS:m/z461.1[MH+]实施例22N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4-甲基-苯基)-乙酰胺APCI-MS:m/z419.1[MH+]实施例23N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-氟-苯基)-乙酰胺APCI-MS:m/z423.1[MH+]实施例241-[3-(4-氯-苯氧基)-吡咯烷-1-基]-3-(1H-吲哚-7-基氧基)-丙-2-醇APCI-MS:m/z387.1[MH+]实施例251-(7-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮APCI-MS:m/z429.1[MH+]实施例26N-(4-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-联苯-3-基)-乙酰胺APCI-MS:m/z481.1[MH+]实施例27N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4-氟-苯基)-乙酰胺APCI-MS:m/z423.1[MH+]实施例28N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺APCI-MS:m/z419.1[MH+]实施例29N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z405.1[MH+]实施例30N-(5-氯-2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z423.1[MH+]实施例31N-(3-乙酰基-2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺APCI-MS:m/z445.3[MH+]实施例32N-(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4-甲基-苯基)-乙酰胺APCI-MS:m/z403.3[MH+]实施例33N-(5-氟-2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z407.1[MH+]实施例341-[3-(4-氟-苯氧基)-吡咯烷-1-基]-3-(1H-吲哚-7-基氧基)-丙-2-醇APCI-MS:m/z371.1[MH+]实施例351-(7-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮APCI-MS:m/z413.1[MH+]实施例36N-(4-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-联苯-3-基)-乙酰胺APCI-MS:m/z465.3[MH+]实施例37N-(4-氟-2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z407.1[MH+]实施例38N-(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺APCI-MS:m/z403.1[MH+]实施例39N-(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z389.1[MH+]实施例40N-(5-氯-2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z441.1[MH+]实施例41N-(3-乙酰基-2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺APCI-MS:m/z463.3[MH+]实施例42N-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4-甲基-苯基)-乙酰胺APCI-MS:m/z421.1[MH+]实施例43N-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-氟-苯基)-乙酰胺APCI-MS:m/z425.1[MH+]实施例441-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-3-(1H-吲哚-7-基氧基)-丙-2-醇APCI-MS:m/z389.1[MH+]实施例451-(7-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮APCI-MS:m/z431.1[MH+]实施例46N-(4-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-联苯-3-基)-乙酰胺APCI-MS:m/z483.3[MH+]实施例47N-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4-氟-苯基)-乙酰胺APCI-MS:m/z425.1[MH+]实施例48N-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺APCI-MS:m/z421.1[MH+]实施例49N-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z407.1[MH+]实施例50N-(5-氯-2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z487.1489.1[MH+]实施例51N-(3-乙酰基-2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺APCI-MS:m/z509.1511.1[MH+]实施例52N-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-4-甲基-苯基)-乙酰胺APCI-MS:m/z467.1469.1[MH+]实施例53N-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-5-氟-苯基)-乙酰胺APCI-MS:m/z471.1473.1[MH+]对比实施例541-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-3-(1H-吲哚-7-基氧基)-丙-2-醇APCI-MS:m/z435.1437.1[MH+]实施例551-(7-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮APCI-MS:m/z477.1479.1[MH+]实施例56N-(4-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-联苯-3-基)-乙酰胺APCI-MS:m/z429.1431.1[MH+]实施例57N-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-4-氟-苯基)-乙酰胺APCI-MS:m/z471.1 473.1[MH+]实施例58N-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺APCI-MS:m/z467.1469.1[MH+]实施例59N-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z453.1455.1[MH+]实施例60N-(5-氯-2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z453.1455.1[MH+]实施例61N-(3-乙酰基-2-{3-[4-(4-氯-苯氧基)-哌啶-1-基}-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺APCI-MS:m/z475.3[MH+]实施例62N-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-4-甲基-苯基)-乙酰胺APCI-MS:m/z433.1[MH+]实施例63N-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-5-氟-苯基)-乙酰胺APCI-MS:m/z437.1[MH+]对比实施例641-[4-(4-氯-苯氧基)-哌啶-1-基]-3-(1H-吲哚-7-基氧基)-丙-2-醇APCI-MS:m/z401.1[MH+]实施例651-(7-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮APCI-MS:m/z443.1[MH+]实施例66N-(4-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-联苯-3-基)-乙酰胺APCI-MS:m/z495.3[MH+]实施例67N-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-4-氟-苯基)-乙酰胺APCI-MS:m/z437.1[MH+]实施例68N-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-5-甲基-苯基)-乙酰胺APCI-MS:m/z433.1[MH+]实施例69N-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z419.1[MH+]实施例70N-{5-氯-2-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-苯基}-乙酰胺APCI-MS:m/z448.1450.1[MH+]实施例71N-{3-乙酰基-2-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-5-甲基-苯基}-乙酰胺APCI-MS:m/z470.1[MH+]实施例72N-{2-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-4-甲基-苯基}-乙酰胺APCI-MS:m/z428.1[MH+]实施例73N-{2-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-5-氟-苯基}-乙酰胺APCI-MS:m/z432.1[MH+]实施例741-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-3-(1H-吲哚-7-基氧基)-丙-2-醇APCI-MS:m/z396.1[MH+]实施例751-{7-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-吲哚-1-基}-乙酮APCI-MS:m/z438.1[MH+]实施例76N-{4-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-联苯-3-基}-乙酰胺APCI-MS:m/z490.1[MH+]实施例77N-{2-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-4-氟-苯基}-乙酰胺APCI-MS:m/z432.1[MH+]实施例78N-{2-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-5-甲基-苯基}-乙酰胺APCI-MS:m/z428.1[MH+]实施例79N-{2-[3-(8-氯-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-苯基}-乙酰胺APCI-MS:m/z414.1[MH+]实施例80N-{5-氯-2-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-苯基}-乙酰胺APCI-MS:m/z432.1[MH+]实施例81N-{3-乙酰基-2-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-5-甲基-苯基}-乙酰胺APCI-MS:m/z454.3[MH+]实施例82N-{2-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-4-甲基-苯基}-乙酰胺APCI-MS:m/z412.1[MH+]实施例83N-{5-氟-2-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-苯基}-乙酰胺APCI-MS:m/z 16.1[MH+]实施例841-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-3-(1H-吲哚-7-基氧基)-丙-2-醇APCI-MS:m/z380.1[MH+]实施例851-{7-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-吲哚-1-基}-乙酮APCI-MS:m/z422.1[MH+]实施例86N-{4-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-联苯-3-基}-乙酰胺APCI-MS:m/z474.3[MH+]实施例87N-{4-氟-2-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-苯基}-乙酰胺APCI-MS:m/z416.1[MH+]实施例88N-{2-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-5-甲基-苯基}-乙酰胺APCI-MS:m/z412.1[MH+]实施例89N-{2-[3-(8-氟-1,3,4,5-四氢-吡啶并[4,3-b]吲哚-2-基)-2-羟基-丙氧基]-苯基}-乙酰胺APCI-MS:m/z398.1[MH+]实施例90N-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z453,455[MH+]实施例913-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯APCI-MS:m/z482,484[MH+]实施例921-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-3-(2,6-二甲氧基-苯氧基)-丙-2-醇APCI-MS:m/z456,458[MH+]实施例931-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-3-(2-甲氧基-苯氧基)-丙-2-醇APCI-MS:m/z 426,428[MH+]实施例942-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺APCI-MS:m/z467,469[MH+]实施例951-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮APCI-MS:m/z452,454[MH+]实施例961-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酮APCI-MS:m/z438,440[MH+]实施例973-(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯APCI-MS:m/z418[MH+]实施例981-(2,6-二甲氧基-苯氧基)-3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-丙-2-醇APCI-MS:m/z392[MH+]实施例991-[3-(4-氟-苯氧基)-吡咯烷-1-基]-3-(2-甲氧基-苯氧基)-丙-2-醇APCI-MS:m/z362[MH+]实施例100(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯APCI-MS:m/z447[MH+]实施例101(2-{3-[3-(4-氯-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯APCI-MS:m/z491[MH+]实施例1022-(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-2-甲基-丙酸甲酯APCI-MS:m/z475[MH+]实施例1032-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺APCI-MS:m/z403[MH+]实施例1041-(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-6-甲氧基-苯基)-乙酮APCI-MS:m/z404[MH+]实施例1051-(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮APCI-MS:m/z 388[MH+]实施例1061-(2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酮APCI-MS:m/z374[MH+]实施例107N-[2-(3-{[1-(3,4-二氯苄基)-4-哌啶基]氨基}-2-羟基丙氧基)-4-甲基苯基]乙酰胺APCI-MS:m/z480[MH+]实施例1083-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯APCI-MS:m/z436[MH+]实施例1091-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-3-(2-甲氧基-苯氧基)-丙-2-醇APCI-MS:m/z380[MH+]实施例110(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯APCI-MS:m/z465[MH+]实施例1112-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺APCI-MS:m/z421[MH+]实施例1121-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-6-甲氧基-苯基)-乙酮APCI-MS:m/z 422[MH+]实施例1131-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮APCI-MS:m/z 406[MH+]实施例1141-(2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酮APCI-MS:m/z 392[MH+]实施例115N-(2-{3-[4-(3,4-二氯苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z452.1[MH+]实施例1163-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯APCI-MS:m/z434[MH+]实施例1171-[3-(4-氯-苯氧基)-吡咯烷-1-基]-3-(2,6-二甲氧基-苯氧基)-丙-2-醇APCI-MS:m/z408[MH+]实施例1181-[3-(4-氯-苯氧基)-吡咯烷-1-基]-3-(2-甲氧基-苯氧基)-丙-2-醇APCI-MS:m/z378[MH+]实施例119(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯APCI-MS:m/z463[MH+]实施例1202-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-2-甲基-丙酸甲酯APCI-MS:m/z491[MH+]实施例1212-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺APCI-MS:m/z419[MH+]实施例1221-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-6-甲氧基-苯基)-乙酮APCI-MS:m/z420[MH+]实施例1231-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮APCI-MS:m/z404[MH+]实施例1241-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酮APCI-MS:m/z390[MH+]实施例125N-(2-{3-[3-(4-氰基-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z 396[MH+]实施例1263-(2-{3-[3-(4-氰基-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯APCI-MS:m/z425[MH+]实施例127(2-{3-[3-(4-氰基-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯APCI-MS:m/z 454[MH+]实施例1282-{3-[3-(4-氰基-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-N,N-二甲基苯甲酰胺APCI-MS:m/z 410[MH+]实施例1294-{1-[2-羟基-3-(2-丙酰基-苯氧基)-丙基]-吡咯烷-3-基氧基}-苄腈APCI-MS:m/z395[MH+]实施例130N-(2-{2-羟基-3-[3-(4-甲氧基-苯氧基)-吡咯烷-1-基]-丙氧基}-苯基)-乙酰胺APCI-MS:m/z401[MH+]实施例131N-(4-氯-2-{3-[4-(3,4-二氯苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z486[MH+]实施例1323-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯APCI-MS:m/z468,470[MH+]实施例1331-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-3-(2-甲氧基-苯氧基)-丙-2-醇APCI-MS:m/z 412,414[MH+]实施例134(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯APCI-MS:m/z497,499[MH+]实施例1352-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-2-甲基-丙酸甲酯APCI-MS:m/z525,527[MH+]实施例1362-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺APCI-MS:m/z453,455[MH+]实施例1371-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-6-甲氧基-苯基)-乙酮APCI-MS:m/z454,456[MH+]实施例1381-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮APCI-MS:m/z438,440[MH+]实施例1391-(2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酮APCI-MS:m/z424,426[MH+]实施例140N-(2-{3-[4-(3,4-二氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z421[MH+]实施例1413-(2-{3-[4-(3,4-二氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯APCI-MS:m/z450[MH+]实施例1422-{3-[4-(3,4-二氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺APCI-MS:m/z435[MH+]实施例1431-(2-{3-[4-(3,4-二氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮APCI-MS:m/z420[MH+]实施例144(2-{3-[4-(3,4-二氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯APCI-MS:m/z479[MH+]实施例145N-(2-{3-[3-(3,4-二氟-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z435[MH+]实施例146N-(2-{3-[4-(4-氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z403[MH+]实施例1473-(2-{3-[4-(4-氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯APCI-MS:m/z432[MH+]实施例1481-(2,6-二甲氧基-苯氧基)-3-[4-(4-氟-苯氧基)-哌啶-1-基]-丙-2-醇APCI-MS:m/z406[MH+]实施例1491-[4-(4-氟-苯氧基)-哌啶-1-基]-3-(2-甲氧基-苯氧基)-丙-2-醇APCI-MS:m/z376[MH+]实施例1501-(2-{3-[4-(4-氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酮APCI-MS:m/z388[MH+]实施例1512-{3-[4-(4-氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺APCI-MS:m/z417[MH+]实施例1521-(2-{3-[4-(4-氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮APCI-MS:m/z402[MH+]实施例153(2-{3-[4-(4-氟-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯APCI-MS:m/z461[MH+]实施例154N-(2-{3-[3-(4-氟-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z417[MH+]实施例1553-(2-{3-[3-(4-氟-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯APCI-MS:m/z446[MH+]实施例1561-[3-(4-氟-苯氧基甲基)-哌啶-1-基]-3-(2-甲氧基-苯氧基)-丙-2-醇APCI-MS:m/z390[MH+]实施例1571-(2-{3-[3-(4-氟-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酮APCI-MS:m/z402[MH+]实施例1582-(2-{3-[3-(4-氟-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-2-甲基-丙酸甲酯APCI-MS:m/z503[MH+]实施例1592-{3-[3-(4-氟-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺APCI-MS:m/z431[MH+]实施例1601-(2-{3-[3-(4-氟-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-6-甲氧基-苯基)-乙酮APCI-MS:m/z432[MH+]实施例161N-(2-{3-[4-(4-乙酰氨基-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z442[MH+]实施例162N-(4-{1-[3-(2-乙酰基-苯氧基)-2-羟基-丙基]-哌啶-4-基氧基}-苯基)-乙酰胺APCI-MS:m/z 427[MH+]实施例163N-(4-氰基-2-{3-[4-(3,4-二氯苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z477[MH+]实施例1643-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯APCI-MS:m/z448[MH+]实施例1651-[4-(4-氯-苯氧基)-哌啶-1-基]-3-(2-甲氧基-苯氧基)-丙-2-醇APCI-MS:m/z392[MH+]实施例1661-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酮APCI-MS:m/z404[MH+]实施例1672-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-2-甲基-丙酸甲酯APCI-MS:m/z505[MH+]实施例1682-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺APCI-MS:m/z433[MH+]实施例1691-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-6-甲氧基-苯基)-乙酮APCI-MS:m/z434[MH+]实施例1701-(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮APCI-MS:m/z418[MH+]实施例171(2-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯甲酰氨基)-乙酸甲酯APCI-MS:m/z477[MH+]实施例172N-(2-{3-[3-(4-氯-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺APCI-MS:m/z433[MH+]实施例1733-(2-{3-[3-(4-氯-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙酸甲酯APCI-MS:m/z462[MH+]实施例1741-(2-{3-[3-(4-氯-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酮APCI-MS:m/z418[MH+]实施例1752-{3-[3-(4-氯-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-N,N-二甲基-苯甲酰胺APCI-MS:m/z447[MH+]实施例1761-(2-{3-[3-(4-氯-苯氧基甲基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-丙-1-酮APCI-MS:m/z432[MH+]实施例177N-[2-({(1R,2R)-2-[4-(3,4-二氯苯氧基)-1-哌啶基]-1-羟基环戊基}甲氧基)苯基]乙酰胺实施例178(2S,4R)-1-{3-[2-(乙酰氨基)苯氧基]-2-羟基丙基}-4-[(4-氯苄基)氧基]-2-吡咯烷甲酸甲酯盐酸盐实施例179-189原料:A)(3,4-二氯-苯基)-哌啶-4-基-胺
在充满氮气的反应容器中,将4-氧代-哌啶-1-甲酸叔丁基酯(2.46g,12.3mmol)和3,4-二氯-苯胺(1.0g,6.17mmol)溶于二氯甲烷(28ml)和乙酸(2.12ml)中。室温下,加入三乙酰氧基硼氢化钠(3.67g,17.3mmol)。将反应物搅拌过夜,然后倒入碳酸氢钠溶液(5%)中。用乙酸乙酯(EtOAc)将水相振摇3次。将合并的有机相经硫酸钠干燥,蒸发,经快速层析纯化(EtOAc∶庚烷3∶7)得到1.7g,81%的纯化合物。将该BOC-保护的标题化合物溶于二氯甲烷(26ml)和三氟乙酸(13ml)中,室温下搅拌3小时,蒸发,溶于乙醚和氢氧化钠(1M)中。分离有机层,将水相用乙醚洗涤2次。将合并的有机层用少量盐水洗涤,经硫酸钠干燥,蒸发得到1.15g(76%)的标题化合物。1H-NMR(400MHz,DMSO-d6):δ7.20(d,1H,J=8.9Hz),6.73(d,1H,J=2.7Hz),6.54(dd,1H,J=8.8,2.7Hz),5.95(d,1H,J=8.1Hz),3.22(m,1H),2.91(bd,2H,J=12.6Hz),2.51(m,2H),2.02(bs,1H),1.81(bd,2H,J=12.4Hz),1.18(m)APCI-MS:m/z245[MH+]B)(4-氯-苯基)-哌啶-4-基-胺
按照与(A)相同的方法,由4-氧代-哌啶-1-甲酸叔丁基酯(3.59g,18.0mmol)、4-氯-苯胺(1.15g,9.0mmol)和三乙酰氧基硼氢化钠(5.34g,25.2mmol)的二氯甲烷(40ml)和乙酸(3.1ml)溶液合成。在二氯甲烷(37ml)和三氟乙酸(18ml)中进行脱保护。收率1.5g,79%。1H-NMR(400MHz,DMSO-d6):δ7.04(d,2H,J=8.9Hz),6.55(d,2H,J=8.9Hz),5.62(d,1H,J=8.1Hz),3.18(m,1H),2.92(bd,2H,J=12.6Hz),2.50(m,2H),1.99(bs,1H),1.82(d,2H,J=12.7Hz),1.18(m,2H)。APCI-MS:m/z211[MH+]C)(4-氟-苯基)-哌啶-4-基-胺
按照与(A)相同的方法,由4-氧代-哌啶-1-甲酸叔丁基酯(3.59g,18.0mmol)、4-氟-苯胺(1.0g,9.0mmol)和三乙酰氧基硼氢化钠(5.34g,25.2mmol)的二氯甲烷(40ml)和乙酸(3.1ml)溶液合成。在二氯甲烷(37ml)和三氟乙酸(18ml)中进行脱保护。收率1.1g,63%。1H-NMR(400MHz,DMSO-d6):δ6.85(t,2H,J=9.0Hz),6.51(dd,2H,J=9.1,4.6Hz),5.27(d,1H,J=8.2Hz),3.13(m,1H),2.89(bd,2H,J=12.5Hz),2.48(m,2H),1.80(bd,2H,J=12.3Hz),1.14(m,2H)。APCI-MS:m/z 195[MH+]D)(3,4-二氟-苯基)-哌啶-4-基-胺
按照与(A)相同的方法,由4-氧代-哌啶-1-甲酸叔丁基酯(3.59g,18.0mmol)、3,4-二氟-苯胺(1.16g,9.0mmol)和三乙酰氧基硼氢化钠(5.34g,25.2mmol)的二氯甲烷(40ml)和乙酸(3.1ml)溶液合成。在二氯甲烷(37ml)和三氟乙酸(18ml)中进行脱保护。收率1.26g,66%。1H-NMR(400MHz,DMSO-d6):δ7.05(dt,1H,J=10.8,9.2Hz),6.50(ddd,1H,J=14.1,7.0,2.8Hz),6.32(bd,1H,J=9.20Hz),5.64(d,1H,J=8.14Hz),3.17(m,1H),2.90(bd,2H,J=12.6Hz),2.50(m,2H),2.00(bs,1H),1.81(bd,2H,J=12.6Hz),1.16(m,2H)。APCI-MS:m/z213[MH+]实施例179N-(2-{3-[4-(3,4-二氯苯胺基)-1-哌啶基]-2-羟基丙氧基}-4-甲基苯基)乙酰胺APCI-MS:m/z466[MH+]实施例180N-(2-{3-[4-(4-氯苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z418[MH+]实施例181N-(4-氯-2-{3-[4-(4-氯苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)-乙酰胺APCI-MS:m/z452[MH+]实施例182N-(2-{3-[4-(4-氯苯胺基)-1-哌啶基]-2-羟基丙氧基}-4-氰基苯基)乙酰胺APCI-MS:m/z443[MH+]实施例183N-(2-{3-[4-(4-氯苯胺基)-1-哌啶基]-2-羟基丙氧基}-4-甲基苯基)乙酰胺APCI-MS:m/z432[MH+]实施例184N-(5-氯-2-{3-[4-(4-氟苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z436[MH+]实施例185N-(5-氯-2-{3-[4-(3,4-二氟苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z454[MH+]实施例186N-(5-氰基-2-{3-[4-(4-氟苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z427[MH+]实施例187N-(5-氰基-2-{3-[4-(3,4-二氟苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z445[MH+]实施例188N-(2-{3-[4-(4-氟苯胺基)-1-哌啶基]-2-羟基丙氧基}-4-甲基苯基)乙酰胺APCI-MS:m/z416[MH+]实施例189N-(2-{3-[4-(3,4-二氟苯胺基)-1-哌啶基]-2-羟基丙氧基}-4-甲基苯基)乙酰胺APCI-MS:m/z434[MH+]实施例190N-(2-{3-[3(S)-(4-氯-苯氧基)-吡咯烷-1-基]-2-(R)-羟基-丙氧基-苯基)乙酰胺i)3-(S)-(4-氯-苯氧基)-吡咯烷CF3COOH
在0℃下,向三苯膦(4.2g,16.02mmol)的THF(75ml)溶液中加入偶氮二甲酸二乙酯(2.52mL),15分钟后,加入4-氯苯酚(2.05g,16.02mmol),再过10分钟后,慢慢加入3-羟基-吡咯烷-1-甲酸叔丁基酯(3.0g,16.02mmol)的THF(20mL)溶液。加入完毕后,移去冰浴,将反应混合液在室温下保持过夜。真空除去溶剂,将残留物与乙醚搅拌,滤除固体的三苯膦。残留物经快速层析纯化(0-0.5%MeOH的CHCl3液)得到副标题化合物(3.65g,76%),将其溶于二氯甲烷(60mL)中,加入三氟乙酸(15mL)。将反应混合液在室温下保持30分钟。真空除去溶剂。将残留物溶于二氯甲烷中,加入乙醚和己烷。滤去固体,得到副标题化合物3.70g,97%。1H-NMR(CDCl3,400MHz):δ10.20(s,1H),9.99(s,1H),7.25(d,J8.8Hz,2H),6.78(d,J 8.8Hz,2H),4.99(m,1H),3.41(m,4H),2.30(m,1H),2.20(m,1H)。APCI-MS:m/z198(MH+)ii)N-(2-{3-[3(S)-(4-氯-苯氧基)-吡咯烷-1-基]-2-(R)-羟基-丙氧基-苯基)乙酰胺
在65℃下,将3-(S)-(4-氯-苯氧基)-吡咯烷CF3COOH(312mg,1.0mmol)、N-乙酰基-2-(2,3-环氧丙氧基)苯胺(207mg,1.0mmol)、K2CO3(560mg)的混合物的EtOH(10mL)溶液搅拌4小时。真空除去溶剂。将残留物在乙酸乙酯和水之间分配。将有机层用NHCl水溶液和水顺次洗涤。该有机层经Na2SO4干燥,过滤,浓缩。残留物经快速层析纯化(0-3%MeOH的CHCl3液)得到非对映体混合物(310mg,77%)。将该非对映体混合物通过HPLC分离得到N-(2-{3-[3(S)-(4-氯-苯氧基)-吡咯烷-1-基]-2-(R)-羟基-丙氧基-苯基)乙酰胺(57mg)。1H-NMR(CDCl3,400MHz):δ8.36(m,1H),8.25(s,1H),7.25(m,2H),6.99(m,2H),6.93(m,1H),6.75(m,2H),4.80(m,1H),4.08(m,2H),3.96(m,1H),3.11(dd,J 5.9,10.5Hz,1H),3.01(m,1H),2.82(m,2H),2.59(m,1H),2.51(dd,J 3.2,12.0Hz,1H),2.29(m,1H),2.19(s,3H),2.01(m,1H)。APCI-MS:m/z 405(MH+)实施例191N-(2-{3-[3S-(4-氯-苯氧基)-吡咯烷-1-基]-2S-羟基-丙氧基}-苯基)-乙酰胺盐酸盐
按照与实施例190类似的方法进行该反应。1H-NMR(CDCl3,400MHz):δ8.35(m,1H),8.26(s,1H),7.24(m,2H),6.99(m,2H),6.92(m,1H),6.75(m,2H),4.80(m,1H),4.12(m,2H),3.95(m,1H),2.95(m,2H),2.80(m,3H),2.52(dd,3.4,12.2Hz,1H),2.30(m,1H),2.19(s,3H),2.01(m,1H)。APCI-MS:m/z405(MH+)实施例192N-(2-{3-[3(R)-(4-氯-苯氧基)-吡咯烷-1-基]-2-(S)-羟基-丙氧基-苯基)乙酰胺
按照与实施例190类似的方法进行该反应。1H-NMR(CDCl3,400MHz):δ8.36(m,1H),8.25(s,1H),7.25(m,2H),6.99(m,2H),6.93(m,1H),6.75(m,2H),4.80(m,1H),4.08(m,2H),3.96(m,1H),3.11(dd,J 5.9,10.5Hz,1H),3.01(m,1H),2.82(m,2H),2.59(m,1H),2.51(dd,J 3.2,12.0Hz,1H),2.29(m,1H),2.19(s,3H),2.01(m,1H)。APCI-MS:m/z405(MH+)实施例193N-[5-氯-2-({(2S)-3-[(3S)-3-(4-氯-苯氧基)-吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺
按照与实施例190类似的方法进行该反应。1H-NMR(CDCl3,400MHz):δ8.45(m,1H),8.36(br.s,1H),7.23(m,2H),6.95(m,1H),6.85(m,1H),6.75(m,2H),4.80(m,1H),4.07(m,2H),3.91(m,1H),2.95(m,2H),2.80(m,3H),2.49(dd,J 3.2,12.0Hz,1H),2.30(m,1H),2.19(s,3H),2.03(m,1H)。APCI-MS:m/z439(MH+)实施例194N-[5-氯-2-({(2R)-3-[(3R)-3-(4-氯-苯氧基)-吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺
按照与实施例190类似的方法进行该反应。1H-NMR(CDCl3,400MHz):δ8.45(m,1H),8.36(br.s,1H),7.23(m,2H),6.95(m,1H),6.85(m,1H),6.75(m,2H),4.80(m,1H),4.07(m,2H),3.91(m,1H),2.95(m,2H),2.80(m,3H),2.49(dd,J 3.2,12.0Hz,1H),2.30(m,1H),2.19(s,3H),2.03(m,1H)。APCI-MS:m/z439(MH+)实施例195N-[5-氯-2-({(2S)-3-[(3R)-3-(4-氯-苯氧基)吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺
按照与实施例190类似的方法进行该反应。1H-NMR(CDCl3,400MHz):δ8.45(m,1H),8.34(br.s,1H),7.22(m,2H),6.94(m,1H),6.85(m,1H),6.75(m,2H),4.80(m,1H),4.08(m,2H),3.90(m,1H),3.11(dd,J 5.9,10.5Hz,1H),3.02(m,1H),2.81(m,2H),2.58(m,1H),2.49(dd,J 3.5,12.1Hz,1H),2.30(m,1H),2.18(s,3H),2.01(m,1H)。APCI-MS:m/z439(MH+)实施例196N-[5-氯-2-({(2R)-3-[(3S)-3-(4-氯-苯氧基)-吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺
按照与实施例190类似的方法进行该反应。1H-NMR(CDCl3,400MHz):δ8.45(m,1H),8.34(br.s,1H),7.22(m,2H),6.94(m,1H),6.85(m,1H),6.75(m,2H),4.80(m,1H),4.08(m,2H),3.90(m,1H),3.11(dd,J 5.9,10.5Hz,1H),3.02(m,1H),2.81(m,2H),2.58(m,1H),2.49(dd,J 3.5,12.1Hz,1H),2.30(m,1H),2.18(s,3H),2.01(m,1H)。APCI-MS:m/z439(MH+)实施例197N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4,5-二氟-苯基)-乙酰胺i)4,5-二氟-2-硝基-苯酚
在烧瓶中,将3,4-二氟苯酚(3.10g,23.7mmol)溶于乙酸(15ml)中。向经搅拌的该溶液中滴加发烟HNO3(1.25g,29.7mmol)的乙酸(6ml)溶液。在整个加料过程中,保持温度在50℃以下。加入完毕后,将混合液再搅拌1小时。然后将反应混合液倒入冰水中,得到黄色固体沉淀。过滤收集固体,干燥。该固体经硅胶纯化(庚烷∶EtOAc 5∶1),得到副标题化合物(2.05g,50%),为黄色油状物,放置后结晶。1H-NMR(400MHz,CDCl3):δ10.61(1H,s);8.00(1H,dd,J 9.6,8.2Hz);7.00(1H,dd,J 10.4,6.8Hz)。ii)N-(4,5-二氟-2-羟基-苯基)-乙酰胺
在烧瓶中,加入i)中得到的产物(0.59g,3.37mmol)和乙酸(10ml)。在搅拌下将该溶液加热至90℃,加入锡(粉末,1.60g,13.5mmol)。将烧瓶密封,在搅拌下再加热1小时,通过硅藻土过滤该热溶液。然后将滤器另用10ml热乙酸洗涤。向滤液中加入水(25ml)和乙酸酐(0.5ml,5.29mmol),搅拌下,将得到的混合液在60℃下加热20分钟。将混合液冷却,在EtOAc和水之间分配。收集有机相,用水和盐水洗涤。蒸发有机相得到0.63g(100%)的固体副标题化合物。1H-NMR(400MHz,DMSO-d6):δ10.25(1H,s);9.31(1H,bs);7.88(1H,dd,J 12.8,7.9Hz);6.83(1H,dd,J 12.1,7.7Hz);2.08(3H,s)。iii)N-(4,5-二氟-2-环氧乙烷基甲氧基-苯基)-乙酰胺
在小瓶中加入ii)中得到的化合物(0.4g,2.137mmol)、表溴醇(0.35g,2.55mmol)、K2CO3(0.6g,4.4mmol)和DMF(2ml)。将小瓶密封,并在搅拌下加热(2小时,60℃)。然后将混合液在EtOAc和水之间分配,将有机相用水洗涤2次,用盐水洗涤1次,最后蒸发得到棕色固体。该粗品环氧化物经硅胶纯化,得到0.27g(52%)的副标题化合物,为浅粉色固体。1H-NMR(400MHz,CDCl3):δ8.37(1H,dd,J 12.2,8.8Hz);7.85(1H,bs);6.78(1H,dd,J 11.2,7.1Hz);4.34(1H,dd,11.5,2.2Hz);3.90(1H,dd,11.6,6.3Hz);3.40-3.36(1H,m);2.98(1H,t,J 4.5Hz);2.81(1H,dd,J 4.7,6.3Hz);2.22(3H,s)。iv)N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-4,5-二氟-苯基)乙酰胺
在小瓶中加入iii)中得到的化合物(0.059g,0.24mmol)、3-(4-氯苯氧基)-吡咯烷(0.048g,0.24mmol)和乙醇(2ml,99.5%)。将小瓶密封,在搅拌下,将该内容物加热至75℃保持2小时。将该粗溶液蒸发,得到的油状物经经硅胶纯化,得到标题化合物的盐酸盐,冷冻干燥。得到的标题化合物为白色固体(0.075g,65%)。该化合物是四种对NMR光谱有影响的立体异构体的混合物。1H-NMR(400MHz,DMSO-d6):δ10.78-10.30(1H,m);9.30(1H,s);8.07(1H,dd,J 12.8,9.3Hz);7.40-7.34(2H,m);7.23(1H,dd,J 12.7,7.5Hz);7.05-6.99(2H,m);6.19(1H,bs);5.23-5.11(1H,m);4.35(1H,bs);4.08-3.97(1.5H,m);3.69-3.90(1H,m);3.84-3.70(1.5H,m);3.63-3.23(4H,m);2.66-2.00(5H,m)。APCI-MS:m/z411.1[MH+]实施例198N-{5-氯-2-[2-羟基-3-(3-苯氧基-吡咯烷-1-基)-丙氧基]-苯基}-乙酰胺
进行与实施例197类似操作制备本化合物。1H-NMR(400MHz,DMSO-d6):δ10.80-10.36(1H,m);9.26(1H,s);8.14(1H,s);7.32(2H,t,J 8.35Hz);7.11-6.95(5H,m);631-6.02(1H,m);5.24-5.12(1H,m);4.37(1H,bs);4.10-3.97(1.5H,m);3.95-3.88(1H,m);3.84-3.68(1.5H,m);3.64-3.26(4H,m);2.65-2.52(0.5H,m);2.35-2.02(4.5H,m)。APCI-MS:m/z 405.2[MH+]实施例199N-(5-氯-2-{2-羟基-3-[3-(4-硝基-苯氧基)-吡咯烷-1-基]-丙氧基}-苯基}-乙酰胺
进行与实施例197类似操作制备本化合物。1H-NMR(400MHz,DMSO-d6):δ10.95-10.48(1H,m);9.26(1H,s);8.24(2H,d,J 9.6Hz);8.13(1H,bs);7.23-7.17(2H,m);7.12-7.02(2H,m);6.20(1H,bs);5.43-5.30(1H,m);4.38(1H,m);4.18-4.06(0.5H,m);4.05-3.97(1H,m);3.95-3.87(1H,m);3.86-3.72(1.5H,m);3.69-3.27(4H,m);2.73-2.60(0.5H,m);2.46-2.08(4.5H,m)。APCI-MS:m/z450.1[MH+]实施例200N-(5-乙酰基-2-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺
根据实施例197类似方法制备该化合物。APCI-MS:m/z481.2,483.2[MH+]实施例2014-乙酰氨基-3-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酸甲酯
根据实施例197类似方法制备该化合物。APCI-MS:m/z497.1,499.2[MH+]实施例202N-(3-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-萘-2-基)-乙酰胺
根据实施例197类似方法制备该化合物。APCI-MS:m/z489.2,491.2[MH+]实施例203N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-5-氰基-苯基)-乙酰胺
根据实施例197的方法制备标题化合物。APCI-MS:m/z430.2[MH+]实施例2044-乙酰氨基-3-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯甲酸甲酯
根据实施例197类似方法制备该化合物。APCI-MS:m/z463.2[MH+]实施例205N-(3-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]2-羟基-丙氧基}-萘-2-基)-乙酰胺
根据实施例197的方法制备标题化合物。APCI-MS:m/z455.2[MH+]实施例206N-(5-氰基-2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺
根据实施例197的方法制备标题化合物。APCI-MS:m/z478.2,480.1[MH+]实施例207N-(2-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-5-三氟甲基-苯基)-乙酰胺
根据实施例197的方法制备标题化合物。APCI-MS:m/z521.1,523.2[MH+]实施例208N-(5-氯-2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺三氟乙酸盐
根据实施例197的方法制备标题化合物。APCI-MS:m/z423.1,424.9[MH+]实施例209N-(5-乙酰基-2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]2-羟基-丙氧基}-苯基)-乙酰胺三氟乙酸盐i)N-(5-乙酰基-2-环氧乙烷基甲氧基-苯基)-乙酰胺
向4-乙酰基-2-硝基苯酚(0.50g,2.76mmol)的THF(20ml)溶液中加入10%Pd/C(0.15g)。在1atm(大气压)下,将反应混合液用H2氢化5小时,然后通过硅藻土过滤,蒸发得到0.63g红色油状物。加入水(20ml)和乙酸酐(0.35g,3.44mmol),将混合液剧烈搅拌5分钟。然后在搅拌下,将反应混合液加热至60℃保持30分钟,之后冷却。形成红色固体,过滤收集沉淀,用水洗涤,干燥得到0.27g(1.40mmol)的N-(5-乙酰基-2-羟基-苯基)-乙酰胺。将其溶于DMF(5ml)中。加入K2CO3(0.34g,2.45mmol)和表溴醇(0.21g,1.54mmol),在50℃、搅拌下,将得到的混合液加热3小时。将该混合液在EtOAc和水40+40ml之间分配。将有机相用水洗涤2次,用盐水洗涤1次,最后真空浓缩得到红色油状物。该粗产物经硅胶纯化(庚烷∶EtOAc,1∶2-1∶4)得到110mg(16%)的副标题化合物。1H-MR(400MHz,CDCl3):δ9.03(1H,d,J 1.9Hz),7.81(1H,bs),7.74(1H,dd,J 8.6,2.3Hz),6.96(1H,d,J 8.6Hz),4.48(1H,dd,J 11.3,2.4Hz),4.00(1H,dd,J 11.4,6.4Hz),3.45-3.40(1H,m),2.99 (1H,t,J4.4Hz),2.79(1H,dd,J 4.7,2.6Hz),2.59(3H,s),2.26(3H,s)。ii)N-(5-乙酰基-2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]2-羟基-丙氧基}-苯基)-乙酰胺三氟乙酸盐
根据实施例197中说明的方法制备标题化合物。APCI-MS:m/z447,449[MH+]实施例210N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}-苯基)-甲磺酰胺i)1-(2-氨基苯氧基)-3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-丙醇二盐酸盐
将N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}苯基)乙酰胺(0.95g,2.34mmol)和浓盐酸(25ml)的混合物加热(100-105℃)3小时,然后在室温下放置过夜。将混合液减压浓缩至其体积的三分之一,用饱和碳酸氢钠碱化。将得到的悬浮液用乙酸乙酯萃取2次。将该有机萃取物干燥,减压蒸发溶剂,得到淡棕色油状物。将该油状物溶于尽少量的甲醇中,用乙醚稀释,加入用HCl饱和的乙醚液沉淀产物。过滤产物得到该副标题化合物(0.93g,91.2%)。APCI-MS:m/z363[MH+],游离碱ii)N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}苯基)-甲磺酰胺
将甲磺酰氯(35mg,0.3mmol)加入到冷却(0℃)、搅拌的以上得到的胺(110mg,0.25mmol)和吡啶(0.4mL)的无水二氯甲烷(10mL)混合液中。然后在室温下将混合液搅拌1.5小时,浓缩。将残留物在乙酸乙酯和水之间分配。将有机相浓缩,残留物经快速层析纯化(硅胶,二氯甲烷-甲醇,25∶1),得到标题化合物(68mg,61.8%),为泡沫状物。1H-NMR(400MHz,CDCl3):δ7.51(dd,1H,J=1.4和8.0Hz),7.22(m,2H),7.10(m,1H),7.68(m,1H),6.92(d,1H,J=9.0Hz),6.76(m,2H),5.78(非常宽的单峰,1H),4.80(m,1H),4.20(m,1H),4.08(m,1H),3.98(m,1H),3.16(m,1H),3.01(m,1H),2.96(s,3H),2.89(m,2H),2.74(m,M),2.68(dd,1H,J=4.0和12.2Hz),2.3(m,1H)和2.02(m,1H)。13C-NMR(400MHz,CDCl3):δ 155.9,149.4,129.4,126.9,125.8,125.77,125.75,122.29,122.26,122.17,115.5,113.52,113.50,76.52,76.49,72.15,72.09,67.18,67.08,60.24,60.07,57.96,57.94,53.18,52.98,39.1,31.92,31.90。APCI-MS:m/z441[MH+]实施例211N-(5-氯-2-[3-[3,4-二氯苯氧基)-1-吡咯烷基]-2-羟基-丙氧基]苯基)脲i)N-(5-氯-2-羟基苯基)脲
将氰酸钾(6.14g,75.6mmol)的水(50mL)溶液滴加入经搅拌的2-氨基-4-氯苯酚(5.00g,34.8mmol)在乙酸(350mL)和水(250mL)混合液中的悬浮液中,将得到的溶液在室温下搅拌3小时。将反应混合液用乙醚萃取3次。将乙醚萃取液合并,浓缩得到浓稠油状物。向以上油状物中加入碳酸氢钠的10%溶液(250mL)。过滤固体产物,用水洗涤数次,重结晶(含少量甲醇的甲苯),得到副标题化合物(3.27g,50.4%)。1H-NMR(400MHz,DMSO-d6):δ10.1(s,1H),8.07(d,1H,J=2.2Hz),8.04(s,1H),6.75-6.78(m,2H),6.29(bs,2H)。13C-NMR:δ156.0,144.1,130.0,122.5,120.2,117.5,115.2。ii)N-[5-氯-2-(2-环氧乙烷基甲氧基)苯基]脲
室温下,将N-(5-氯-2-羟基苯基)脲(53mg,0.28mmol)、碳酸铯(92mg,0.28mmol)和表溴醇(49mg,0.36mmol)的无水DMF(0.6mL)悬浮液搅拌24小时。然后将混合液在乙酸乙酯和水之间分配。将有机相用水洗涤3次,干燥,浓缩得到固体残留物。将该粗产物重结晶(乙醚和庚烷),得到副标题化合物(18mg,26.5%)。1H-NMR(400MHz,DMSO-d6):δ8.20(d,1H,J=2.2Hz),8.00(s,1H),7.00(d,1H,J=8.8Hz),6.88(dd,1H,J=2.4和8.6Hz),6.40(bs,2H),4.40(dd,1H,J=2.2和12.0Hz),3.90(dd,1H,J=6.6和12.0Hz),3.37(m,1H),2.88(t,1H,J=4.8Hz),2.74(m,1H)。iii)N-(5-氯-2-[3-[3,4-二氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基]苯基)脲
将副标题化合物(ii)(16mg,0.07mmol)和3-(3,4-二氯苯氧基)吡咯烷(17mg,0.07mmol)的无水乙醇(1mL)溶液搅拌2小时。减压除去溶剂,残留物经快速层析纯化(二氯甲烷-甲醇,15∶1),得到标题化合物(11mg,33%)。1H-NMR(400MHz,DMSO-d6):δ8.18(d,1H,J=2.6Hz),7.94(s,1H),7.5(d,1H,J=0.0Hz),7.16(d,1H,J=2.1Hz),6.82-6.98(m,3H),6.33(bs,2H),4.98(m,1H),4.90(m,1H),3.85-4.07(m,3H),2.63-2.93(m,5H),2.21-2.30(m,1H),1.74(m,1H)。APCI-MS:m/z198[MH+]实施例2121-(3-{2-[(氨基羰基)氨基]苯氧基}-2-羟基丙基)-3-(4-氯苯氧基)吡咯烷鎓2,2,2-三氟乙酸盐i)N-(2-羟基苯基)脲
在15分钟内,将氰酸钾(3.94g,48.6mmol)的水(30mL)溶液加入到2-氨基苯酚(2.41g,22.1mmol)的50%乙酸水溶液(160mL)的悬浮液中。室温下,将得到的溶液放置过夜,然后用乙醚萃取(3次)。将合并的有机萃取液浓缩至少量体积,然后倒入冷的饱和碳酸氢钠水溶液中。过滤固体,用水洗涤,得到副标题化合物(1.61g,47.9%)。1H-NMR(400MHz,DMSO-d6):δ9.88(s,1H),7.97(s,1H),7.80(bd,1H),6.77(m,1H),6.68(m,1H),6.17(s,2H)。ii)N-[2-(2-环氧乙烷基甲氧基)苯基]脲
将表溴醇(0.94g,6.84mmol)的无水DMF(2mL)溶液滴加到经搅拌的N-(2-羟基苯基)脲(0.65g,4.27mmol)和碳酸铯(2.22g,6.84mmol)的DMF(8mL)悬浮液中。2小时后,将混合液在水和乙酸乙酯之间分配。将水相用乙酸乙酯萃取,将合并的有机相用水洗涤(3次),干燥,浓缩。将半固体残留物溶于二氯甲烷/乙醚中,过滤,向该混浊液中加入庚烷。室温放置过夜后,过滤固体,得到副标题化合物(0.28g,32%)。1H-NMR(400MHz,DMSO-d6):δ8.07(m,1H),7.82(s,1H),6.97(m,1H),6.85(m,2H),6.24(bs,2H),4.37(dd,1H,J=2.5和11.6Hz),3.89(dd,1H,J=6.4和11.6Hz),3.38(m,1H),2.87(t,1H,J=4.6Hz),2.75(dd,1H,J=2.6和5.2HZ)。APCI-MS:m/z209[MH+]iii)1-(3-{2-[(氨基羰基)氨基]苯氧基}-2-羟基丙基)-3-(4-氯苯氧基)吡咯烷鎓2,2,2-三氟乙酸盐
将N-[2-(2-环氧乙烷基甲氧基)苯基]脲(78mg,0.37mmol)和3-(4-氯苯氧基)吡咯烷(70mg,0.36mmol)的无水乙醇(4mL)溶液加热回流2.5小时。然后浓缩混合液,残留物经HPLC纯化,得到标题化合物(102mg,54.5%)。1H-NMR(400MHz,DMSO-d6+D2O):δ7.98(bd,1H,J=7.2Hz),7.36(d,2H,J=8.8Hz),6.95-7.02(m,3H),6.88(m,2H),5.15(bd,1H),4.26(m,1H)。余下的10个脂族质子在δ2.04-4.04之间呈现出复杂的重叠多重峰。APCI-MS:m/z406[MH+]和408[MH++2]为游离碱实施例2131-(3-{2-[(氨基羰基)氨基]苯氧基}-2-羟基丙基)-3-(3,4-二氯苯氧基)吡咯烷鎓2,2,2-三氟乙酸盐
将N-[2-(2-环氧乙烷基甲氧基)苯基]脲(在实施例22步骤ii中说明;69mg,0.33mmol)和3-(3,4-二氯苯氧基)吡咯烷(77mg,0.33mmol)的无水乙醇(4.5mL)溶液在70℃加热2小时。蒸发溶剂后,残留物经HPLC纯化,得到标题化合物(133mg,72.3%)。1H-NMR(400MHz,DMSO-d6+D2O):δ7.96(bd,1H,J=7.4Hz),7.54(bd,1H,J=9.0Hz),7.27(bs,1H),6.84-7.00(m,4H),5.20(bd,1H),4.26(m,1H)。余下的10个脂族质子在δ2.05-4.03之间呈现出复杂的重叠多重峰。APCI-MS:m/z439.9[M]和442[M+2]为游离碱实施例2141-(3-{2-[(氨基羰基)氨基]-4-氯苯氧基}-2-羟基丙基)-3-(4-氯苯氧基)吡咯烷鎓2,2,2-三氟乙酸盐
将N-[2-(2-环氧乙烷基甲氧基)苯基]脲(在实施例212步骤ii中说明;47mg,0.22mmol)和3-(4-氯苯氧基)吡咯烷(41mg,0.2mmol)的无水乙醇(3mL)溶液在70℃加热1.5小时。然后蒸发溶剂,残留物经HPLC纯化,得到标题化合物(67mg,60.9%)。1H-NMR(400MHz,CD3OD):δ8.04(s,1H),7.31(d,2H,J=8.6Hz),6.94-6.98(m,4H),5.20(bs,1H),4.40(m,1H)。余下的10个脂族质子在δ2.25-4.13之间呈现出复杂的重叠多重峰。APCI-MS:m/z440.1[M]和442.1[M+2]为游离碱实施例215N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}-苯基)-N’-乙基脲盐酸盐
在室温下,在密封管中,将N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}苯基)脲[通过将盐酸盐(110mg,0.25mmol)用1MNaOH处理并用乙醚萃取获得]的乙醚溶液用异氰酸乙酯(16μl,0.2mmol)处理15小时。蒸发并经硅胶快速层析纯化(EtOAc/MeOH100/5)后,将适当的部分用1M HCl酸化,从乙酸冷冻干燥,得到标题化合物,为白色无定形固体(35mg,37%)。该物质是两个成对非对映体的混合物。APCI-MS:m/z434[MH+]实施例216N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}苯基)-N’-甲基脲盐酸盐
向N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}苯基)脲[通过将盐酸盐(44mg,0.1mmol)用1M NaOH处理并用乙醚萃取获得]的DCM(3ml)溶液中,加入三碳酸二叔丁基酯(26mg,0.1mmol),将该溶液放置15分钟。加入甲胺(2M的DCM液,100μl,0.2mmol),将该溶液放置过夜。蒸发后,粗产物经制备RP-HPLC纯化,用含有0.1%TFA的乙腈和水作为流动相。将适当的部分真空浓缩,用1MNaOH和乙醚萃取。将有机相中的残留物用1M HCl酸化,从乙酸中冷冻干燥,得到标题化合物,为白色无定形固体(15mg,30%)。该物质是两个成对非对映体的混合物。APCI-MS:m/z420[MH+]实施例217(2S,4S)-1-{3-[2-(乙酰氨基)苯氧基]-2-羟基丙基}-4-(4-氯苯氧基)-2-吡咯烷甲酸;与三氟乙酸的化合物i)(2S,4S)-1-{3-[2-(乙酰氨基)苯氧基]-2-羟基丙基}-4-(4-氯苯氧基)-2-吡咯烷甲酸甲酯盐酸盐
在100℃下,在密封管中,将溶于叔丁醇(7ml)中的(2S,4S)-4-(4-氯苯氧基)-2-吡咯烷甲酸甲酯(370mg,1.0mmol)和N-[2-(2-环氧乙烷基甲氧基)苯基]乙酰胺(207mg,1.0mmol)搅拌过夜。经硅胶快速层析(DCM/MeOH100/2)处理粗产物,将适当的部分用1M HCl酸化,从乙酸中冷冻干燥,得到副标题化合物,为白色无定形固体(360mg,72%)。该物质是非对映体混合物。APCI-MS:m/z463[MH+]ii)(2S,4S)-1-{3-[2-(乙酰氨基)苯氧基]-2-羟基丙基}-4-(4-氯苯氧基)-2-吡咯烷甲酸;三氟乙酸化合物
将化合物(i)(50mg,0.1mmol)溶于乙腈(2ml)和水(3ml)中。加入溶于水(0.5ml)中的氢氧化锂水合物(8mg,0.2mmol)。反应在0.5小时后完成,通过分析HPLC确定。将该混合物用TFA酸化,经制备RP-HPLC纯化,用含有0.1%TFA的乙腈和水作为流动相。将适当的部分真空浓缩,残留物在乙酸中冷冻干燥,得到标题化合物,为白色无定形固体(27mg,48%)。该物质是非对映体的混合物。APCI-MS:m/z449[MH+],431[MH+,内酯,微量]实施例218(2S,4S)-1-{3-[2-(乙酰氨基)苯氧基]-2-羟基丙基}-4-(3,4-二氯苯氧基)-2-吡咯烷甲酸乙酯;三氟乙酸盐i)(2S,4S)-4-(3,4-二氯苯氧基)-2-吡咯烷甲酸甲酯
按照与实施例217(ii)类似的方法,用N-Boc-cis-4-羟基-L-脯氨酸甲酯和3,4-二氯苯酚制备该化合物。1H-NMR(400MHz,DMSO-d6):δ9.64(bs,2H);7.58(d,1H);7.25(d,1H);6.94(dd,1H);5.24(m,1H);4.66(dd,1H);3.76(s,3H);3.55(dd,1H);3.47(d,1H);2.67-2.58(m,1H);2.38(d,1H)。APCI-MS:m/z 290,292[MH+,同位素方式]ii)(2S,4S)-1-{3-[2-(乙酰氨基)苯氧基]-2-羟基丙基}-4-(3,4-二氯苯氧基)-2-吡咯烷甲酸乙酯;三氟乙酸盐
按照与实施例217类似的方法,由化合物i)(404mg,1.0mmol)和N-[2-(2-环氧乙烷基甲氧基)苯基]乙酰胺(207mg,1.0mmol)制备该化合物,但用乙醇作为溶剂。发生再次酯化,经后处理和纯化后,分离出标题化合物,为白色固体(209mg,33%)。该物质是非对映体的混合物。APCI-MS:m/z511,513[MH+,同位素方式]实施例219N-[2-({(2S)-3-[(2S,4S)-4-(4-氯苯氧基)-2-(羟甲基)吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺;三氟乙酸盐和N-[2-({(2R)-3-[(2S,4S)-4-(4-氯苯氧基)-2-(羟甲基)吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺;三氟乙酸盐i)[(2S,4S)-4-(4-氯苯氧基)吡咯烷基]甲醇
在0℃、氩气气氛下,在40分钟内,将(2S,4S)-4-(4-氯苯氧基)-2-吡咯烷甲酸甲酯(根据实施例217ii)的方法,由顺式-4-羟基-L-脯氨酸甲酯制备)(850mg,3.32mmol)的无水THF(20ml)溶液加入到氢化铝锂(505mg,13.3mmol)的无水THF(10ml)混合液中。室温下搅拌过夜后,加入硫酸钠十水合物(1g),接着滴加水(0.5ml)、氢氧化钠(15%w/v,0.5ml)和水(1.5ml)。过滤,蒸发得到浆状物,经硅胶快速层析纯化(二氯甲烷/甲醇/浓氨100/20/1),得到副标题化合物(0.60g,79%)。1H-NMR(400MHz,CDCl3):δ7.22(m,2H),6.78(m,2H),4.79(m,1H),3.62(m,2H),3.39(m,1H),3.23(bd,2H),3.14(dd,1H,J 5.0Hz,12.2Hz),2.28(m,1H),1.72(m,1H)。MS-APCI+:m/z228[MH+]ii)N-[2-({(2S)-3-[(2S,4S)-4-(4-氯苯氧基)-2-(羟甲基)吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺;三氟乙酸盐和N-[2-({(2R)-3-[(2S,4S)-4-(4-氯苯氧基)-2-(羟甲基)吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺;三氟乙酸盐
将[(2S,4S)-4-(4-氯苯氧基)吡咯烷基]甲醇(380mg,1.67mmol)和N-[2-(2-环氧乙烷基甲氧基)苯基]乙酰胺(414mg,2.00mmol)溶于叔丁醇(5ml)中,在100℃下,在密封管中,搅拌3小时。将该溶液浓缩,残留物经硅胶快速层析纯化(二氯甲烷/甲醇13/1),接着经制备RP-HPLC纯化,用含有0.1%三氟乙酸的乙腈/水作为流动相。将适当的部分冷冻干燥,得到标题化合物(差向异构体A:248mg,27%,差向异构体B:115mg,13%;未测出差向异构体中心的立体化学)。差向异构体A:1H-NMR(400MHz,MeOD):δ7.82(dd,1H,J 1.3Hz,8.0Hz),7.31(m,2H),7.14(m,1H),7.04(m,1H),6.96(m,3H),5.20(m,1H),4.40(m,1H),4.11(bd,2H),3.79-4.05(m,5H),3.73(dd,1H,J 5.2Hz,12.5Hz),3.43(dd,1H,J 2.6Hz,13.0Hz),2.80(m,1H),2.1 8(s,3H),2.12(m,1H)。MS-APCI+:m/z435[MH+]差向异构体B:1H-NMR(400MHz,MeOD):δ7.79(dd,1H,J 1.3Hz,7.9Hz),7.32(m,2H),7.14(m,1H),7.04(m,1H),6.97(m,3H),5.18(m,1H),4.49(m,1H),3.83-4.19(m,7H),3.69(dd,1H,J 4.8Hz,13.2Hz),3.34(m,1H),2.72(m,1H),2.18(s,3H),2.07(m,1H)。MS-APCI+:m/z435[MH+]实施例220N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基-2-甲基丙氧基}苯基)乙酰胺盐酸盐i)N-{2-[(2-甲基-2-丙烯基)氧基]苯基}乙酰胺
按照与实施例8(i)类似的方法,由3-氯-2-甲基丙烯(1.09g,11.9mmol)和2-乙酰氨基苯酚(1.50g,9.92mmol)制备该化合物(1.74g,85%)。1H-NMR(400MHz,CDCl3):δ8.36(dd,1H,J 1.7Hz,7.8Hz),7.80(bs,1H),6.98(m,2H),6.87(dd,1H,J1.6Hz,7.9Hz),5.08(s,1H),5.04(s,1H),4.51(s,2H),2.21(s,3H),1.85(s,3H)。ii)N-{2-[(2-甲基-2-环氧乙烷基)甲氧基]苯基}乙酰胺
根据实施例8(ii)中说明的类似方法,用N-{2-[(2-甲基-2-丙烯基)氧基]苯基}乙酰胺(800mg,3.90mmol)和间氯过苯甲酸(80%,1.10g,5.22mmol)制备该化合物(0.56g,65%)。1H-NMR(400MHz,CDCl3):δ8.36(m,1H),8.01(bs,1H),7.01(m,2H),6.91(m,1H),4.07(m,2H),2.96(d,1H,J 4.8Hz),2.79(d,1H,J 4.8Hz),2.22(s,3H),1.49(s,3H)。iii)N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基-2-甲基丙氧基}苯基)乙酰胺盐酸盐
根据实施例1(iii)中说明的类似方法,用N-{2-[(2-甲基-2-环氧乙烷基)甲氧基]苯基}乙酰胺(123mg,0.557mmol)和3-(4-氯苯氧基)吡咯烷(100mg,0.506mmol)制备标题化合物(255mg,110%)。1H-NMR(400MHz,MeOD):δ7.61(m,1H),7.29(m,2H),7.18(m,1H),7.10(m,1H),6.96(m,3H),5.18(m,1H),3.91-4.22(m,4H),3.37-3.76(m,4H),2.66(m,1/2H),2.37(m,1H),2.25(m,1/2H),2.15(m,3H),1.45(m,3H)。MS-APCI+:m/z 419[MH+]实施例221-230原料的制备和通用步骤制备环氧化物:A)N-(2-{[(2S*,3S*)-3-甲基环氧乙烷基]甲氧基}苯基)乙酰胺i)N-{2-[(E)-1-丙烯基氧基]苯基}乙酰胺
将市售提供的1-氯-2-丁烯(Aldrich,主要是反式)(453mg,0.49mL,5.00mmol)、2-乙酰氨基苯酚(756mg,5.00mmol)和碳酸钾(691mg,5.00mmol)的丙酮(10ml)非均质混合液加热回流过夜。蒸发溶剂后,将残留物吸收至乙酸乙酯和水中。将有机相用水、5%氢氧化钠和盐水洗涤,蒸发溶剂,得到粗品,经硅胶快速层析纯化(己烷/EtOAc=3∶2)。得到732mg(71%)的棕黄色固体。反式∶顺式=81∶19(根据1H-NMR;400MHz,CDCl3测定比率)。MS-APCI+:m/z206.1[MH+]ii)将间氯过苯甲酸(70%;270mg,1.92mmol,2.0当量)加入到冰浴冷却的溶于二氯甲烷(3ml)中的化合物i)(112mg,546μmol)的溶液中,不需再冷却,搅拌过夜。加入乙酸乙酯,将混合液用饱和亚硫酸钠、5%氢氧化钠和盐水洗涤。经硫酸钠干燥,蒸发溶剂,经硅胶快速层析纯化得到86mg(71%)的产物,为米色固体,1H-NMR测定的反式∶顺式比率为83∶17。1H-NMR(400MHz,CDCl3;仅给出主要异构体的信号):δ8.35(1H,m),7.90(1H,br.s),7.00(2H,m),6.88(1H,m),4.30(1H,dd,J 11.4,2.5Hz),3.96(1H,dd,J 11.4,5.7Hz),3.08(2H,m),2.21(3H,s),1.40(3H,d,J5.2Hz)。MS-APCI+:m/z222.1[MH+]B)N-(2-{[(2S,3R)-3-甲基环氧乙烷基]甲氧基}苯基)乙酰胺i)N-[2-(2-丁炔基氧基)苯基]乙酰胺
将1-溴代-2-丁炔(1.39g,10.4mmol)、2-乙酰氨基苯酚(1.58mg,10.4mmol)、无水碳酸钾(1.44g,10.4mmol)和碘化钠(30mg)的丁酮(50ml)混合液加热回流过夜。然后将反应混合液过滤,蒸发滤液,将得到的残留物溶于乙酸乙酯中。将得到的溶液用5%氢氧化钠、盐水和水洗涤,经硫酸钠干燥,蒸发。粗产物用庚烷/MTB(1∶1)重结晶,得到1.57g(74%)的浅棕色针状物MS-APCI+:m/z 204.1[MH+]ii)N-{2-[(Z)-2-丁烯基氧基]苯基}乙酰胺
在室温、大气压力下,将炔i)(357mg,1.76mmol)和5%Pd/BaSO4(22mg)的吡啶(2.0mL)混合液氢化2小时30分钟。此时原料完全消耗掉,但通过LC/MS观测到一些对应烷烃的过度还原产物。将反应混合液通过硅藻土过滤,用乙酸乙酯充分洗涤。然后将该滤液用1N HCl洗至酸性,最后用盐水洗至中性。经硫酸钠干燥,蒸发溶剂,得到318mg(88%)的粗产物,其除含有所需的z-烯烃外,还含有一些作为副产物的E-烯烃和相应的烷烃。根据1H-NMR(400MHz,CDCl3)测定的比率是E∶Z∶烷烃=83∶10∶7。粗品不经进一步纯化直接用于下一步骤。MS-APCI+:m/z206.1[MH+]iii)将烯烃ii)(310mg,1.51mmol)溶于二氯甲烷(10ml)中,在0℃下,加入间氯过苯甲酸(80%;587mg,2.72mmol,1.8当量)。室温下搅拌过夜,接着蒸发溶剂,将得到的残留物溶于乙酸乙酯,用饱和亚硫酸钠、5%氢氧化钠和盐水洗涤,经硫酸钠干燥。蒸发溶剂,经硅胶快速层析(乙酸乙酯/庚烷=2∶1持续至乙酸乙酯)得到269mg(81%)的环氧化物,E∶Z比率为82∶18(经1H-NMR测定),为白色粉末。1H-NMR(400MHz,CDCl3;仅给出主要异构体的信号):δ8.37(1H,dd,J 7.5,2.1Hz),7.81(1H,br.s),7.02(2H,m),6.91(1H,dd,J 7.4,1.7Hz),4.32(1H,dd,J 11.1,3.6Hz),4.03(1H,dd,J 11.1,6.9Hz),3.33(1H,dt,J 7.0,4.0Hz),3.24(1H,dt,J 9.9,5.5Hz),2.21(3H,s),1.38(3H,d,J 5.7Hz)。MS-APCI+:m/z222.1[MH+]C)N-{2-[(1R,2S,5R)*-6-氧杂双环[3.1.0]己-2-基氧基]苯基}乙酰胺i)(2-环戊烯-1-基氧基)(三异丙基)硅烷
室温下,将2-环戊烯醇(K.Alder,F.H.Flock,Chem.Ber.1956,89,1732.)(2.31g,27.5mmol)、(三异丙基)氯硅烷(5.30g,5.9mL,27.5mmol)、咪唑(2.06g,30.2mmol)的DMF(50mL)溶液搅拌3小时,再在50℃下搅拌1小时。然后将该溶液用乙酸乙酯稀释,用水洗涤4次,经硫酸钠干燥。蒸发溶剂得到6.32g(96%)的甲硅烷基醚513/13,为无色液体。1H-NMR光谱中未见主要杂质。1H-NMR(400MHz,CDCl3):δ5.88(1H,m),5.76(1H,m),4.98(1H,m),2.48(1H,m),2.27-2.17(2H,m),1.70(1H,m),1.12-1.05(21H,m)。ii)三异丙基[(1R,2R,5R)*-6-氧杂双环[3.1.0]己-2-基氧基]硅烷
将间氯过苯甲酸(70%;5.41g,21.9mmol,1.7当量)加入到冰浴冷却的溶于二氯甲烷(25ml)中的化合物i)(3.10g,12.9mmol)的溶液中,不需再冷却,再搅拌90分钟。过滤反应混合液,蒸发滤液,将残留物溶于乙酸乙酯中,用饱和亚硫酸钠、5%氢氧化钠和盐水洗涤,经硫酸钠干燥。蒸发溶剂得到粗品,为非对映体环氧化物的混合物,反式/顺式比为78∶22(1H-NMR)。经硅胶快速层析分离(庚烷/乙酸乙酯=95∶5持续至90∶10)得到1.65g(50%)所需的反式环氧化物(1R,2R,5R)*,为先洗脱的非对映体。两种非对映体环氧化物的总收率为2.86g(87%)。1H-NMR(400MHz,CDCl3):δ4.39(1H,d,J 3.4Hz),3.54(1H,d,J 2.5Hz),3.37(1H,d,J 2.5Hz),1.94(1H,m),1.84(dtd,J 13.7,9.3,1.1Hz),1.60-1.55(2H,m),1.13-1.04(21H,m)。iii)(1S,2R,5R)*-6-氧杂双环[3.1.0]己-2-醇
向甲硅烷基醚ii)(280mg,1.09mmol)的THF(2.0mL)溶液中,加入氟化四丁基铵(1.0M的THF溶液;1.2mL,1.20mmol)。室温下搅拌3小时后,将混合液用乙酸乙酯稀释,用盐水洗涤,经硫酸钠干燥。经硅胶层析滤过(庚烷/叔丁基甲基醚2∶1持续至乙酸乙酯)得到79mg(72%)浅黄色油状物。1H-NMR(400MHz,CDCl3):δ4.36(1H,d,J 5.1Hz),3.55(1H,s),3.42(1H,d,J 1.5Hz),1.99(1H,m),1.84(1H,dddd,J 13.9,10.1,9.0,1.1Hz),1.69-1.53(3H,m)。iv)根据下列通法(I)制备标题化合物。1H-NMR(400MHz,CDCl3):δ8.38(1H,m),7.91(1H,br.s),7.02-6.98(2H,m),6.94(1H,m),4.78(1H,td,J 8.0,1.2Hz),3.61(1H,m),3.54(1H,d,J 2.7Hz),2.21(3H,s),2.21(1H,m),2.10(1H,dt,J 12.8,12.0Hz),1.76(1H,dtd,J 14.3,10.4,1.4Hz),1.58(1H,m)。MS-APCI+:m/z234.1[MH+]N-{2-[(1R,2S,5R)*-6-氧杂双环[3.1.0]己-2-基氧基]苯基}乙酰胺的制备通法(I)步骤1-Mitsunobu偶合:
向冰浴冷却的环氧乙醇546/16(1.0当量)、三苯膦(1.2当量)和2-硝基苯酚(1.0当量)的无水THF(2mL/mmol)溶液中,滴加重氮二甲酸二乙酯(1.2当量)。不再冷却,继续搅拌过夜。水溶液、碱性处理,接着经硅胶快速层析纯化(典型洗脱:庚烷/乙酸乙酯=1∶1),得到2-硝基苯酚的酯,其中经常含有等摩尔量的副产物1,2-肼二甲酸二乙酯。步骤2-氢化:
在室温、大气压力下,将步骤1中得到的2-硝基苯酚酯、二异丙基(乙基)胺(2.0当量)、乙酸酐(2.0当量)和5%Pt/C(10mg/mmol)的乙酸乙酯(10mL/mmol)混合液氢化1小时。在有未卤化的芳族物质的情况下,可用Pd/C和更短的反应时间,一般约为5分钟。然后用填充硅藻土的滤器漏斗滤除催化剂(catalysator),用乙醇洗涤。蒸发滤液,剩余的残留物经水溶液、碱性处理。然后经硅胶快速层析(典型洗脱液:乙酸乙酯/庚烷=2∶1)得到各自的乙酰胺,一般收率为50-70%(2步)。D)N-{5-氯-2-[(1R,2S,5R)*-6-氧杂双环[3.1.0]己-2-基氧基]苯基}乙酰胺
根据方法(I)制备。1H-NMR(400MHz,CDCl3):δ8.47(1H,d,J 2.5Hz),7.89(1H,br.s),6.97(1H,dd,J 8.8,2.5Hz),6.85(1H,d,J 8.8Hz),4.74(1H,td,J 8.0,1.3Hz),3.58(1H,m),3.56(1H,m),2.21(1H,m),2.21(3H,s),2.09(dt,J 13.0,7.4Hz),1.76(1H,dtd,J 14.3,10.1,1.3Hz),1.56(1H,m)。MS-APCI+:m/z268.0[MH+]E)N-{4-氟-2-[(1R,2S,5R)*-6-氧杂双环[3.1.0]己-2-基氧基]苯基}乙酰胺
根据方法(I)制备。1H-NMR(400MHz,CDCl3):δ8.23(1H,dd,J 10.7,2.8Hz),7.99(1H,br.s),6.89(1H,dd,J 9.0,5.5Hz),6.69(1H,ddd,J 11.1,9.0,3.1Hz),4.70(1H,t,J7.8Hz),3.56(2H,s),2.21(1H,dd,J 14.7,8.4Hz),2.21(3H,s),2.08(1H,dt,J13.0,8.2Hz),1.75(1H,dtm,J14.3,9.5Hz)。MS-APCI+:m/z252.1[MH+]将氨基环加入到取代的2-(芳氧基甲基)环氧乙烷中的制备通法(II)
在密闭管中,将溶解于饱和LiClO4的乙腈溶液(1ml/100μmol)中的等摩尔量的氨基环和环氧化物加热至100℃。反应时间一般为从打开环氧化物的链的3小时至形成氧杂双环[3.1.0]己烷的18小时之间。冷却至室温后,将反应混合液用乙酸乙酯稀释,再进行水溶液处理。通常可定量得到粗产物,经硅胶快速层析纯化(典型洗脱液:乙酸乙酯/甲醇=80∶20)。
根据通法(I)和(II),制备下列实施例221-230。实施例221N-(2-{(1S*,2R*,3S*)-3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-环戊基氧基}-苯基)-乙酰胺1H-NMR(400MHz,CDCl3):δ8.20(1H,d,J 7.4Hz),8.07(1H,br.s),7.21(2H,m),7.01-6.96(2H,m),6.92(1H,dm,J 7.4Hz),6.77(2H,dm,J8.8Hz),4.77(1H,m),4.54(1H,br.q,J 4.8Hz),4.15(1H,m),3.04-2.91(3H,m),2.81(1H,q,J 6.8Hz),2.62(1H,五重峰,J 7.3Hz),2.29(1H,m),2.16(3H,s),2.13-1.90(5H,m),1.63(1H,m)。MS-APCI+:m/z431.2[MH+]实施例222N-(2-{(1R*,2R*,3S*)-3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-环戊基氧基}-苯基)-乙酰胺1H-NMR(400MHz,CDCl3):δ8.26(1H,m),7.90(1H,br.d,J 9.5Hz),7.20(2H,m),6.97(2H,m),6.88(1H,br.d,J 7.3Hz),6.76(2H,m),4.76(1H,m),4.50(1H,m),4.21(1H,dt,J 14.1,5.5Hz),3.00-2.89(3H,m),2.67-2.54(2H,m),2.28(1H,m),2.15(3H,s),2.11(1H,m),1.97(2H,m),1.87(2H,m)。MS-APCI+:m/z431.2[MH+]实施例223N-(2-{(2R*,3R*)-3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丁氧基}-苯基)-乙酰胺1H-NMR(400MHz,CDCl3):δ8.27(1H,dd,J 7.6,1.6Hz),8.07(1H,br.s),7.30(1H,d,J 8.8Hz),7.04-6.92(4H,m),6.74(1H,dd,J 8.8,2.9Hz),4.26(1H,m),4.23(1H,dd,J 9.9,2.7Hz),4.06(1H,m),3.96(1H,dd,J 9.9,8.0Hz),2.86-2.72(3H,m),2.58(1H,m),2.47(1H,m),2.18(3H,s),1.99(2H,m),1.80(2H,m),1.12(3H,d,J 6.9Hz)。MS-APCI+:m/z469.1[MH+]实施例224N-(2-{(1S*,2R*,3S*)-3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-环戊基氧基}-苯基)-乙酰胺1H-NMR(400MHz,CDCl3):δ8.26(1H,m),8.20(1H,br.s),7.19(2H,m),7.02(2H,m),6.95(1H,m),6.84(2H,m),4.49(1H,q,J 5.2Hz),4.31(1H,m),4.15(1H,m),2.95(2H,q,J 7.8Hz),2.87(1H,m),2.51(2H,br.q,J10.2Hz),2.19(3H,s),2.10-1.95(5H,m),1.86(2H,m),1.60(1H,m)。MS-APCI+:m/z445.0[MH+]实施例225N-(2-{(2R*,3S*)-3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]2-羟基-丁氧基}-苯基)-乙酰胺1H-NMR(400MHz,CDCl3):δ8.47(1H,br.s),8.36(1H,dd,J 7.2,1.3Hz),7.32(1H,d,J 9.0),7.04-6.93(4H,m),6.75(1H,dd,J 9.0,2.9Hz),4.34(1H,m),4.11(1H,m),3.96(1H,dd,J 10.5,5.2Hz),3.66(1H,m),3.00-2.80(2H,m),2.71(2H,m),2.42(1H,m),2.19(3H,s),2.05(1H,m),1.94-1.81(2H,m),1.08(3H,d,J 6.7Hz)。MS-APCI+:m/z466.9[MH+]实施例226N-(2-{(2R*,3R*)-3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丁氧基}-苯基)-乙酰胺1H-NMR(400MHz,CDCl3):δ8.34(1H,t,J 4.5Hz),8.18(1H,br.s),7.22(2H,m),6.99(2H,m),6.93(1H,m),6.76(2H,m),4.78(1H,m),4.20(1H,m),4.07(1H,dt,J 10.1,2.9Hz),3.95(1H,dd,J 10.1,8.2Hz),3.15(0.5H,dd,J 10.7,6.1Hz),2.97-2.94(1.5H,m),2.89(0.5H,q,J 7.6Hz),2.82(0.5H,dd,J 10.5,2.5Hz),2.73(0.5H,qm,J 7.5Hz),2.65(0.5H,m),2.58(1H,m),2.26(1H,m),2.01(1H,m),1.09(3H,显示为dd,J 6.7,1.7Hz)。MS-APCI+:m/z419.1[MH+]实施例227N-(2-{(2R*,3S*)-3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丁氧基}-苯基)-乙酰胺1H-NMR(400MHz,CDCl3):δ8.48(1H,m),8.37(1H,m),7.22(2H,m),7.04-6.93(3H,m),6.77(2H,m),4.80(1H,m),4.12(1H,m),3.97(1H,dd,J10.5,5.3Hz),3.65(1H,m),3.09(0.5H,dd,J 10.3,6.0Hz),3.09-2.99(1.5H,m),2.94(0.5H,q,J 8.0Hz),2.87-2.67(2.5H,m),2.25(1H,m),2.02(1H,m),1.05(3H,显示为dd,J 6.7,5.2Hz)。MS-APCI+:m/z418.9[MH+]实施例228N-(2-{(1S*,2R*,3S*)-3-[4-(3-氯-苯氧基)-哌啶-1-基]-2-羟基-环戊基氧基}-苯基)-乙酰胺1H-NMR(400MHz,CDCl3):δ 8.25(1H,m),8.17(1H,br.s),7.18(1H,t,J8.1Hz),7.01(2H,m),6.97-6.90(3H,m),6.79(1H,dm,J 9.0Hz),4.48(1H,q,J 5.5Hz),4.34(1H,七重峰,J 3.5Hz),4.15(1H,dd,J 7.2,5.5Hz),2.95(2H,q,J 7.4Hz),2.87(1H,m),2.52(2H,br.q,J 9.6Hz),2.19(3H,s),2.09-1.94(6H,m),1.86(2H,m),1.59(1H,m)。MS-APCI+:m/z445.1[MH+]实施例229N-[5-氯-2-({(1S,2R,3S)*-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基环戊基}氧基)苯基]乙酰胺1H-NMR(400MHz,CDCl3):δ8.38(2H,m),7.31(1H,d,J 8.7Hz),6.99(1H,d,J 8.8Hz),6.95(1H,dd,J 8.8,2.6Hz),6.86(1H,d,J 8.8Hz),6.75(1H,dd,J 8.8,2.9Hz),4.38(1H,q,J 4.0Hz),4.31(1H,七重峰,J3.7Hz),4.10(1H,dd,J≈7,6Hz),3.00(1H,q,J 7.1Hz),2.91-2.82(1H,m),2.53(2H,m),2.17(3H,s),2.08-1.93(5H,m),1.85(2H,m),1.60(1H,m)。MS-APCI+:m/z513.1[MH+]实施例230N-[4-氟-2-({(1S,2R,3S)*-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基环戊基}氧基)苯基]乙酰胺1H-NMR(400MHz,CDCl3):δ8.58(1H,br.s),8.19(1H,dd,J 10.9,3.2Hz),7.3 1(1H,d,J 8.8Hz),7.00(1H,d,J 2.9Hz),6.89(1H,dd,J 9.0,5.2Hz),6.75(1H,dd,J 9.0,2.9Hz),6.67(1H,td,J 8.8,3.1Hz),4.35-4.29(2H,m),4.09(1H,dd,J 7.8,5.0Hz),3.04(1H,q,J 7.8Hz),2.88(2H,m),2.54(2H,m),2.18(3H,s),2.08(5H,m),1.85(2H,m),1.61(1H,m)。MS-APCI+:m/z497.2[MH+]实施例231-248原料的制备A)(S*R*)-1-(3,4-二氯苄基)-2,5-二甲基-哌嗪
将1,2-二氯-4-氯甲基-苯(1.1ml,7.89mmol)的DMF(5ml)溶液加入到溶于DMF(25ml)中的2,5-二甲基-哌嗪(1.0g,8.77mmol)中。将反应物搅拌过夜,倒入EtOAc和碳酸钠(5%)的混合物中。将水相用EtOAc洗涤2次,将合并的有机相用盐水洗涤一次,经硫酸钠干燥。蒸发后,将粗产物溶于甲醇中。二苄基化的哌嗪不溶解。将滤液通过短硅胶柱过滤,用甲醇作为洗脱剂,蒸发得到纯产物。收率:812mg,38%。1H-NMR(400MHz,DMSO-d6):δ7.56(d,1H,J=8.1Hz),7.52(d,1H,J=1.8Hz),7.20(dd,1H,J=8.2,1.8Hz),3.97(d,1H,J=14.1Hz),3.04(d,1H,J=14.2Hz),2.76(dd,1H,J=11.9,3.0Hz),2.59(m),2.48(dd,1H,J=11.9,2.6Hz),2.37(t,1H,J=10.8Hz),2.12(m),1.89(s),1.57(t,1H,J=10.4Hz),1.00(d,1H,J=6.1Hz),0.82(d,1H,J=6.3Hz)。APCI-MS:m/z273[M+]B)(S*R*)-1-(4-二氯-苄基)-2,5-二甲基-哌嗪
按照与A)相同的方法,在DMF中,用1-氯-4-氯甲基-苯(1.27g,7.89mmol)和2,5-二甲基哌嗪(1.0g,8.77mmol)合成。收率:701mg,37%。1H-NMR(400MHz,DMSO-d6):δ7.36(d,2H,J=8.4Hz),7.30(d,2H,J=8.4Hz),3.97(d,1H,J=13.9Hz),3.01(d,1H,J=13.8Hz),2.75(dd,1H,J=11.9,3.0Hz),2.57(m,1H,J=10.8,2.6Hz),2.47(dd,1H,J=10.9,2.6Hz),2.36(dd,1H,J=11.6,10.1Hz),2.10(m,1H),1.88(bs,1H),1.53(t,1H,J=10.5Hz),1.01(d,3H,J=6.1Hz),0.80(d,3H,J=6.4Hz)。APCI-MS:m/z239[MH+]C)1-(3,4-氯苄基)哌嗪
室温下,将3,4-氯苄基氯(170mg,0.872mmol)加入到哌嗪(150mg,1.74mmol)和三乙胺(1ml)的DMF(10ml)溶液中。2小时后,真空浓缩该溶液。将得到的残留物在乙醚中研磨,将得到的固体用水洗涤,然后溶解于甲醇中,与甲苯共蒸发,得到固体产物89mg。APCI-MS:m/z245,247[MH+]1H-NMR(400MHz,CD3OD):δ7.41(d,1H,J=2.0Hz),7.37(d,1H,J=8.2Hz),7.13(dd,1H,J=8.2Hz,J=2.0Hz),3.5(s,2H),3.05(m,4H),2.57(m,4H)。D)1-(4-氯苄基)哌嗪
根据以上C)类似的方法制备。实施例231N-(2-{3-[4-(3,4-二氯苄基)-1-哌嗪基]-2-羟基丙氧基}-苯基)乙酰胺二盐酸盐
将N-乙酰基-2-(2,3-环氧丙氧基)苯胺(87.53mg,0.422mmol)和1-(3,4-氯苄基)哌嗪的乙醇(10ml,99.5%)溶液回流3小时。减压蒸除溶剂,得到的残留物经硅胶柱层析纯化(二氯甲烷/甲醇20∶1),得到标题化合物,为胶状物。加入1.0M醚制HCl溶液,得到白色固体产物78mg(40%)。APCI-MS:m/z452,454[MH+]1H-NMR(400MHz,CD3OD):δ8.0(1H,dd,J=1.53Hz,J=8.01Hz),7.5(1H,d,J=1.91Hz),7.45(1H,d,J=8.2Hz),7.23(1H,dd,J=6.1Hz,J=2.1Hz),6.89-7.08(4H,m),4.15(1H,m),3.9-4.1(2H,m),3.48(2H,s),2.45-2.60(10H,m),2.17(3H,s)。
根据实施例231的方法,用以上原料A)-D)合成实施例232-248。实施例232N-(2-{3-[4-(3,4-二氯苄基)-1-哌嗪基]-2-羟基丙氧基}-4-氟苯基)乙酰胺APCI-MS:m/z470[MH+]实施例233N-(2-{3-[4-(3,4-二氯苄基)-2,5-二甲基-1-哌嗪基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z480[MH+]实施例234N-(5-氯-2-{3-[4-(3,4-二氯苄基)-1-哌嗪基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z486[MH+]实施例235N-(5-氯-2-{3-[4-(3,4-二氯苄基)-2,5-二甲基-1-哌嗪基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z480[MH+]实施例236N-(2-{3-[4-(3,4-二氯苄基)-2,5-二甲基-1-哌嗪基]-2-羟基丙氧基}-4-甲基苯基)乙酰胺APCI-MS:m/z494[MH+]实施例237N-(2-{3-[4-(3,4-二氯苄基)-2,5-二甲基-1-哌嗪基]-2-羟基丙氧基}-4-氟苯基)乙酰胺APCI-MS:m/z498[MH+]实施例238N-(2-{3-[(S*R*)-4-(3,4-二氯苄基)-2,5-二甲基-1-哌嗪基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z480[MH+]实施例239N-(2-{3-[(S*R*)-4-(4-氯苄基)-2,5-二甲基-1-哌嗪基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z446[MH+]实施例240N-(5-氯-2-{3-[(S*R*)-4-(3,4-二氯苄基)-2,5-二甲基哌嗪基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z514[MH+]实施例241N-(5-氯-2-{3-[(S*R*)-4-(4-氯苄基)-2,5-二甲基哌嗪基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z480[MH+]实施例2421-(5-氯-2-{3-[4-(4-氯苯甲酰基)-1-哌嗪基]-2-羟基丙氧基}苯基)-1-乙酮APCI-MS:m/z451[MH+]实施例243N-(5-氰基-2-{3-[(S*R*)-4-(3,4-二氯苄基)-2,5-二甲基哌嗪基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z505[MH+]实施例244N-(2-{3-[(S*R*)-4-(4-氯苄基)-2,5-二甲基哌嗪基]-2-羟基丙氧基}-5-氰基苯基)乙酰胺APCI-MS:m/z471[MH+]实施例245N-(5-氯-2-{3-[4-(4-氯苄基)-1-哌嗪基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z452[MH+]实施例246N-(4-氯-2-{3-[4-(4-氯苄基)-2,5-二甲基-1-哌嗪基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z460[MH+]实施例247N-(2-{3-[4-(4-氯苯甲酰基)-1-哌嗪基]-2-羟基丙氧基}-5-氰基苯基)乙酰胺APCI-MS:m/z457[MH+]实施例248N-(2-{3-[4-(4-氯苯甲酰基)-1-哌嗪基]-2-羟基丙氧基}-4-甲基苯基)乙酰胺APCI-MS:m/z446[MH+]实施例249N-[5-氯-2-({(1R,2S,3R)-3-[(3S)-3-(4-氯苯氧基)吡咯烷基]-2-羟基环戊基}氧基)苯基]乙酰胺MS-APCI+:m/z464.9[MH+][α]22=-47.6(CH2C2)实施例250N-{2-[(2S)-(3-{(3S)-3-[(4-氯苯基)氧基]-1-吡咯烷基}-2-羟基丙基)氧基]-4-氟苯基}乙酰胺APCI-MS:m/z423.1[M+]实施例251N-[2-({(2S)-3-[(3S)-3-(4-氯苄基)吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺盐酸盐i)3-(4-氯苄基)吡咯烷
在N2下,用两三分钟的时间,向搅拌下的3-(4-氯苄基)-2-吡咯烷酮(420mg,2mmol)的无水THF(25mL)溶液中,按份加入LAH(190mg,5mmol)。将温度升高至60℃,继续搅拌2.5小时。将混合液用200μL水、200μL5M NaOH和600μL水猝灭。滤除固体Li-和Al-盐,蒸发滤液得到无色油状物(387mg,99%)。APCI-MS:m/z196,198[MH+]ii)(2S)-1-[3-(4-氯苄基)-1-吡咯烷基]-3-(2-硝基苯氧基)-2-丙醇将化合物(i)(387mg,2mmol)和(2S)-2-[(2-硝基苯氧基)-甲基]环氧乙烷(390mg,2mmol)的乙醇(6mL)溶液回流,直至通过LCMS确定反应完成(2h)。蒸发溶剂得到橙色油状物(650mg,83%),将其不经进一步纯化使用。APCI-MS:m/z391,393[MH+]iii)(2S)-1-(2-氨基苯氧基)-3-[3-(4-氯苄基)-1-吡咯烷基]-2-丙醇
在60℃下,向化合物(ii)(650mg,1.67mmol)的乙醇(10mL)溶液中,加入氯化锡(II)二水合物(2.25g,10mmol)和35%盐酸(2.5mL)的混合物。将温度快速升至75℃。在60℃下,将混合液再搅拌30分钟。蒸发溶剂后,将残留物用5M NaOH和乙醚萃取。将有机相用水洗涤,干燥,蒸发。残留物经RP-HPLC纯化,用含0.1%TFA的乙腈和水作为流动相。将适当的部分蒸发,将残留物用1M NaOH和乙醚萃取。从有机相中得到副标题化合物,为无色油状物(400mg,66%)。APCI-MS:m/z361,363[MH+]iv)向化合物(iii)(400mg,1.1mmol)的DCM(10mL)溶液中,加入乙酸酐(200μL,2.1mmol),将混合液放置过夜。蒸发后,将残留物溶于甲醇中,加入1.5M甲醇钠的甲醇(2mL)溶液。将混合液放置2小时,蒸发,用乙醚和水吸收。从有机相中得到两种非对映体的混合物。经手性柱HPLC分离该非对映体,用异己烷、2-丙醇和甲醇的混合液作为流动相。将分离的对映体溶于甲醇(1mL)中,用1M盐酸(1mL)酸化,用水稀释,冷冻干燥得到标题化合物,为白色无定形固体(156mg和173mg)。未测定出绝对立体异构构型。APCI-MS:m/z403,405[MH+]实施例252N-(5-氯-2-{3-[3-(4-氯苄基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)乙酰胺三氟乙酸盐i)3-(4-氯-苄基)-吡咯烷-2-酮
在烧瓶中加入二异丙基胺(3.22g,31.8mmol)和无水THF(60ml)。将烧瓶中的内容物保持在氮气下,然后冷却至-76℃。向该冷却的溶液中滴加正丁基锂(n-BuLi,32mmol,20ml,1.6M己烷溶液)。加入完毕后,将溶液搅拌10分钟,再滴加1-三甲基硅烷基-吡咯烷-2-酮(5.00g,31.8mmol,根据文献方法制备)的无水THF(5ml)溶液。然后将该溶液再搅拌20分钟,在5分钟内,通过注射器加入4-氯苄基氯(5.13g,32mmol)的THF(5ml)溶液。在-76℃下,将得到的混合液搅拌1小时,然后使温度达到室温,搅拌过夜。加入水(40ml),将混合液剧烈搅拌60分钟。分离两相,将有机相用盐水洗涤,最后蒸发,得到油状物,放置结晶。将该固体用庚烷∶EtOAc 2∶1研磨,过滤,得到部分纯的固体。该固体经硅胶纯化(DCM至DCM∶MeOH 99∶1至98∶2至97∶3梯度),得到1.3g(20%)副标题化合物。1H-NMR(400MHz,CDCl3):δ7.27(2H,d,J 8.4Hz),7.16(2H,d,J 8.4Hz),5.43(1H,bs),3.31-3.13(3H,m),2.74-2.61(2H,m),2.20-2.12(1H,m),1.88-1.77(1H,m)。ii)3-(4-氯-苄基)吡咯烷
在烧瓶中,将a)中得到的化合物(0.20g,0.95mmol)溶于无水THF(10ml)中。在10分钟内,以小份加入LiAlH4(0.17g,4.53mmol)。加入完毕后,在氮气下,将混合液加热至60℃约3小时,通过LC-MS监测反应,反应完成后,猝灭反应物。在猝灭之前,将反应物冷至室温,小心地滴入水(0.160ml)。滴加NaOH(10%水溶液,0.16ml),最后再加部分水(0.48ml)。将混合液搅拌1小时,然后过滤。真空浓缩滤液,得到副标题化合物(0.18g,97%),为无色油状物。APCI-MS:m/z196.1[M+H]iii)N-(5-氯-2-{3-[3-(4-氯苄基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)乙酰胺三氟乙酸盐
根据实施例1iii)中说明的方法,用ii)中得到的化合物,制备标题化合物。1H-NMR(400MHz,DMSO):δ9.93-9.62(1H,m),9.12(1H,s),8.11(1H,s),7.38(2H,d,J 8.9Hz),7.29-7.23(2H,m),7.13-7.02(2H,m),6.11-6.02(1H,m),4.29-4.16(1H,bs),4.05-3.95(1H,m),3.95-3.87(1H,m),3.75-3.50(2H,m),3.40-3.22(3H,m),2.91-2.65(3H,m),2.62-2.52(1H,m),2.13(3H,s),2.11-1.94(1H,m),1.81-1.55(1H,m)。实施例253N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}-4-甲基苯基)-1-吡咯烷甲酰胺三氟乙酸盐i)2-[(5-甲基-2-硝基苯氧基)甲基]环氧乙烷
将5-甲基-2-硝基苯酚(7.7g,50mmol)、碳酸钾(13.8g,0.1mmol)和表溴醇(8.25mL,0.1mmol)的混合物溶于DMF(100mL)中,在通氮气、100℃下,搅拌2-3小时。将混合液用乙醚(0.5L)稀释,用水萃取至pH=7。将有机相蒸发,残留物经硅胶快速层析纯化(DCM),得到副标题化合物,为黄色固体(8.65g,83%)。1H-NMR(400MHz,CDCl3):δ7.80(d,1H);6.91(s,1H);6.86(d,1H);4.39(dd,1H);4.15(dd,1H);3.43-3.37(m,1H);2.93(dd,1H);2.89(dd,1H);2.42(s,3H)。ii)1-[3-(4-氯苯氧基)-1-吡咯烷基]-3-(5-甲基-2-硝基苯氧基)-2-丙醇
将化合物i)(1.05g,5.0mmol)和3-(4-氯苯氧基)吡咯烷(988mg,5.0mmol)的乙醇(12mL)混合液回流2小时。蒸发溶剂,得到粗产物,为橙色油状物,将其不经进一步纯化使用。APCI-MS:m/z407,409[MH+]iii)1-(2-氨基-5-甲基苯氧基)-3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-丙醇
在50℃下,向经搅拌的化合物ii)(2.1g,5.0mmol)的乙醇(10mL)溶液中,加入氯化锡(II)二水合物(5.6g,25mmol)的35%盐酸(6mL)溶液。放热反应开始,温度快速升至75℃。将混合液维持在60℃下0.5小时。将冷却的混合液用1M氢氧化钠(180mL)碱化,用乙醚萃取,将有机相用水洗涤,干燥,蒸发得到副标题化合物,为浅黄色油状物(1.34g,71%)。NMR:由于是两对非对应体的混合物,积分得到的是部分质子。1H-NMR(400MHz,CDCl3):δ7.23(d,2H);6.77(d,2H);6.67-6.65(m,1H);6.64-6.63(m,1H);4.83-4.76(m,1H);4.14-4.06(m,1H);4.01(d,2H);3.71(bs,2H);3.41(bs,1H);3.10(dd,0.5H);3.01-2.90(m,1.75H);2.87-2.70(m,2.7H);2.66-2.57(m,1.5H);2.28(h,1H);2.25(s,3H);2.06-1.95(m,1H)。APCI-MS:377,379[MH+]iv)N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}-4-甲基苯基)-1-吡咯烷甲酰胺三氟乙酸盐
室温下,将化合物(iii)(75mg,0.2mmol)和三碳酸二叔丁基酯(53mg,0.2mmol)的DCM(3ml)溶液搅拌1小时。加入吡咯烷(33μl,0.4mmol),继续搅拌1小时。通过LCMS监测反应完成。加入TFA(1mL),将溶液放置1小时。蒸发挥发性部分,粗品经制备RP-HPLC纯化,用含有0.1%TFA的乙腈和水作为流动相。将适当的部分真空浓缩,将残留物冷冻干燥,得到标题化合物,为白色无定形固体(85mg,72%)。NMR:由于是两对非对应体的混合物,积分得到的是部分质子。数据是游离碱的数据。1H-NMR(400MHz,CDCl3):δ8.03(dd,1H);7.24(d,2H);6.94(bs,1H);6.82-6.74(m,2H);6.78(d,2H);6.73-6.68(m,1H);4.85-4.76(m,1H);4.11-3.94(m,3H);3.52-3.42(m,5.6H);3.11(dd,0.5H);3.05-2.92(m,0.45H);2.95(d,1H);2.87-2.72(m,2.5H);2.62-2.52(m,1.4H);2.37-2.21(m,0.7H);2.29(s,3H);2.08-1.90(m,4.6H)。APCI-MS:m/z474,476[MH+]实施例254N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}-4-羟基苯基)乙酰胺三氟乙酸盐
室温、N2下,向经搅拌的以下实施例265iii)化合物的游离碱(128mg,0.29mmol)的DCM(4mL)溶液中,加入1M三溴化硼的DCM(0.58mL,0.58mmol)溶液。将该非均质混合液搅拌过夜,倒入甲醇中。蒸发后,粗品经RP-HPLC纯化,用含有0.1%TFA的乙腈和水作为流动相。将适当的部分冷冻干燥,得到标题化合物,为白色无定形固体(113mg,73%)。APCI-MS:m/z421,423[MH+]实施例255N-[2-({(2S)-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基丙基}氧基)-4-氟苯基]乙酰胺三氟乙酸盐i)(2S)-2-[(5-氟-2-硝基苯氧基)甲基]环氧乙烷
在烧瓶中加入(R)-缩水甘油(0.994g,13.4mmol)、三苯膦(3.52g,13.4mmol)、THF(20ml,经分子筛干燥)和5-氟-2-硝基苯酚(2.10g,13.4mmol)。将混合液搅拌至形成均相溶液。将溶液冰浴冷却,用数分钟滴加偶氮二甲酸二乙酯(DEAD,2.11ml,13.4mmol)。加入完毕后,将烧瓶升至室温,再搅拌2小时。真空除去溶剂,向残留物中加入氯仿(5-10ml)。过滤除去沉淀(PPh3O),将固体再用氯仿(5-10ml)洗涤。将滤液加入到快速柱(SiO2,庚烷∶乙酸乙酯4∶1),纯化,将纯品部分浓缩后得到2.02g(71%)的副标题化合物,为晶体物质。1H-NMR(400MHz,CDCl3):δ7.97(1H,dd,J 9.3,6.0Hz);6.86(1H,dd,J10.0,2.5Hz);6.80-6.74(1H,m);4.44(1H,dd,J 11.4,2.6Hz);4.12(1H,dd,J 11.2,5.1Hz);3.44-3.38(1H,m);2.95(1H,t,J 4.5Hz);2.90(1H,dd,J 4.8,2.6)。ii)(2S)-1-[4-(3,4-二氯苯氧基)-1-哌啶基]-3-(5-氟-2-硝基苯氧基)-2-丙醇
在管中加入4-(3,4-二氯苯氧基)-哌啶(0.123g,0.5mmol)、i)中得到的化合物(0.106g,0.5mmol)和乙醇(99.5%,3ml)。将管密封,在60℃、搅拌下,将内容物加热3小时,用LC-MS监测反应。将管冷却,蒸发溶剂,得到油状物,经硅胶纯化(DCM至DCM∶MeOH 99∶1至98∶2至97∶3作为分级梯度)。将纯品部分蒸发,得到0.22g(96%)的副标题化合物,为油状物。
APCI-MS(m/z):459.1[M+H]
iii)N-[2-({(2S)-3-[4-(3,4-二氯苯氧基)-1-哌啶基]-2-羟基丙基}氧基)-4-氟苯基]乙酰胺三氟乙酸盐
将ii)中得到的化合物(0.22g,0.48mmol)溶于乙醇(99.5%,7mL)中,搅拌下加热至60℃。加入SnCl2×2H2O(0.56g,5当量)的浓盐酸(0.63ml)溶液,在60℃下搅拌1小时。然后将混合液冷却。通过加入过量的2M NaOH碱化该溶液,将溶液用乙醚萃取(3×50ml)。将合并的醚制溶液用盐水洗涤,蒸发。将得到的油状物溶于THF(8ml)中,加入水(8ml),接着加入乙酸酐(50ml,0.52mmol)。在40℃下,将混合液搅拌15分钟。真空除去有机溶剂,将残留物用EtOAc(3×30ml)萃取。将合并的有机相用盐水洗涤,然后真空浓缩。残留的油状物经制备HPLC纯化,冷冻干燥纯品部分后,得到55g(20%,98%纯度)的标题化合物,为三氟乙酸盐,白色固体。
APCI-MS(m/z):471.0,472.0,473.0和474.0[M+H]
实施例256
N-(2-(3-(4-氯-苯氧基)-吡咯烷-1-基)-2-羟基-丙氧基)-4,6-二氟苯基)乙酰胺盐酸盐
i)3,5-二氟-6-硝基苯酚
向经搅拌的2,3,4-三氟硝基苯(5g,28.23mmol)的无水甲醇(70ml)溶液中,加入钠(0.68,29.46)的无水甲醇(30ml)溶液。将溶液搅拌至原料完全消耗掉(~2h)。浓缩后,加入水,将该溶液用乙醚萃取,经Na2SO4干燥,过滤,浓缩得到黄色残留物(4.65g)。向该黄色残留物的二氯甲烷(140ml)溶液中加入三溴化硼(1M二氯甲烷溶液,40ml),室温下搅拌过夜。然后加入水,将溶液再搅拌30分钟。分离有机相,将水相用乙醚萃取。合并的有机相经Na2SO4干燥,过滤,真空浓缩得到棕色残留物。将残留物吸收入乙醚中,用2M氢氧化钠和水洗涤。合并水和氢氧化钠的洗液,用6MHCl中和,用乙醚萃取,经Na2SO4干燥,蒸发得到黄色残留物,经硅胶快速层析纯化,用EtOAc∶庚烷1∶2为洗脱剂,得到所需产物2g,11.42mmol。GC-MS:m/z175(M+)1H-NMR(400MHz,CD3OD):δppm 6.63-6.68(1H,m),6.60-6.67(1H,dt)。ii)2-[(3,5-二氟-2-硝基苯氧基)甲基]环氧乙烷
向3,5-二氟-6-硝基苯酚(100mg,0.571mmol)和碳酸钾(394mg)的DMF(5ml)混合液中,加入表溴醇(80mg,0.582mmol),在70℃下,搅拌3小时。加入乙酸乙酯和水,分离有机相,干燥,浓缩。得到的残留物经层析纯化(乙酸乙酯∶庚烷3∶1),得到所要求的固体产物161mg(0.696mmol)。GC-MS:m/z231(M+)iii)1-[3-(4-氯苯氧基)-1-吡咯烷基]-3-(3,5-二氟-2-硝基苯氧基)-2-丙醇
将3-(4-氯苯氧基)-吡咯烷和2-[(3,5-二氟-2-硝基苯氧基)甲基]环氧乙烷(50mg,0.216mmol)的乙醇溶液回流3小时。减压馏去溶剂,得到的残留物经硅胶柱层析纯化(二氯甲烷/甲醇20∶1),得到45mg(0.105mmol)的固体标题化合物。iv)N-(2-(3-(4-氯-苯氧基)-吡咯烷-1-基)-2-羟基-丙氧基)-4,6-二氟苯基)乙酰胺盐酸盐
将氧化铂-碳加入到1-[3-(4-氯苯氧基)-1-吡咯烷基]-3-(3,5-二氟-2-硝基苯氧基)-2-丙醇(40mg,0.0932mmol)的乙醇溶液中,在1atm下,将混合液氢化4小时。将混合液通过硅藻土过滤,用热乙醇洗涤数次,将合并的滤液真空浓缩。向得到的黄色残留物中加入二氯甲烷,再向该溶液中加入乙酸酐。室温下,将该溶液搅拌2小时,然后浓缩。加入1.0M醚化氯化氢溶液,生成固体的标题化合物20mg。APCI-MS:m/z441[MH+]实施例257N-[2-({(2S)-3-[(2S,4S)-4-(4-氯苯氧基)-2-甲基吡咯烷基]-2-羟基丙基}氧基)-4-氟苯基]乙酰胺三氟乙酸盐根据以下实施例260中说明的方法,制备标题化合物。1H-NMR(400MHz,DMSO-d6):δ9.89(1H,bs);9.05(1H,s);7 79(1H,dd,J 8.8,6.6Hz);7.37(2H,d,J 9.6Hz);7.00-6.94(3H,m);6.75(1H,dt,J 8.6,2.6Hz);6.00(1H,bs);5.17-5.10(1H,m);4.32-4.20(1H,m);4.05(1H,dd,J0.1,4.6Hz);3.97(1H,dd,J 9.9,5.7Hz);3.78-3.50(3H,m);3.47(1H,t,J 11.6Hz);3.17(1H,t,J 13.3Hz);2.83(1H,p,J 6.9Hz);2.07(3H,s);1.90-1.80(1H,m);1.42(3H,d,J 6.4Hz)。实施例258N-[2-({(2S)-3-[(3R)-3-(4-氯苄基)吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺盐酸盐
根据实施例251中说明的方法制备。实施例259N-{2-[(2R)-(3-{(3S)-3-[(4-氯苯基)氧基]-1-吡咯烷基}-2-羟基丙基)氧基]-4-氟苯基}乙酰胺APCI-MS:m/z423.1[M+]实施例260N-[2-({(2S)-3-[(2R,4S)-4-(4-氯苯氧基)-2-甲基吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺三氟乙酸盐i)(2S,4R)-4-羟基-1,2-吡咯烷二甲酸1-叔丁基2-甲基酯
在烧瓶中,将(2S,4R)-4-羟基-脯氨酸盐酸盐(5.4g,30mmol)溶于THF(200ml)、水(170ml)和NaOH(30ml,2M水溶液,60mmol)的混合液中。向该乳液中加入二碳酸二叔丁基酯(Boc2O,6.54g,30mmol),将混合液剧烈搅拌1小时。加入乙醚(100ml),使相分离。将水相再用100ml乙醚萃取。弃去水相,将合并的有机相用1MHCl水溶液、碳酸钾(饱和水溶液)和盐水洗涤。萃取物经Na2SO4干燥,真空浓缩得到残留物,经硅胶纯化(庚烷∶EtOAc 5∶1至3∶1至1∶1分级梯度,用I2/MeOH可见斑点)。真空浓缩蒸发纯品部分,得到4.2g(57%)的副标题化合物,为无色油状物。1H-NMR(400MHz,CDCl3):δ4.50(1H,bs);4.45-4.35(1H,m);3.74(3H,s);3.64(1H,dd,J 11.7,4.3Hz);3.59-3.42(1H,m);2.35-2.20(1H,m);2.14-2.03(1H,m);1.97(1H,dd,J 23.3,3.7Hz);1.44(9H,d,J 18.9Hz)。ii)(2S,4S)-4-(4-氯苯氧基)-1,2-吡咯烷二甲酸1-叔丁基2-甲酯
在烧瓶中,在磁力搅拌下,将i)中得到的化合物(2.54g,10.3mmol)、三苯膦(2.71g,10.3mmol)和4-氯苯酚(1.33g,10.3mmol)溶于THF(50ml,经分子筛干燥)中。将烧瓶在冰浴中冷却,用几分钟,向该搅拌的溶液中加入偶氮二甲酸二乙酯(DEAD,1.8g,10.3mmol)。将反应物放置过夜,让冰融化,反应物升至室温。蒸发溶剂,将残留物用乙醚(30ml)处理,使氧化磷沉淀。滤除固体,真空浓缩滤液。残留物经硅胶纯化(庚烷∶EtOAc 8∶1至6∶1至3∶1分级梯度,用Seebach氏试剂在TLC上可见斑点)。浓缩纯品部分,得到2.51g(68%)的副标题化合物,为无色粘稠油状物。1H-NMR(400MHz,CDCl3):δ7.26-7.20(2H,m);6.77-6.70(2H,m);4.86(1H,bs);4.55(1/2H,dd,J 8.6,2.6Hz);4.43(1/2H,dd,J 7.6,3.9Hz);3.84-3.60(5H,m);2.53-2.36(2H,m);1.47(9H,d,J 18.2Hz)。iii)(2S,4S)-4-(4-氯苯氧基)-2-(羟甲基)-1-吡咯烷甲酸叔丁基酯
在烧瓶中,将ii)中得到的化合物(0.951g,2.67mmol)溶于THF(10ml,经分子筛干燥)中。将该溶液在冰浴中冷却,加入LiBH4(0.09g,4.07mmol)。将混合液搅拌过夜,让冰融化,使溶液升至室温。然后将该粗混合液在EtOAc(100ml)和水(100ml)之间分配。弃去水相,将有机溶液用0.5M HCl(水溶液)、NaHCO3(饱和水溶液)和盐水洗涤。将该溶液蒸发,得到看似被无机盐污染的油状物。将其溶于DCM中,通过Celite过滤,得到0.82g(94%)副标题化合物,为无色油状物。1H-NMR(400MHz,DMSO-d6):δ7.33(2H,d,J 9.5Hz);6.95(2H,d,J9.5);4.96(1H,bs);4.71(1H,bs);3.84-3.55(3H,m);3.32(2H,bs);2.29-2.07(2H,m);1.41(9H,s)。iv)(2S,4S)-4-(4-氯苯氧基)-2-{[(甲磺酰基)氧基]甲基}-1-吡咯烷甲酸叔丁基酯
在烧瓶中,将iii)中得到的化合物(0.82g,2.5mmol)溶于二氯甲烷(10ml,经分子筛干燥)中。将烧瓶在冰浴中冷却,用注射器加入三乙胺(0.69ml,5.0mmol)。用几分钟滴加甲磺酰氯(0.30ml,3.86mmol),将得到的混合液搅拌过夜,让冰融化。向该混合液中加入DCM(60ml),将该溶液用1M HCl(水溶液)、NaHCO3(饱和水溶液)和盐水洗涤。将该溶液蒸发,得到0.876g(86%)的副标题化合物,为黄色油状物,不经进一步纯化直接用于下一步。1H-NMR(400MHz,DMSO-d6):δ7.35(2H,d,J 9.4Hz);6.99(2H,d,J9.4Hz);5.07-5.01(1H,m);4.37(1H,dd,J 8.9,4.2Hz);4.20-4.05(2H,m);3.71(1H,dd,J 11.8,5.0Hz);3.32(2H,s);3.15(3H,s);2.07(1H,d,J14.4Hz);1.41(9H,s)。v)(2R,4S)-4-(4-氯苯氧基)-2-甲基-1-吡咯烷甲酸叔丁基酯
在烧瓶中,将iv)中得到的化合物(0.876g,2.16mmol)溶于THF(10ml,经分子筛干燥)中。将反应混合液保持在惰性气体下,然后在冰浴中冷却。用15分钟,通过注射器加入Li(Et)3H(1M三乙基硼氢化锂的THF溶液,9ml,9mmol)。移去冰浴,将混合液搅拌过夜。将该粗混合液在EtOAc(100ml)和水(100ml)之间分配。移去水相,将有机相用1MHCl(水溶液)、NaHCO3(饱和水溶液)和盐水洗涤。将该溶液蒸发,残留物经硅胶纯化(庚烷∶EtOAc 10∶1至5∶1至4∶1至2∶1梯度,用Seebach氏试剂观测TLC斑点),得到0.401g(60%)的副标题化合物,为无色油状物。1H-NMR(400MHz,DMSO-d6):δ7.33(2H,d,J 8.7Hz);6.96(2H,d,J8.7Hz);5.00-4.94(1H,m);3.89(1H,bs);3.64(1H,dd,J 12.5,5.2Hz);3.38(1H,d,J 12.2Hz);2.41-2.28(1H,m);1.79(1H,d,J 13.7Hz);1.40(9H,s);1.23(3H,d,J 6.6Hz)。vi)(2R,4S)-4-(4-氯苯氧基)-2-甲基吡咯烷三氟乙酸盐
在烧瓶中,将v)中得到的化合物(0.390g,1.25mmol)溶于二氯甲烷(DCM,15ml)中。向该溶液中加入TFA(三氟乙酸,6ml),将混合液放置3小时,然后真空除去挥发物。将残留物与DCM共蒸发2次,得到副标题化合物,为油状物。APCI-MS:m/z212[M+H]vii)N-[2-({(2S)-3-[(2R,4S)-4-(4-氯苯氧基)-2-甲基吡咯烷基]-2-羟基丙基}氧基)苯基]乙酰胺三氟乙酸盐
根据实施例255中说明的方法,用vi)中得到的化合物和(2S)-2-[(2-硝基苯氧基)甲基]环氧乙烷制备标题化合物。以25%的收率得到化合物。1H-NMR(400MHz,DMSO-d6):δ9.88(1H,bs);9.02(1H,s);7.89(1H,d,J 7.7Hz);7.37(2H,d,J 7.7Hz);7.09-6.88(5H,m);6.02(1H,bs);5.18-5.11(1H,m);4.34-4.22(1H,m);4.02(1H,dd,J 10.2,4.3Hz);3.94(1H,dd,J 9.8,5.7Hz);3.77-3.30(4H,m);3.19(1H,t,J 10.7Hz);2.84(1H,p,J6.7Hz);2.09(3H,s);1.91-1.81(1H,m);1.43(3H,d,J 6.4Hz)。APCI-MS:m/z419.2[M+H]实施例261N-{2-[(2S)-(3-{(3R)-3-[(4-氯苯基)氧基]-1-吡咯烷基}-2-羟基丙基)氧基]-4-氟苯基}乙酰胺APCI-MS:m/z423.1[M+]实施例262N’-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}-4-甲基苯基)-N,N-二甲基脲三氟乙酸盐
根据实施例253中说明的类似方法,用化合物iii)(75mg,0.2mmol)和二甲胺(2M的THF溶液,200μL,0.4mmol)制备标题化合物。得到的物质为白色无定形固体(73mg,65%)。1H-NMR(400MHz,MeOH-d4):δ7.54(dd,1H);7.51(d,2H);7.16和7.15(d,2H);7.05(bs,1H);6.96(bd,1H);5.40-5.35(m,1H);4.54-4.46(m,1H);4.27(d,2H);4.16-3.56(m,6H);3.20(bs,6H);2.84-2.59(m,1H);2.59-2.44(m,1H);2.50(s,3H)。APCI-MS:m/z448,450[MH+]实施例263N-(2-{3-[3-(4-氯苯胺基)-1-吡咯烷基]-2-羟基丙氧基}-苯基)乙酰胺i)3-羟基-1-吡咯烷甲酸叔丁基酯
向3-羟基-1-吡咯烷(871mg,10mmol)的THF(30mL)溶液中加入二碳酸二叔丁基酯(2.18g,10mmol)的THF(2mL)溶液,室温下,将反应混合液搅拌过夜。真空除去溶剂,残留物经快速层析(0-2%MeOH的CHCl3溶液)纯化,得到副标题化合物(1.7g)。1H-NMR(CDCl3,400MHz):δ4.45(m,1H);3.55-3.25(m,4H);2.18-1.85(m,3H);1.45(s,9H)。APCI-MS:m/z166(M-Boc)ii)2-氧代-1-吡咯烷甲酸叔丁基酯
将氧化铬(vi)(800mg,8.0mmol)加入到吡啶(1.6mL)的CH2Cl2(10mL)溶液中,室温下,将得到的溶液搅拌15分钟。加入3-羟基-1-吡咯烷甲酸叔丁基酯(374.5mg,2.0mmol)的CH2Cl2(5mL)溶液,随即加入乙酸酐,将反应混合液在室温下保持15分钟。加入乙酸乙酯,倾析,通过短硅胶柱过滤。浓缩滤液,得到副标题产物(193mg),直接用于下一步。iii)3-(4-氯苯胺基)-1-吡咯烷甲酸叔丁基酯
将2-氧代-1-吡咯烷甲酸叔丁基酯(190mg,1.02mmol)、4-氯苯胺(64mg,0.5mmol)和乙酸(184mg)在二氯乙烷(5mL)中混合。加入三乙酰氧基硼氢化钠(326.5mg),室温、搅拌下,将反应混合液保持过夜。加入NaHCO3水溶液后,加入乙酸乙酯将反应混合液稀释。分离两层。有机层经Na2SO4干燥,过滤,浓缩。残留物经快速层析纯化(0-15%乙酸乙酯的石油溶剂油(40-60)溶液),得到副标题产物(140mg)。1H-NMR(CDCl3,400MHz):δ7.18(m,2H);6.50(m,2H);3.99(m,1H);3.70(m,2H);3.46(m,2H);3.20(m,1H);2.18(m,1H);1.87(m,1H);1.45(s,9H)。APCI-MS:m/z197(M-Boc)(iv)N-(4-氯苯基)-3-吡咯烷胺(2xCF3COOH)
向3-(4-氯苯胺基)-1-吡咯烷甲酸叔丁基酯(130mg,0.438mmol)的CH2Cl2(5mL)溶液中,加入CF3COOH(1mL)。30分钟后,真空除去挥发物,得到副标题产物(186mg),直接用于下一步。(v)N-(2-{3-[3-(4-氯苯胺基)-1-吡咯烷基]-2-羟基丙氧基}-苯基)乙酰胺
在65℃,将N-(4-氯苯基)-3-吡咯烷胺(2xCF3COOH)(186mg,0.438mmol)、N-[2-(2-环氧乙烷基甲氧基)苯基]乙酰胺(91mg,0.438mmol)和K2CO3(200mg)的乙醇(6ml)混合液持续搅拌2.5小时。真空除去挥发物。将残留物在乙酸乙酯和NH4Cl水溶液之间分配。将有机层用水洗涤,经Na2SO4干燥,过滤,浓缩。残留物经快速层析纯化(0-3%MeOH的CHCl3液),得到标题化合物(70mg)。1H-NMR(CDCl3,400MHz):δ8.35(m,1H);8.21(br.s,1H);7.12(m,2H);7.01(m,2H);6.92(m,1H);6.48(m,2H);4.13-3.92(m,4H);3.84(br.s,1H);2.99(m,1H);2.87-2.30(m,6H);2.18(s,3H);1.66(m,1H)。APCI-MS:m/z446(MH+)实施例264N-{2-[(3-{3-[(4-氯苯基)氧基]-1-吡咯烷基}-2-羟基-1-甲基丙基)氧基]苯基}乙酰胺盐酸盐i)N-{2-[(1-甲基-2-丙烯基)氧基]苯基}乙酰胺
根据实施例8i)中说明的类似方法,用3-氯-1-丁烯(747ml,7.42mmol)和2-乙酰氨基苯酚(1.02g,6.75mmol),制备该化合物(557mg,40%)。1H-NMR(400MHz,CDCl3):δ8.37(m,1H);7.80(bs,1H);6.94(m,3H);5.39(m,1H);5.25(m,2H);4.84(m,1H);2.21(s,3H);1.49(d,J 6.3Hz,3H)。ii)N-{2-[1-(2-环氧乙烷基)乙氧基]苯基}乙酰胺
根据实施例8(ii)中说明的类似方法,用N-{2-[(1-甲基-2-丙烯基)氧基]苯基}乙酰胺(549mg,2.67mmol)和间氯过苯甲酸(80%,923mg,4.28mmol),制备该化合物。用石油醚/乙酸乙酯10/15为洗脱剂,经硅胶纯化。分离出两种非对映体对。非对映体1:(53mg,9%),Rf=0.27非对映体2:(406mg,69%),Rf=0.201H-NMR(400MHz,CDCl3):δ8.39(m,1H);8.01(bs,1H);7.00(m,3H);3.98(m,1H);3.24(m,1H);2.94(t,J 4.5Hz,1H);2.71(dd,J 2.6Hz,J4.5Hz,1H);2.23(s,3H);1.47(d,J 6.3Hz,3H)。iii)N-{2-[(3-{3-[(4-氯苯基)氧基]-1-吡咯烷基}-2-羟基-1-甲基丙基)氧基]苯基}乙酰胺盐酸盐
根据实施例1(iii)中说明的类似方法,用N-[2-(1-环氧乙烷基乙氧基)苯基]乙酰胺非对映体2(123mg,0.557mmol)和3-(4-氯苯氧基)吡咯烷(100mg,0.506mmol),制备标题化合物。1H-NMR(400MHz,MeOD):δ7.86(m,1H),7.30(m,2H),7.09(m,2H),6.97(m,3H),5.21(m,1H),4.51(m,1H),3.83-4.22(m,3H),3.37-3.62(m,4H),2.68(m,1/2H),2.38(m,1H),2.27(m,1/2H),2.19(m,3H),1.32(m,3H)。MS-APCI+:m/z419[MH+]实施例265N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}-4-甲氧基苯基)乙酰胺盐酸盐i)1-[3-(4-氯苯氧基)-1-吡咯烷基]-3-(5-甲氧基-2-硝基苯氧基)-2-丙醇
根据实施例253ii)中说明的类似方法,用2-[(5-甲氧基-2-硝基苯氧基)甲基]环氧乙烷(320mg,1.6mmol)和3-(4-氯苯氧基)吡咯烷(365mg,1.6mmol),制备副标题化合物。得到黄色油状物的粗产物(580mg),不经进一步纯化使用。APCI-MS:m/z423,425[MH+]ii)1-(2-氨基-5-甲氧基苯氧基)-3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-丙醇
根据实施例253iii)中说明的类似方法,用化合物i)(290mg,0.7mmol)制备副标题化合物。得到无色油状物的粗化合物(233mg,85%),不经进一步纯化使用。APCI-MS:m/z393,395[MH+]iii)N-(2-{3-[3-(4-氯苯氧基)-1-吡咯烷基]-2-羟基丙氧基}-4-甲氧基苯基)乙酰胺盐酸盐
向化合物(ii)(157mg,0.4mmol)的吡啶(3mL)溶液中,加入乙酸酐(1mL)。室温下,将混合液搅拌1小时。蒸发,然后将残留物溶于甲醇(mL)中,加入1.5M甲醇钠的甲醇溶液(1mL)。室温下将混合物放置过夜。蒸发后,将残留物溶于乙醚和水中。从有机相中得到标题化合物的游离碱,为无色油状物(171mg,98%)。将该游离碱(43mg)溶于甲醇(5mL)中,用1M盐酸酸化至pH<2,用水(50mL)稀释,冷冻干燥。得到标题化合物,为白色无定形固体(30mg,64%)APCI-MS:m/z 435,437[MH+]实施例266N-(2-[3-(4-氯-苄氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺三氟乙酸盐i)3-(4-氯-苄氧基)-吡咯烷-1-甲酸叔丁基酯
将3-羟基-1-吡咯烷甲酸叔丁基酯(0.27g,1.44mmol)的无水THF(4mL)溶液滴加到冷的(0℃)、搅拌的氢化钠(0.078g,2.17mmol,约50%油的悬浮液)的THF(10mL)悬浮液中。30分钟后,加入4-氯苄基溴(0.36g,1.74mmol)的THF(2mL)溶液,室温下,将得到的悬浮液搅拌过夜。将反应混合液在水和乙酸乙酯之间分配。将水相用乙酸乙酯萃取,将合并的有机相用饱和氯化钠水溶液洗涤,干燥,浓缩。残留物经快速层析纯化(庚烷-乙酸乙酯,6∶1),得到副标题化合物3-(4-氯-苄氧基)-吡咯烷-1-甲酸叔丁基酯,为油状物(0.30g,66.8%)。1H-NMR(CDCl3):δ7.30(m,4H),4.49(bs,2H),4.11(m,1H),3.45(m,4H);1.90-2.08(m,2H),1.46(s,9H)。ii)3-(4-氯-苄氧基)-吡咯烷
在(0℃)下,将3-(4-氯-苄氧基)-吡咯烷-1-甲酸叔丁基酯(0.28g,0.9mmol)在90%含水甲酸(7.5mL)中的溶液搅拌30分钟,然后在室温下过夜。减压除去溶剂,将残留物用饱和碳酸钾水溶液处理,用正丁醇萃取2次。将合并的有机萃取液浓缩,残留物经快速层析纯化(SiO2,二氯甲烷-甲醇-氢氧化铵,8∶8∶1然后50∶10∶1),得到副标题化合物3-(4-氯-苄氧基)-吡咯烷(0.13g,70%)。1H-NMR(DMSO-d6):δ7.32-7.41(m,4H),4.42(s,2H),4.02(m,1H),3.18(bs,3H),2.75-2.86(m,3H),2.68(m,1H),1.66-1.81(m,2H)。APCI-MS:m/z212[MH+]iii)N-(2-[3-(4-氯-苄氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-苯基)-乙酰胺三氟乙酸盐
在密闭管中,在70℃下,将3-(4-氯-苄氧基)-吡咯烷(0.050g,0.24mmol)和N-(2-环氧乙烷基甲氧基-苯基)-乙酰胺(0.049g,0.24mmol)的无水乙醇(3mL)溶液加热2小时。产物经HPLC纯化,得到标题化合物(0.60g,47%)1H-NMR(CD3OD):δ7.85(m,1H),7.35(m,4H),7.12(m,1H),7.02(d,1H,J=8Hz),6.96(m,1H),4.56(m,2H),4.39(m,2H),4.05(d,2H,J=5.9Hz),3.85(m,2H),3.48(m,4H),2.10-2.55(m,5H)。APCI-MS:m/z419[MH+]和421[MH+2+]实施例267N-(2-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-2-甲基-丙氧基}苯基)乙酰胺
根据以下实施例270类似的方法制备该混合物。APCI-MS:m/z419[MH+]实施例268N-(2-{(1S,2R,3S)*-3-[(3S)-3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-环戊基氧基}-5-氯-苯基)乙酰胺(非对映体混合物)
根据与下述实施例271类似的方法,用N-{5-氯-2-[(1R,2S,5S)*-6-氧杂双环[3.1.0]己-2-基氧基]苯基}乙酰胺(5.3mg,20μmol)和(3S)-3-(3,4-二氟-苯氧基)-吡咯烷(4.0mg,20μmol)进行制备。MS-APCI+:m/z467[M+]实施例269N-[2-({(2R,3S)*-3-[(3S)-3-(4-氯苯氧基)吡咯烷基]-2-羟基丁基}氧基)-4-甲基苯基]乙酰胺(非对映体混合物)
根据与下述实施例271类似的方法,用N-(4-甲基-2-{(2S,3R)*-3-甲基环氧乙烷基]甲氧基}苯基)乙酰胺(4.7mg,20μmol)和(3S)-3-(4-氯-苯氧基)-吡咯烷(4.0mg,20μmol)进行制备。MS-APCI+:m/z433[M+]实施例270N-{2-[(3-{4-[(3,4-二氯苯基)氧基]-1-哌啶基}-2-羟基-2-甲基丙基)氧基]-4-氟苯基}乙酰胺盐酸盐i)N-[4-氟-2-(2-甲基-烯丙氧基)-苯基]-乙酰胺
将3-氯-2-甲基丙烯(1.36g,15mmol)加入到5-氟-2-硝基苯酚(1.57g,10mmol)、碳酸钾(2.76g,20mmol)、四丁基硫酸氢铵(0.068g,0.2mmol)和乙腈(30ml)混合液中,将混合液加热回流18小时。将冷却的反应混合液用甲苯稀释,用5%碳酸钾水溶液洗涤,干燥,蒸发。在75℃下,将部分残留物(0.631g,3mmol)、连二亚硫酸钠(1.04g,6mmol)的EtOH-THF-H2O(2∶1∶1,3ml)溶液加热4小时。将混合液在二氯甲烷和15%碳酸钾水溶液之间分配,将有机溶液干燥,浓缩。将得到的残留物用甲醇(1.5ml)稀释,在50℃下,与乙酸酐(1.5ml)反应2分钟,然后用20分钟时间使达到室温,加入吡啶(4ml),再在50℃下,将该溶液加热3分钟,冷却,浓缩。得到物质经硅胶层析纯化(轻石油-乙酸乙酯2∶1),得到95mg副标题化合物。1H-NMR(300 MHz,CDCl3):δ8.28(dd,1H),7.62(bs,1H),6.70-6.60(m,2H),5.07(dd,2H),4.49(s,2H),2.20(s,3H),1.84(s,3H)。ii)N-(4-氟-2-{[(2-甲基-2-环氧乙烷基)甲基]氧基}苯基)乙酰胺
根据实施例8ii)中说明的类似方法,用N-[4-氟-2-(2-甲基-烯丙氧基)-苯基]-乙酰胺制备副标题化合物。1H-NMR(300 MHz,CDCl3):δ8.31-8.26(dd,1H),7.79(bs,1H),6.75-6.65(m,2H),4.14(d,1H),3.97(d,1H),2.93(d,1H),2.80(d,1H),2.21(s,3H),1.50(s,3H)。APCI-MS:m/z240[MH+]iii)N-{2-[(3-{4-[(3,4-二氯苯基)氧基]-1-哌啶基}-2-羟基-2-甲基丙基)氧基]-4-氟苯基}乙酰胺盐酸盐
在密封管中,在77℃下,将4-(3,4-二氯-苯氧基)-哌啶(36mg,0.146mmol)、N-(4-氟-2-{[(2-甲基-2-环氧乙烷基)甲基]氧基}苯基)乙酰胺(35g,0.146mmol)的EtOH(1ml,95%)溶液搅拌2.5小时。蒸发溶剂,残留物经硅胶纯化(二氯甲烷-甲醇,15∶1,含1%的NH4OH(25%)),得到45mg标题化合物对应的游离胺。该标题化合物的对应游离胺的1H-NMR(400MHz,CDCl3):δ8.26-8.22(dd,1H),7.89(bs,1H),7.31(d,1H),7.01(d,1H),6.77-6.65(m,3H),4.30(m,1H),3.80(dd,2H),2.93-2.81(m,2H),2.67(d,1H),2.63-2.51(m,2H),2.45(d,1H),2.19(s,3H),1.96(m,2H),1.83(m,2H),1.62(bs,1H),1.31(s,3H)。iv)N-{2-[(3-{4-[(3,4-二氯苯基)氧基]-1-哌啶基}-2-羟基-2-甲基丙基)氧基]-4-氟苯基}乙酰胺盐酸盐
将游离胺的甲醇溶液(10ml)用HCl(浓,0.020ml)酸化至pH3,浓缩。将残留物与甲苯共蒸发3次,得到标题盐酸盐化合物,为白色粉末。APCI-MS:m/z485,487[MH+]实施例271N-(2-{(1S,2R,3S)*-3-[(3S)-3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-环戊基氧基}-4-氟-苯基)乙酰胺(非对映体混合物)
将N-{4-氟-2-[(1R,2S,5R)-6-氧杂双环[3.1.0]己-1-基氧基]苯基}乙酰胺(5.0mg,20μmol)和(3S)-3-(4-氯-苯氧基)-吡咯烷(3.9mg,20μmol)溶于2M LiClO4的乙腈(0.2ml)溶液中,在密封管中,加热至100℃。用乙酸乙酯稀释,中性水溶液处理,蒸发溶剂,得到粗产物,不经进一步纯化使用。MS-APCI+:m/z449[M+]实施例272N-(5-氯-2-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}苯基)-乙酰胺APCI-MS:m/z441.1[MH+]实施例273N-(5-氯-2-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}苯基)-乙酰胺APCI-MS:m/z423.1[MH+]实施例274N-(4-氰基-2-{3-[4-(3,4-二氯苯胺基)-1-哌啶基]-2-羟基丙氧基}苯基)乙酰胺APCI-MS:m/z477[MH+]实施例245N-(4-羟基-2-{(1S,2R,3S)*-3-[(3S)-3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-环戊基氧基}-苯基)-乙酰胺(非对映体混合物)i)将N-{4-甲氧基-2-[(1R,2S,5R)*-6-氧杂双环[3.1.0]己-]-基氧基]苯基}乙酰胺(32mg,122μmol)和(3S)-3-(4-氯-苯氧基)-吡咯烷(24mg,122μmol)溶于2M LiClO4的乙腈(1ml)溶液中,在密封管中,加热至100℃。用乙酸乙酯稀释,中性水溶液处理,蒸发溶剂,得到62mg(110%)的粗加成产物,室温下,使其与三溴化硼(1M的CH2Cl2溶液,0.37mL,371μmol)的二氯甲烷(1mL)溶液反应过夜。将反应物用甲醇(1.0mL)猝灭,蒸发所有挥发性组分。剩余的粗品经反相HPLC纯化,得到30mg(54%)的标题化合物,为非对映体混合物。MS-APCI+:m/z447.1[MH+]
ii)分离非对映体
将以上i)项下说明的非对映体混合物经手性HPLC(固定相:Chiralpak AD;流动相:异己烷/异丙醇/甲醇/二乙胺=80∶16∶4∶0.1)分离,先洗脱出的立体异构体为实施例276化合物,第二个洗脱出的立体异构体为实施例277化合物。各立体异构体下的绝对构型的分配(assignment)可按需要进行设定,是可以变化的。实施例276N-(4-羟基-2-{(1S,2R,3S)-3-[(3S)-3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-环戊基氧基}-苯基)-乙酰胺1H-NMR(400 MHz,CDCl3;OH-质子忽略):δ8.02(1H,s),7.49(1H,d,J 8.4Hz),7.17(2H,d,J 8.9Hz),6.71(2H,d,J 8.8Hz),6.43(1H,s),6.34(1H,d,J 7.2Hz),4.76(1H,m),4.39(1H,m),4.09(1H,m),3.10-2.95(3H,m),2.89(1H,m),2.77(1H,m),2.24(1H,m),2.08(3H,s),2.10-1.84(3H,m),1.75(1H,m),1.59(1H,m)。MS-APCI+:m/z447.1[MH+][α]22=+49.5(CH2C2)实施例277N-(4-羟基-2-{(1R,2S,3R)-3-[(3S)-3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-环戊基氧基}-苯基)-乙酰胺1H-NMR(400MHz,CDCl3;OH-质子忽略):δ7.75(1H,s),7.60(1H,d,J 8.4Hz),7.19(2H,d,J 8.3Hz),6.73(2H,d,J 8.6Hz),6.57(1H,s),6.38(1H,d,J 8.4Hz),4.77(1H,m),4.43(1H,m),4.21(1H,m),3.09-2.94(3H,m),2.79(1H,m),2.68(1H,m),2.28(1H,m),2.08(3H,s),2.05-1.90(3H,m),1.86(1H,m),1.53(1H,m)。MS-APCI+:m/z447.1[MH+][α]22=-45.2(CH2C2)
根据制备实施例221-230化合物所用的类似方法,制备实施例278和279的非对映体,并根据以上实施例275中所述进行分离。各异构体的绝对构型的分配可如上所述按需要进行设定,因此是可以变化的。实施例278N-[2-({(1S,2R,3S)-3-[(3S)-3-(4-氯苯氧基)吡咯烷基]-2-羟基环戊基}氧基)苯基]乙酰胺先洗脱的异构体。MS-APCI+:m/z 431.1[MH+][α]22=+72.2(CH2C2)实施例279N-[2-({(1R,2S,3R)-3-[(3S)-3-(4-氯苯氧基)-吡咯烷基]-2-羟基环戊基}氧基)苯基)乙酰胺第二次洗脱的异构体。MS-APCI+:m/z431.1[MH+][α]22=-51.4(CH2C2)
根据制备实施例221-230化合物所用的类似的方法,制备实施例280和249的非对映体,并根据以上实施例275中所述进行分离。实施例280化合物是先被洗脱出的异构体,实施例249化合物是第二个被洗脱出的异构体。各异构体的绝对构型可如上所述按需要进行设定,因此是可以变化的。实施例280N-[5-氯-2-({(1S,2R,3S)-3-[(3S)-3-(4-氯苯氧基)吡咯烷基]-2-羟基环戊基}氧基)苯基]乙酰胺MS-APCI+:m/z464.9[MH+][α]22=+53.0(CH2C2)实施例281N-{5-氯-2-[((1S,2R,3S)*-3-{[1-(4-氯苄基)-4-哌啶基]氨基}-2-羟基环戊基)氧基]苯基}乙酰胺(外消旋体混合物)
根据实施例271的类似方法,用N-{5-氯-2-[(1R,2S,5R)*-6-氧杂双环[3.1.0]己-2-基氧基]苯基}乙酰胺(5.3mg,20μmol)和1-(4-氯苄基)-4-哌啶胺(4.5mg,20μmol)进行制备。MS-APCI+:m/z492[M+]实施例282N-[2-({(2S)-3-[(3S)-3-(4-氯苯氧基)吡咯烷基]-2-羟基丙基}氧基)-4-羟基苯基]乙酰胺i)(2S)-2-[(5-甲氧基-2-硝基苯氧基)甲基]环氧乙烷
在Mitsunobu条件下,采用无水THF作为溶剂,用(R)-(+)-缩水甘油(198mg,1mmol)、5-甲氧基-2-硝基苯酚(169mg,1mmol)、三苯膦(263mg,1mmol)和DEAD(157μl,1mmol)制备副标题化合物。粗产物经硅胶快速层析纯化,用乙酸乙酯和庚烷的混合液作为流动相。收集适当的部分,得到不纯的产物,为白色结晶(175mg)。该产物被还原的DEAD以摩尔比1∶1污染,其收率等于100mg,44%所需产物。1H-NMR(400MHz,CDCl3):δ8.00(d,1H);6.60(d,1H);6.55(dd,1H);6.4(bs,1H,还原的DEAD);4.41(dd,1H);4.22(q,4H,还原的DEAD);4.13(dd,1H);3.89(s,3H);3.44-3.39(m,1H);2.95(dd,1H);2.92(dd,1H);1.29(t,6H,还原的DEAD)。APCI-MS:m/z226[MH+]ii)(2S)-1-[(3S)-3-(4-氯苯氧基)吡咯烷基]-3-(5-甲氧基-2-硝基苯氧基)-2-丙醇
根据实施例1(ii)类似的方法,用(i)(169mg,0.43mmol)和(3S)-3-(4-氯苯氧基)吡咯烷(85mg,0.43mmol)制备副标题化合物。得到的产物为黄色油状物,不用进一步纯化使用。APCI-MS:m/z423,425[MH+]iii)(2S)-1-(2-氨基-5-甲氧基苯氧基)-3-[(3S)-3-(4-氯苯氧基)吡咯烷基]-2-丙醇
根据实施例253iii)中说明的类似方法,用化合物ii)(0.43mmol)制备副标题化合物。得到的产物(无色油状物,163mg)是所需产物与被还原的DEAD以摩尔比5∶1的混合物。该产物可直接使用。1H-NMR(400MHz,CDCl3):δ7.23(d,2H);6.77(d,2H);6.67(d,1H);6.49(d,1H);6.41(bs,还原的DEAD);6.39(dd,1H);4.83-4.77(m,1H);4.22(q,还原的DEAD);4.14-4.07(m,1H);4.01(d,2H);3.75(s,3H);3.01-2.91(m,2H);2.88-2.72(m,3H);2.62(dd,1H);2.29(六重峰,1H);2.06-1.96(m,1H);1.29(t,还原的DEAD)。APCI-MS:m/z393,395[MH+]iv)N-[2-({(2S)-3-[(3S)-3-(4-氯苯氧基)吡咯烷基]-2-羟基丙基}氧基)-4-甲氧基苯基]乙酰胺
向化合物iii)(157mg)在乙腈(10mL)和水(2mL)混合液中的溶液中,加入乙酸酐(1mL),室温下,将混合液搅拌过夜。加入1.5M甲醇钠的甲醇溶液(1mL),继续搅拌1小时。蒸发,然后将残留物溶于乙醚和水中。从有机相中得到副标题化合物,为无色油状物(155mg)。1H-NMR(400NHz,CDCl3):δ8.18(d,1H);7.95(bs,1H);7.24(d,2H);6.78(d,2H);6.56-6.52(m,2H);4.85-4.78(m,1H);4.22(q,还原的DEAD);4.10-4.02(m,2H);4.00-3.92(m,1H);3.78(s,3H);3.00-2.91(m,2H);2.87-2.73(m,3H);2.53(dd,1H);2.36-2.25(m,1H);2.17(s,3H);2.07-1.99(m,1H);1.29(t,还原的DEAD)。APCI-MS:m/z 435,437[MH+]v)N-[2-({(2S)-3-[(3S)-3-(4-氯苯氧基)吡咯烷基]-2-羟基丙基}氧基)-4-羟基苯基]乙酰胺
根据实施例254类似的方法,用iv)(150mg)制备标题化合物。冷冻干燥后得到产物,为白色无定形固体(101mg,57%)。1H-NMR(400 MHz,CDCl3+1滴DMSO-d6):δ8.7(bs,1H);8.34(s,1H);8.73(d,1H);7.18(d,2H);6.73(d,2H);6.40-6.31(m,2H);4.99-4.93(m,1H);4.4-1.9(bm,6H);4.31-4.23(m,1H);3.88-3.78(m,2H);3.39-3.25(m,2H);2.4-2.2(m,2H);2.07(s,3H)。APCI-MS:m/z421,423[MH+]THP-1趋化性试验
该试验测定人体单核细胞细胞系THP-1中MIP-1α趋化因子诱发的趋化响应。通过对标准浓度的MIP-1α趋化因子的趋化响应的抑制的能力测定,评估实施例的化合物。方法THP-1细胞的培养
在37℃下,将冷冻等份试样中的细胞快速解冻,然后再混悬于装有5ml培养基的25cm烧瓶中,该培养基为添加有不含抗生素的Glutamax和10%热灭活胎牛血清的RPMI-1640培养基(RPMH+10%HIFCS)。3日后,弃去培养基,加入新鲜培养基。
在添加有不含抗生素的10%热灭活胎牛血清和Glutamax的RPMI-1640培养基中,按常规培养THP-1细胞。细胞最适生长要求每3日将它们传代,并且最小传代培养物的密度为4×10+5细胞/毫升。趋化性试验
将细胞从烧瓶中取出,通过在RPMI+10%HIFCS+glutamax中离心洗涤。然后以2×10+7细胞/毫升的浓度,将细胞再混悬于新鲜培养基(RPMI+10%HIFCS+glutamax)中,向其中加入calcein-AM(将5μl储备液稀释至1m,最终浓度为5×10-6M)。轻轻混合后,在37℃下,在CO2培养箱中,将细胞培养30分钟。然后将细胞用培养基稀释至50ml,以400×g速度,通过离心洗涤2次。然后以1×10+7细胞/毫升的细胞浓度,将标记的细胞再悬浮,在37℃下,在湿度CO2培养箱中,与等体积的MIP-1α拮抗剂(10-10M至10-6M终浓度)将细胞培养30分钟。
采用装备有8μm滤器的Neuroprobe96孔趋化性培养板(目录号101-8)进行趋化性试验。向培养板的较低孔中,加入30μl添加不同浓度拮抗剂或媒介物的化学诱发物,一式三份。然后在顶部小心放置滤器,向该滤器的表面加入25μl与对应浓度拮抗剂或媒介物预培养的细胞。然后在37℃下,在湿度CO2培养箱中,将培养板温育2小时。通过吸附除去遗留在表面上的细胞,以2000rpm的速度,将整个培养板离心10分钟。然后移出滤器,通过测定与calcein-AM有关细胞的荧光性,对迁移至较低孔中的细胞定量。用减去试剂空白后的荧光单位表达细胞迁移,通过将该荧光值与已知数目的标记细胞的荧光值比较,将该值统一为迁移百分率。当将迁移细胞的数量与媒介物进行比较时,以抑制百分率计算拮抗作用。
Claims (18)
1.一种通式(I”)的化合物或其药学上可接受的盐或溶剂化物:其中:
R代表基团:
m为0、1、2或3;
R1各自独立代表卤素、氰基、硝基、羧基、羟基、C3-C6环烷基、C1-C6烷氧基、C1-C6烷氧基羰基、C1-C6卤代烷基、C1-C6卤代烷氧基、-NR9R10、C3-C6环烷基氨基、C1-C6烷硫基、C1-C6烷基羰基、C1-C6烷基羰基氨基、氨磺酰基、C1-C6烷基磺酰基、-C(O)NR11R12、-NR13C(O)-(NH)PR14、苯基或者任选被羧基或C1-C6烷氧基羰基取代的C1-C6烷基;
p为0或1;
X代表氧或硫原子或者CH2、CH(CH3)、OCH2、CHO、CH2NH、NH或者羰基,Y代表氮原子或者CH或C(OH)基团,条件是当X代表氧或硫原子或者CH2O、CH2NH或NH时,Y代表CH基团;
Z1代表键或者基团(CH2)q,其中q为1或2;
Z2代表键或者基团CH2,条件是Z1和Z2不同时代表键;
Q代表氧或硫原子或者CH2或NH;
R2代表以下基团: 或
n为0、1或2;
R3各自独立代表C1-C6烷基、C1-C6烷氧基羰基、-CH2OH或羧基;
R4、R5、R6和R7各自独立代表氢原子或C1-C6烷基,或者R4、R5、R6和R7一起代表C1-C4亚烷基链,并连接与其相连的两个碳原子形成4-至7-元饱和碳环,或者R5、R6和R7各自代表氢原子而R4和R8同与其相连的碳原子一起形成5-至6-元饱和碳环;
R8代表氢原子、C1-C6烷基,或者按如上说明与R4相连;
R9和R10各自独立代表氢原子或C1-C6烷基,或者R9和R10同与其相连的氮原子一起形成4-至7-元饱和杂环;
R11和R12各自独立代表氢原子或者任选被C1-C6烷氧基羰基取代的C1-C6烷基;
R13代表氢原子或者C1-C6烷基;
R14代表氢原子或者任选被羧基、C1-C6烷氧基或C1-C6烷氧基羰基取代的C1-C6烷基;
条件是当X为氧原子或基团CH2,Y为CH,Z1和Z2各自代表基团CH2,并且Q为氧原子时,R2不是未取代的吲哚基。
2.权利要求1的化合物,其中X代表氧原子或者CH2、OCH2、CH2O、NH或羰基。
3.权利要求1或2的化合物,其中Y代表氮原子或者CH基团。
4.权利要求1-3中任一项的化合物,其中Q代表氧原子。
5.权利要求1-4中任一项的化合物,其中R2代表下示基团:或
6.权利要求1的式(I”)化合物或其药学上可接受的盐或其溶剂化物,选自:
1-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-3-(1H-吲哚-7-基氧基)-丙-2-醇,
1-(7-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮,
1-[3-(4-氯-苯氧基)-吡咯烷-1-基]-3-(1H-吲哚-7-基氧基)-丙-2-醇,
1-(7-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮,
1-[3-(4-氟-苯氧基)-吡咯烷-1-基]-3-(1H-吲哚-7-基氧基)-丙-2-醇,
1-(7-{3-[3-(4-氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮,
1-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-3-(1H-吲哚-7-基氧基)-丙-2-醇,
1-(7-{3-[3-(3,4-二氟-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮,
1-(7-{3-[4-(3,4-二氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮,
1-(7-{3-[4-(4-氯-苯氧基)-哌啶-1-基]-2-羟基-丙氧基}-吲哚-1-基)-乙酮,
N-(3-{3-[3-(3,4-二氯-苯氧基)-吡咯烷-1-基]2-羟基-丙氧基}-萘-2-基)-乙酰胺,和
N-(3-{3-[3-(4-氯-苯氧基)-吡咯烷-1-基]-2-羟基-丙氧基}-萘-2-基)-乙酰胺。
8.一种药用组合物,它包含权利要求1-6中任一项的式(I”)化合物或其药学上可接受的盐或溶剂化物,并结合药学上可接受的佐剂、稀释剂或载体。
9.一种制备权利要求8的药用组合物的方法,它包括将权利要求1-6中任一项的式(I”)化合物或其药学上可接受的盐或溶剂化物与药学上可接受的佐剂、稀释剂或载体混合。
10.一种用于治疗的权利要求1-6中任一项的式(I”)化合物或其药学上可接受的盐或溶剂化物。
11.权利要求1-6中任一项的式(I”)化合物或其药学上可接受的盐或溶剂化物在制备用于治疗的药物中的应用。
12.权利要求1-6中任一项的式(I”)化合物或其药学上可接受的盐或溶剂化物在制备用于治疗其中趋化因子受体活性的调节是有利的人体疾病或症状的药物中的应用。
13.权利要求1-6中任一项的式(I”)化合物或其药学上可接受的盐或溶剂化物在制备用于治疗类风湿性关节炎的药物中的应用。
14.权利要求1-6中任一项的式(I”)化合物或其药学上可接受的盐或溶剂化物在制备用于治疗慢性阻塞性肺病的药物中的应用。
15.权利要求1-6中任一项的式(I”)化合物或其药学上可接受的盐或溶剂化物在制备用于治疗哮喘的药物中的应用。
16.权利要求1-6中任一项的式(I”)化合物或其药学上可接受的盐或溶剂化物在制备用于治疗多发性硬化病的药物中的应用。
17.一种对患有炎症或有患上该病危险的患者进行治疗的方法,该方法包括给予该患者治疗有效量的权利要求1-6中任一项的式(I”)化合物或其药学上可接受的盐或溶剂化物。
18.一种对患有呼吸道疾病或有患上该病危险的患者进行治疗的方法,该方法包括给予该患者治疗有效量的权利要求1-6中任一项的式(I”)化合物或其药学上可接受的盐或溶剂化物。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE00006205 | 2000-02-25 | ||
SE0000620A SE0000620D0 (sv) | 2000-02-25 | 2000-02-25 | Novel compounds |
SE00022343 | 2000-06-14 | ||
SE0002234A SE0002234D0 (sv) | 2000-06-14 | 2000-06-14 | Novel compounds |
SE0003979A SE0003979D0 (sv) | 2000-10-31 | 2000-10-31 | Novel Compounds |
SE00039792 | 2000-10-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1426394A true CN1426394A (zh) | 2003-06-25 |
CN1187326C CN1187326C (zh) | 2005-02-02 |
Family
ID=27354503
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018084842A Expired - Fee Related CN1187326C (zh) | 2000-02-25 | 2001-02-23 | 新化合物 |
CN01808426A Pending CN1426412A (zh) | 2000-02-25 | 2001-02-23 | 新化合物 |
CNB018084125A Expired - Fee Related CN1229343C (zh) | 2000-02-25 | 2001-02-23 | 趋化因子受体活性调节剂 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN01808426A Pending CN1426412A (zh) | 2000-02-25 | 2001-02-23 | 新化合物 |
CNB018084125A Expired - Fee Related CN1229343C (zh) | 2000-02-25 | 2001-02-23 | 趋化因子受体活性调节剂 |
Country Status (29)
Country | Link |
---|---|
US (3) | US6951874B2 (zh) |
EP (3) | EP1263724B1 (zh) |
JP (3) | JP2003523999A (zh) |
KR (3) | KR20020075450A (zh) |
CN (3) | CN1187326C (zh) |
AR (1) | AR029806A1 (zh) |
AT (2) | ATE280153T1 (zh) |
AU (3) | AU783496B2 (zh) |
BR (3) | BR0108677A (zh) |
CA (3) | CA2400293A1 (zh) |
CO (1) | CO5300399A1 (zh) |
CZ (1) | CZ20022870A3 (zh) |
DE (2) | DE60110900T2 (zh) |
DK (2) | DK1263725T3 (zh) |
EE (1) | EE05001B1 (zh) |
ES (2) | ES2241796T3 (zh) |
HK (1) | HK1048990A1 (zh) |
HU (1) | HUP0300922A2 (zh) |
IL (2) | IL151208A0 (zh) |
IS (1) | IS6520A (zh) |
MX (3) | MXPA02008243A (zh) |
NO (3) | NO323584B1 (zh) |
NZ (2) | NZ520718A (zh) |
PL (1) | PL358281A1 (zh) |
PT (2) | PT1263725E (zh) |
RU (1) | RU2265011C2 (zh) |
SI (2) | SI1263724T1 (zh) |
SK (1) | SK12132002A3 (zh) |
WO (3) | WO2001062729A1 (zh) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO5300399A1 (es) | 2000-02-25 | 2003-07-31 | Astrazeneca Ab | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen |
US7005439B2 (en) * | 2000-06-20 | 2006-02-28 | Astrazeneca Ab | Compounds |
AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
AR035230A1 (es) * | 2001-03-19 | 2004-05-05 | Astrazeneca Ab | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos |
SE0101038D0 (sv) * | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
ES2330731T3 (es) * | 2001-08-30 | 2009-12-15 | Chemocentryx, Inc. | Compuestos biciclicos como inhibidores de la union de quimioquina a us28. |
SE0104251D0 (sv) * | 2001-12-14 | 2001-12-14 | Astrazeneca Ab | Novel compounds |
TW200303304A (en) | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
US7238717B2 (en) * | 2002-05-24 | 2007-07-03 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
GB0225379D0 (en) * | 2002-10-31 | 2002-12-11 | Pfizer Ltd | Therapeutic proline derivatives |
US7659305B2 (en) | 2002-10-31 | 2010-02-09 | Pfizer Inc. | Therapeutic proline derivatives |
GB0402101D0 (en) * | 2004-01-30 | 2004-03-03 | Novartis Ag | Organic compounds |
SE0400208D0 (sv) | 2004-02-02 | 2004-02-02 | Astrazeneca Ab | Chemical compounds |
EP1863810A4 (en) * | 2005-03-22 | 2010-03-31 | Astrazeneca Ab | NEW TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLDERIVATE AS CB1 'RECEPTOR LIGANDS |
JP2009503063A (ja) * | 2005-08-01 | 2009-01-29 | アストラゼネカ・アクチエボラーグ | 呼吸器疾患の処置に有用なケモカイン受容体モジュレーターとしての新規ピペリジン誘導体 |
TW200738635A (en) * | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
TW200738634A (en) * | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
TW200734305A (en) * | 2005-08-02 | 2007-09-16 | Astrazeneca Ab | New salt III |
JP2009544609A (ja) * | 2006-07-18 | 2009-12-17 | アストラゼネカ・アクチエボラーグ | 置換2−アセチルアミノ−アルコキシフェニルの製造方法 |
GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
WO2008136754A1 (en) * | 2007-05-07 | 2008-11-13 | Astrazeneca Ab | Novel benzyl - 2 -oxo-piperazinyl/ 7-oxo/5-oxa- [1,4] diazepanyl/ 2 -oxo- tetrahydropyrimidinyl derivatives |
WO2008150231A1 (en) * | 2007-06-08 | 2008-12-11 | Astrazeneca Ab | New heterocyclic compounds for treatment of respiratory, airway or inflammatory disorders |
EP2240481A1 (en) | 2008-01-11 | 2010-10-20 | Albany Molecular Research, Inc. | (1-azinone) -substituted pyridoindoles as mch antagonists |
PA8843701A1 (es) | 2008-09-29 | 2010-05-26 | Abbott Lab | Derivados de indolina y métodos para usarlos |
US9625475B2 (en) | 2008-09-29 | 2017-04-18 | Abbvie Inc. | Indole and indoline derivatives and methods of use thereof |
US8618299B2 (en) | 2009-07-01 | 2013-12-31 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof |
US9073925B2 (en) * | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
JP2012532144A (ja) | 2009-07-01 | 2012-12-13 | アルバニー モレキュラー リサーチ, インコーポレイテッド | アジノン置換アゼピノ[b]インドールおよびピリド−ピロロ−アゼピンmch−1拮抗薬、ならびにその作製方法および使用 |
WO2011003007A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
WO2011073662A1 (en) | 2009-12-17 | 2011-06-23 | Astrazeneca Ab | Combination of a benzoxazinone and a further agent for treating respiratory diseases |
US8993765B2 (en) | 2010-12-21 | 2015-03-31 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof |
WO2012088038A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof |
GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
WO2012163848A1 (en) | 2011-05-27 | 2012-12-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of crohn's disease |
GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
CN104710419B (zh) * | 2015-03-18 | 2017-05-24 | 中国药科大学 | 四氢吡啶[4,3‑b]骈吲哚类化合物、其制备方法及医药用途 |
WO2018026371A1 (en) * | 2016-08-04 | 2018-02-08 | Sunovion Pharmaceuticals Inc. | Dual nav1.2/5ht2a inhibitors for treating cns disorders |
EP4115885A1 (en) | 2021-07-05 | 2023-01-11 | Charité - Universitätsmedizin Berlin | A pharmaceutical composition comprising bay 86-5277 and salts thereof for use in the treatment of viral infections and hyperinflammation |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1220440B (de) * | 1962-02-14 | 1966-07-07 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von Derivaten des 1-(o-Bromphenoxy)-2-hydroxy-3-amino-propans und deren Saeureadditionssalzen |
US3577432A (en) | 1968-12-23 | 1971-05-04 | Robins Co Inc A H | 1-substituted-3-phenoxypyrrolidines |
US4029801A (en) * | 1970-09-03 | 1977-06-14 | John Wyeth & Brother Limited | Pharmaceutical compositions and methods of treating hypertension |
JPS5511670B1 (zh) | 1971-07-13 | 1980-03-26 | ||
US3755584A (en) * | 1972-04-03 | 1973-08-28 | Abbott Lab | Tranquilizers |
FR2190430A1 (en) | 1972-06-29 | 1974-02-01 | Ferlux | N-aminomethylhydroxamic acids - with antiinflammatory activity pre-pared by Mannich reaction |
US3775584A (en) | 1972-11-30 | 1973-11-27 | D Moerke | Welding gun |
US3894030A (en) * | 1973-01-04 | 1975-07-08 | Janssen Pharmaceutica Nv | 1-{8 1-(2-Hydroxy-3-aryloxypropyl)-4-piperidyl{9 -2-benzimidazolinones and related compounds |
US3818017A (en) | 1973-01-04 | 1974-06-18 | Janssen Pharmaceutica Nv | 1-{8 1-(2-hydroxy-3-aryloxypropyl)-4-piperidyl{9 -2-benzimidazolinones and related compounds |
US4166119A (en) | 1978-04-14 | 1979-08-28 | American Hoechst Corporation | Analgesic and tranquilizing spiro[dihydrobenzofuran]piperidines and pyrrolidines |
US4264613A (en) | 1979-08-01 | 1981-04-28 | Science Union Et Cie, Societe Francaise De Recherche Medicale | Piperidylbenzimidazolinone compounds |
FR2469411A1 (fr) | 1979-11-15 | 1981-05-22 | Science Union & Cie | Nouveaux derives de la piperidylbenzimidazolinone, leurs procedes de preparation et les compositions pharmaceutiques les renfermant |
EP0095454A3 (de) | 1982-05-13 | 1985-04-03 | Gerot-Pharmazeutika Gesellschaft m.b.H. | Neue kernsubstituierte Pyrogallol-Derivate |
JPS59222484A (ja) | 1983-06-02 | 1984-12-14 | Kowa Co | テトラヒドロナフチルカルボン酸フエニルエステル誘導体 |
US5614533A (en) * | 1987-03-13 | 1997-03-25 | Bio-Mega/Boehringer Ingelheim Research, Inc. | Substituted pipecolinic acid derivatives as HIV protease inhibitors |
DE3723568C2 (de) | 1987-07-16 | 1994-01-27 | Siemens Ag | Differenzstromschutzschalter |
DE3723648A1 (de) * | 1987-07-17 | 1989-01-26 | Sandoz Ag | Indol-derivate, ihre herstellung und sie enthaltende arzneimittel |
ES2027897A6 (es) | 1991-01-24 | 1992-06-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados de la difenilmetilpiperacina. |
IL105716A0 (en) | 1992-06-08 | 1993-09-22 | Richter Gedeon Vegyeszet | Aminopropanol derivatives,their preparation and pharmaceutical compositions containing them |
NZ248332A (en) | 1992-08-07 | 1995-01-27 | Sankyo Co | Hiv protease inhibitor and its use |
US5789402A (en) * | 1995-01-17 | 1998-08-04 | Eli Lilly Company | Compounds having effects on serotonin-related systems |
US5627196A (en) | 1995-01-17 | 1997-05-06 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US5614523A (en) | 1995-01-17 | 1997-03-25 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US5741789A (en) | 1995-01-17 | 1998-04-21 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US5576321A (en) | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
DE19703131A1 (de) | 1997-01-29 | 1998-07-30 | Bayer Ag | Verwendung von Chinoxalin in Dreier-Kombination mit Protease-Inhibitoren und Reverse Transkriptaseinhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen |
IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
WO1999025686A1 (en) | 1997-11-18 | 1999-05-27 | Teijin Limited | Cyclic amine derivatives and their use as drugs |
DE19755268A1 (de) | 1997-12-12 | 1999-06-17 | Merck Patent Gmbh | Benzamidinderivate |
FR2780057B1 (fr) | 1998-06-18 | 2002-09-13 | Sanofi Sa | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
CA2350730A1 (en) | 1998-12-18 | 2000-06-22 | George V. Delucca | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
WO2000035449A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
AU2942000A (en) | 1999-03-11 | 2000-09-28 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivatives |
CZ20013451A3 (cs) | 1999-03-26 | 2002-04-17 | Astrazeneca Ab | Nové sloučeniny |
DE19922316A1 (de) | 1999-05-14 | 2000-11-16 | Goedecke Ag | Verfahren zur Herstellung von (R)-N-[(Benzo[b]furan-2-yl)-alkoxycarbonyl]-tryptophanalkylestern |
US7125895B1 (en) | 1999-05-14 | 2006-10-24 | Bristol-Myers Squibb Pharma Research Labs, Inc. | Cyclic amine derivatives and their uses |
SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
FR2802533B1 (fr) | 1999-12-17 | 2002-02-15 | Sanofi Synthelabo | Phenoxypropanolamines, leur preparation et leur application en therapeutique |
DE60033964T2 (de) | 1999-12-17 | 2007-11-29 | Sanofi-Aventis | Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung |
CO5300399A1 (es) | 2000-02-25 | 2003-07-31 | Astrazeneca Ab | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen |
GB0011838D0 (en) | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
US7005439B2 (en) | 2000-06-20 | 2006-02-28 | Astrazeneca Ab | Compounds |
AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
AR028947A1 (es) * | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
SE0100903D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0101038D0 (sv) | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
-
2001
- 2001-02-22 CO CO01014299A patent/CO5300399A1/es not_active Application Discontinuation
- 2001-02-23 PL PL01358281A patent/PL358281A1/xx not_active Application Discontinuation
- 2001-02-23 PT PT01908558T patent/PT1263725E/pt unknown
- 2001-02-23 CA CA002400293A patent/CA2400293A1/en not_active Abandoned
- 2001-02-23 ES ES01908557T patent/ES2241796T3/es not_active Expired - Lifetime
- 2001-02-23 SI SI200130366T patent/SI1263724T1/xx unknown
- 2001-02-23 MX MXPA02008243A patent/MXPA02008243A/es unknown
- 2001-02-23 EP EP01908557A patent/EP1263724B1/en not_active Expired - Lifetime
- 2001-02-23 JP JP2001561737A patent/JP2003523999A/ja not_active Withdrawn
- 2001-02-23 BR BR0108677-4A patent/BR0108677A/pt not_active IP Right Cessation
- 2001-02-23 EP EP01908559A patent/EP1263760A1/en not_active Withdrawn
- 2001-02-23 AR ARP010100842A patent/AR029806A1/es not_active Application Discontinuation
- 2001-02-23 AT AT01908558T patent/ATE280153T1/de not_active IP Right Cessation
- 2001-02-23 HU HU0300922A patent/HUP0300922A2/hu unknown
- 2001-02-23 CA CA002400435A patent/CA2400435A1/en not_active Abandoned
- 2001-02-23 KR KR1020027011129A patent/KR20020075450A/ko not_active Application Discontinuation
- 2001-02-23 AT AT01908557T patent/ATE295833T1/de not_active IP Right Cessation
- 2001-02-23 DK DK01908558T patent/DK1263725T3/da active
- 2001-02-23 MX MXPA02008241A patent/MXPA02008241A/es active IP Right Grant
- 2001-02-23 AU AU36299/01A patent/AU783496B2/en not_active Ceased
- 2001-02-23 BR BR0108679-0A patent/BR0108679A/pt not_active IP Right Cessation
- 2001-02-23 DK DK01908557T patent/DK1263724T3/da active
- 2001-02-23 WO PCT/SE2001/000404 patent/WO2001062729A1/en active IP Right Grant
- 2001-02-23 BR BR0108678-2A patent/BR0108678A/pt not_active IP Right Cessation
- 2001-02-23 PT PT01908557T patent/PT1263724E/pt unknown
- 2001-02-23 DE DE60110900T patent/DE60110900T2/de not_active Expired - Fee Related
- 2001-02-23 SK SK1213-2002A patent/SK12132002A3/sk unknown
- 2001-02-23 ES ES01908558T patent/ES2227140T3/es not_active Expired - Lifetime
- 2001-02-23 CN CNB018084842A patent/CN1187326C/zh not_active Expired - Fee Related
- 2001-02-23 SI SI200130239T patent/SI1263725T1/xx unknown
- 2001-02-23 CN CN01808426A patent/CN1426412A/zh active Pending
- 2001-02-23 JP JP2001561736A patent/JP2003523998A/ja not_active Withdrawn
- 2001-02-23 US US10/204,754 patent/US6951874B2/en not_active Expired - Fee Related
- 2001-02-23 US US10/204,789 patent/US6927222B2/en not_active Expired - Fee Related
- 2001-02-23 NZ NZ520718A patent/NZ520718A/en unknown
- 2001-02-23 EP EP01908558A patent/EP1263725B1/en not_active Expired - Lifetime
- 2001-02-23 AU AU36301/01A patent/AU3630101A/en not_active Abandoned
- 2001-02-23 US US10/204,790 patent/US6943188B2/en not_active Expired - Fee Related
- 2001-02-23 DE DE60106581T patent/DE60106581T2/de not_active Expired - Fee Related
- 2001-02-23 KR KR1020027011127A patent/KR100752033B1/ko not_active IP Right Cessation
- 2001-02-23 RU RU2002122100/04A patent/RU2265011C2/ru not_active IP Right Cessation
- 2001-02-23 WO PCT/SE2001/000403 patent/WO2001062728A1/en active IP Right Grant
- 2001-02-23 IL IL15120801A patent/IL151208A0/xx unknown
- 2001-02-23 EE EEP200200470A patent/EE05001B1/xx not_active IP Right Cessation
- 2001-02-23 WO PCT/SE2001/000405 patent/WO2001062757A1/en not_active Application Discontinuation
- 2001-02-23 IL IL15120201A patent/IL151202A0/xx unknown
- 2001-02-23 CZ CZ20022870A patent/CZ20022870A3/cs unknown
- 2001-02-23 AU AU36300/01A patent/AU783475B2/en not_active Ceased
- 2001-02-23 KR KR1020027011128A patent/KR20020076338A/ko not_active Application Discontinuation
- 2001-02-23 CA CA002400434A patent/CA2400434A1/en not_active Abandoned
- 2001-02-23 MX MXPA02008244A patent/MXPA02008244A/es active IP Right Grant
- 2001-02-23 NZ NZ520719A patent/NZ520719A/en unknown
- 2001-02-23 CN CNB018084125A patent/CN1229343C/zh not_active Expired - Fee Related
- 2001-02-23 JP JP2001562539A patent/JP2003524011A/ja active Pending
-
2002
- 2002-08-19 NO NO20023934A patent/NO323584B1/no unknown
- 2002-08-19 NO NO20023932A patent/NO20023932L/no not_active Application Discontinuation
- 2002-08-19 NO NO20023933A patent/NO20023933L/no not_active Application Discontinuation
- 2002-08-22 IS IS6520A patent/IS6520A/is unknown
-
2003
- 2003-02-17 HK HK03101130A patent/HK1048990A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1426394A (zh) | 新化合物 | |
CN1307157C (zh) | 化合物 | |
CN1305839C (zh) | 苯基甘氨酸衍生物 | |
CN1104427C (zh) | 法呢基蛋白转移酶的三环抑制剂 | |
CN1267420C (zh) | 药用活性哌啶衍生物 | |
CN1684952A (zh) | 用于治疗趋化因子介导的疾病的新的哌啶衍生物 | |
CN1675218A (zh) | 新的三环螺哌啶或螺吡咯烷 | |
CN1365281A (zh) | 金属蛋白酶抑制剂 | |
CN1193961A (zh) | 取代的苄氨基哌啶化合物 | |
CN1610666A (zh) | 苄脒衍生物 | |
CN1207734A (zh) | 金属蛋白酶抑制剂,含有它们的药物组合物和其药物用途,其制备方法和中间体 | |
CN1387514A (zh) | 芳族砜异羟肟酸金属蛋白酶抑制剂 | |
CN101048393A (zh) | 作为γ-分泌酶抑制剂的取代的N-芳基磺酰基杂环胺 | |
CN1805747A (zh) | 4-( 4-(杂环基烷氧基 )苯基)-1-(杂环基-羰基)哌啶衍生物和相关的化合物作为组胺h3拮抗剂用于治疗神经疾病如阿尔茨海默氏病 | |
CN101068798A (zh) | 1-环丙基甲基-4-[2-(3,3,5,5-四甲基环己基)苯基]哌嗪的盐及结晶 | |
CN1918160A (zh) | 用作趋化因子受体活性调节剂的新颖三环螺环衍生物 | |
CN1298716C (zh) | 1-[(吲哚-3-基)羰基]哌嗪衍生物及其药物组合物 | |
CN1073433A (zh) | 环己烷乙酸衍生物 | |
CN1226825A (zh) | 胺化合物用于制备阻止肿瘤细胞增殖的药物 | |
CN1217932C (zh) | 抗菌剂 | |
CN1756740A (zh) | 具有2,6-二取代苯乙烯基的含氮杂环衍生物 | |
CN1111528C (zh) | 用作神经激肽拮抗药的哌嗪衍生物 | |
CN1178923C (zh) | 1,4-二氮杂环庚烷-2,5-二酮衍生物及其作为nk-1受体拮抗剂的应用 | |
CN1768037A (zh) | 化合物 | |
CN1906200A (zh) | 新化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |